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Abstract 
BK polyomavirus (BKPyV) is a human pathogen that infects the majority of the 
population, worldwide, establishing a lifelong infection. Immunocompromised patients 
following renal transplantation, are likely to suffer from severe clinical complications, 
including polyomavirus-associated nephropathy (PVAN), which can ultimately lead to 
kidney graft failure. Currently, there are no direct acting anti-viral compounds 
targeting BKPyV and the number of renal transplants is increasing significantly. 
Therefore, there is an urgent need to understand the viral life cycle in order to identify 
potential targets that can be exploited for therapeutic development.  
Ion channels play a critical role in kidney physiology by controlling several processes, 
implicating them as candidate proteins required for BKPyV infection. A 
pharmacological analysis was performed in which human primary renal epithelial cells 
were treated with a range of pharmacological modulators of host ion channels and 
the effect on BKPyV production assayed using a fluorescence-based technique. From 
this approach, it was identified that the clinically available drug, Glibenclamide is a 
potent inhibitor of BKPyV infection. Biochemical analysis and molecular-based 
techniques revealed that the cystic fibrosis transmembrane conductance regulator 
(CFTR) was the target of Glibenclamide and time-of-addition experiments indicated 
that CFTR might be required during the entry and trafficking of BKPyV through the 
cytoplasm. These studies provide the first reported requirement for host ion channels 
in the BKPyV life cycle. 
Studies on other related polyomaviruses, including JCPyV, SV40 and Merkel cell 
polyomavirus determined a cell type-dependent requirement of CFTR in the viruses’ 
life cycle, highlighting the importance of understanding the role of host ion channels 
in polyomaviruses’ life cycle. Ion channels are an emerging target for many medical 
conditions and such compounds that target these may represent a novel strategy for 
developing therapeutics to treat PVAN and/or other polyomavirus-associated clinical 
complications. 
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 Introduction 
1.1 Taxonomy, Classification and Characteristics of Polyomaviridae 
Polyomaviruses are double-stranded DNA viruses and their classification has 
undergone several revisions due to discovery of new family members. Formerly, 
papillomaviruses and polyomaviruses were classified in the same family, named as 
Papovaviridae. The name of the family derived from three abbreviations; Pa for 
Papillomavirus, Po for Polyomavirus and Va for “vacuolating”. Family members 
shared many structural features although, they had very different genome 
organization (IARC Working Group on the Evaluation of Carcinogenic Risks to 
Humans, 2014). 
A more recent update in 2010, the Polyomaviridae was divided into three genera. 
These were the Orthopolyomavirus and Wukipolyomavirus genera, which include 
polyomaviruses that infect mammalian species and the Avipolyomavirus that contains 
avian infecting species of virus. The criteria utilized in new viruses’ classification 
include the genetic background, the identity of DNA sequence throughout the genome 
and the host range of the virus (Johne et al., 2011). 
Currently, following another reclassification, the International Committee on 
Taxonomy of Viruses now recognizes four distinct genera, Alphapolyomavirus, 
Betapolyomavirus, Gammapolyomavirus and Deltapolyomavirus based on the amino 
acid sequence of Large Tumour Antigen (TAg) viral protein (Calvignac-Spencer et al., 
2016). Phylogenetic relationships among polyomaviruses are shown in Figure 1.1 
(Moens et al., 2017). Studies have identified that viruses belonging to these genera 
can infect both birds and mammals and most recently, polyomavirus infection was 
detected in fish (Peretti et al., 2015). It is also established that some members of the 
Polyomaviridae are closely associated with cancer and severe clinical complications. 
However, clinical symptoms are observed mainly in immunosuppressed individuals 
(Moens et al., 2017). Members of Alphapolyomavirus genus can infect humans and 
other mammals. Raccoon polyomavirus and Merkel cell polyomavirus are members 
2 
 
of this genus and are closely associated with cancer within their host. 
Betapolyomavirus genus includes members that infect mammals with BKPyV and 
JCPyV being characteristic members of this genus. Members of Gammapolyomavirus 
genus infect birds. Finally, human polyomavirus 6, 7, 10 and 11 belong to 
Deltapolyomavirus genus (Calvignac-Spencer et al., 2016).  
Polyomaviruses are approximately 40-45 nm in diameter and the major capsid 
protein, VP1, represents the 75% of the total virion protein content (Moens et al., 
2017). Two other structural proteins, VP2 and VP3, are detected in most mammalian 
polyomaviruses, whereas an additional viral protein called VP4 has been detected in 
bird polyomaviruses and Simian Virus 40 (SV40) (Shen et al., 2011; Raghava et al., 
2011). The mature virions are non-enveloped with icosahedral symmetry and 
consisted of 72 pentameric capsomers. VP1 is the component of each of these 
pentameres. Furthermore, it has been identified that capsomers are linked by the C-
terminal arm of VP1 and each capsomer is stabilized by disulphide bonds and calcium 
ions (Hurdiss et al., 2016; Hurdiss et al., 2018). A single molecule of the minor capsid 
proteins, VP2 or VP3, is linked to the internal face of each VP1 pentamer. The circular 
double-stranded viral genome is contained in each mature virion and is organized as 
a minichromosome, whereas, histone proteins such as H2A, H2B, H3 and H4 facilitate 
the packaging of viral genome (Pagano, 1984). Polyomavirus minichromosome lacks 
histone H1 (Fang et al., 2010), which is required for chromatin compaction (Thoma et 
al., 1979). This suggests that the minichrosome is not highly compacted within the 
virus particle (Hurdiss et al., 2016). Recent studies have shown that VP1 is bound to 
the viral genomic DNA, although both minor capsid proteins, VP2 and VP3 can also 
be linked with the genomic DNA (Hurdiss et al., 2016).  
Most polyomaviruses contain a genome of approximately 5,000 bp, although the size 
of the genome may vary in some species. For example, the black sea bass-
associated polyomavirus 1 contains a single circular genomic DNA of 7,369 bp 
(Calvignac-Spencer et al., 2016). On the other hand, the smallest polyomavirus 
genome (3,962 bp) has been identified in an unclassified polyomavirus, which is 
linked with the giant guitarfish (Calvignac-Spencer et al., 2016). Small variations are 
also observed in human polyomaviruses, such as Merkel cell polyomavirus and Saint 
Louis polyomavirus. The former contains the largest genome of 5,387 bp and the 
latter has the smallest genome identified of 4,776 bp (Calvignac-Spencer et al., 2016). 
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Most of the polyomaviruses encode for 5 distinct proteins, 2 regulatory and 3 other 
structural proteins. The 2 regulatory proteins, TAg and tAg, are expressed before the 
initiation of genome replication and the 3 structural proteins VP1, VP2 and VP3, are 
expressed following genome replication. However, it is established that several 
polyomaviruses express additional proteins as well. A number of studies describe an 
additional open reading frame, which encodes for a protein called alternative tumour 
antigen (ALTO) or a second exon of middle tumour antigen (MTAg) in some 
polyomaviruses, such as Merkel cell polyomavirus and Trichodysplasia Spinulosa 
polyomavirus (Carter et al., 2013; Lauber et al., 2015; van der Meijden et al., 2015). 
Studies have reported that another late protein, VP4, has been expressed in some 
polyomaviruses and its function is still controversial (Raghava et al., 2011; Raghava 
et al., 2013; Giorda et al., 2012; Henriksen et al., 2016). VP4 open reading frames 
have been detected in SV40, BKPyV, JCPyV and in some non-human primate 
polyomaviruses (Ehlers and Moens, 2014). It is also identified that another auxiliary 
protein, which is named agnoprotein, is expressed by BKPyV, JCPyV and SV40 
(Saribas et al. 2016). Studies have demonstrated that agnoprotein is involved in 
several processes including virus transcription, maturation and egress (Saribas et al., 
2016). A gene detected in avian polyomaviruses in a similar genomic position, was 
originally annotated as an agnogene, although there is no detectable sequence 
similarity to the mammalian examples. The protein product generated by this gene, is 
implicated in capsid formation and genome packaging, resulting to its reclassification 
as VP4 to show its role as a structural protein. However, it is still often referred to as 
avian agnoprotein 1a (Shen et al., 2011; Gerits and Moens, 2012; Müller and Johne, 
2001). 
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Figure 1. 1 A maximum likelihood rooted phylogenetic tree of polyomaviruses based on conserved TAg 
coding sequence. Polyomaviruses, Genbank accession numbers and genome sizes are represented. 
Polyomaviruses are shown into genera by different colouring. Scale bar represents the number of 
substitution per site (Moens et al., 2017). 
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1.2 Human polyomaviruses 
In 1971, the first human polyomaviruses were identified, BK (BKPyV) polyomavirus 
and JC (JCPyV) polyomavirus are named after the initials of the index case patients 
(Gardner et al., 1971; Padgett et al., 1971). BKPyV causes severe clinical 
complications in certain immunocompromised individuals, although primary infections 
in immunocompetent individuals is usually asymptomatic or may be associated with 
signs of a mild respiratory infection (Mazalrey et al., 2015). Serological studies have 
shown that primary BKPyV infection usually occurs at a young age and virus 
establishes a lifelong infection into the hosts (Kean et al., 2009; Stolt et al., 2003; 
Knowles, 2006). Following virus reactivation, under conditions of 
immunosuppression, BKPyV is strongly correlated with two severe diseases, 
polyomavirus-associated nephropathy (PVAN) and hemorrhagic cystitis in patients 
who have undergone renal and bone marrow transplantation, respectively (Kuypers, 
2012). Studies have identified that JCPyV is a neurotropic virus and is characterized 
as the main causative agent of a lethal clinical complication of the central nervous 
system, progressive multifocal leukoencephalopathy (PML), which is usually 
diagnosed in patients with HIV/AIDS (Ferenczy et al., 2012).  
Since 2007, many more human polyomaviruses have been identified and 
categorized. Some of these new polyomaviruses were named after the institution in 
which they were discovered such as Washington University polyomavirus (WUPyV) 
and Karolinska Institute polyomavirus (KIPyV) (Allander et al., 2007; Gaynor et al., 
2007). Malawi polyomavirus (MWPyV), Saint Louis polyomavirus (STLPyV) and New 
Jersey polyomavirus (NJPyV) were named after the geographical source of detected 
virus (Siebrasse et al., 2012; Lim et al., 2013; Mishra et al., 2014). Two more 
polyomaviruses are named after their disease association; Merkel cell polyomavirus 
(MCPyV) and Trichodysplasia spinulosa-associated polyomavirus (TSPyV) (Haycox 
et al., 1999; van der Meijden et al., 2015; Feng et al., 2008). Furthermore, 
polyomavirus 6, 7, 9 and 12 (HPyV6, HPyV7, HPyV9 and HPyV12) were named after 
the chronological order of first detection (Schowalter et al., 2010; Scuda et al., 2011; 
Korup et al., 2013). The table (Table 1.1) below shows a list of human polyomaviruses 
as are listed by Calvignac-Spencer et al., (2016). A very recent study described the 
isolation of a new human polyomavirus in human skin. Lyon IARC polyomavirus 
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(LIPyV) is related to the raccoon polyomavirus based on phylogenetic analyses (Gheit 
et al., 2017). 
Phylogenetic analyses of human polyomaviruses have suggested that there are 
distinct clades of polyomaviruses. DeCaprio and Garcea (2013) represented a 
phylogenetic tree of human polyomaviruses describing the relationship between 
human and primate polyomaviruses based on TAg and VP1 conserved amino acid 
sequences (Figure 1.2). It was identified that polyomaviruses isolated from same 
tissue or sample types were grouped together. In particular, WUPyV and KIPyV are 
grouped together, also HPyV6 with HPyV7 and MWPyV with STLPyV are seen paired 
as they were isolated from nasopharyngeal, skin and stool, respectively. This might 
indicate a potential tissue tropism between closely related polyomaviruses 
(Rozenblatt-Rosen et al., 2012). BKPyV and JCPyV are also closely related to SV40 
and simian agent 12 (SA12). The authors also proposed that HPyV9 is paired with 
African green monkey polyomavirus (AGMPyV) and MCPyV is grouped with Gorilla 
gorilla gorilla polyomavirus 1. Furthermore, TSPyV is very similar to Bornean 
orangutan polyomavirus (DeCaprio and Garcea, 2013).  
 
 
 
 
 
 
7 
 
Table 1. 1 Human polyomaviruses. A list of 13 members of polyomaviruses that infect humans. Species, virus name, abbreviation, year of discovery and clinical 
complications are represented. Adapted from (Calvignac-Spencer et al., 2016) 
Species Virus name Abbreviation Year of discovery Clinical correlate 
Human polyomavirus 1 BK polyomavirus BKPyV 1971 Polyomavirus-associated 
nephropathy and hemorrhagic 
cystitis (DeCaprio and Garcea, 
2013) 
Human polyomavirus 2 JC polyomavirus JCPyV 1971 Progressive multifocal 
leukoencephalopathy 
(DeCaprio and Garcea, 2013) 
Human polyomavirus 3 KI polyomavirus KIPyV 2007 Not known (Allander et al., 
2007) 
Human polyomavirus 4 WU polyomavirus WUPyV 2007 Not known (Gaynor et al., 
2007) 
Human polyomavirus 5 Merkel cell polyomavirus MCPyV 2008 Merkel cell carcinoma 
(DeCaprio and Garcea, 2013) 
Human polyomavirus 6 Human polyomavirus 6 HPyV6 2010 HPyV6-associated pruritic and 
dyskeratotic dermatosis 
(Nguyen et al., 2017) 
Human polyomavirus 7 Human polyomavirus 7 HPyV7 
 
 
2010 HPyV7-related epithelial 
hyperplasia (Nguyen et al., 
2017) 
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Species Virus name Abbreviation Year of discovery Clinical correlate 
Human polyomavirus 8 Trichodysplasia spinulosa 
polyomavirus 
TSPyV 2010 Trichodysplasia spinulosa 
(DeCaprio and Garcea, 2013) 
Human polyomavirus 9 Human polyomavirus 9 HPyV9 2011 Not known (Scuda et al., 2011) 
Human polyomavirus 10 MW polyomavirus MWPyV 2012 Not known (Siebrasse et al., 
2012) 
Human polyomavirus 11 STL polyomavirus STLPyV 2013 Not known (Lim et al., 2013) 
Human polyomavirus 12 Human polyomavirus 12 HPyV12 2013 Not known (Korup et al., 2013) 
Human polyomavirus 13 New Jersey polyomavirus  NJPyV 2014 Not known (Mishra et al., 
2014) 
Human polyomavirus 14 Lyon IARC polyomavirus LIPyV 2017 Not known (Gheit et al., 2017) 
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Figure 1. 2 Phylogenetic tree of human and primate polyomaviruses. Human polyomaviruses are 
represented in yellow and primate polyomaviruses are shown in red. Amino acid sequences from TAg 
and VP1 proteins from 19 different isolates were used to construct this simplified rooted phylogenetic 
tree. Scale bar represents the number of substitution per site (DeCaprio and Garcea., 2013). 
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1.3 Polyomavirus-associated nephropathy (PVAN) 
1.3.1 History and background of the disease 
Polyomavirus-associated nephropathy (PVAN) is the most common viral clinical 
complication in kidney transplant recipients, causing transplant dysfunction and graft 
loss. An increasing prevalence rate of PVAN from 1% to 10% has been reported since 
1995 (Hirsch et al., 2006). This increase might occur due to usage of new-generation 
and stronger immunomodulatory drugs and/or the decrease in acute transplant 
rejection rates. Studies have shown that PVAN causes renal graft rejection in between 
10%-100% of the diagnosed cases, with patients undergoing to haemodialysis within 
6 to 60 months, therefore decreasing the kidney allograft survival (Costa and Cavallo, 
2012). 
The main causative viral agent of PVAN is the human BK polyomavirus (BKPyV) in 
most of the reported cases. In 1978, 4 distinct features of nephropathy after kidney 
transplantation were first described by Mackenzie et al., (1978). The authors stated 
that urinary decoy cells and viral inclusion bodies in uroepithelial cells were detected 
in renal graft biopsies. They also highlighted the difficulties in the diagnosis with acute 
renal rejection and the critical role of immunosuppressive drugs in the development 
of this nephropathy. In 1995, the first clinical case of PVAN was described and 
recognized as a defined clinical complication strongly associated with BKPyV 
(Purighalla et al., 1995). JCPyV alone has been also associated with PVAN, but in 
less than 3% of all the cases (Kazory et al., 2003; Wen et al., 2004) or in conjunction 
with BKPyV (Cavallo et al., 2007). Li et al., (2002) suggested that there might be a 
potential implication of SV40 in PVAN. It is demonstrated that co-infection of BKPyV 
and SV40 has been identified in renal transplant individuals diagnosed with PVAN (Li 
et al., 2002). 
The pathogenesis of PVAN is still only partially understood, however multiple risk 
factors coincide to the development of PVAN including the source of the BKPyV 
infection, host immunity to BKPyV, the immunosuppression and HLA matching 
(Scadden et al., 2017). It is known that primary BKPyV infection from the renal graft 
itself or BKPyV reactivation in the transplant recipient’s native urinary tract may lead 
to development of PVAN (Scadden et al., 2017). Studies have indicated that patients 
11 
 
who are transplanted with an allograft from seropositive donors may show increased 
rate of BKPyV infection within the renal graft, therefore highlighting the importance of 
donor-derived BKPyV infection (Andrews et al., 1988). This was also supported by 
another study stating that BKPyV infection was observed in 46% of renal recipients 
from seropositive donors compared with only 15% of recipients from seronegative 
donors. They also reported that BK viruria was developed faster and lasted longer in 
individuals receiving graft from seropositive donors (Bohl et al., 2005). 
Host innate immunity is implicated with pathogenesis of PVAN and both CD8+ and 
CD4+ T cells are involved in the recognition and clearance of BKPyV (Scadden et al., 
2017). The lack of IgG specific against BKPyV may be crucial for the development of 
PVAN (Chand et al., 2016). Patients being seronegative for BKPyV at the time of 
transplantation have a greater risk of developing BKPyV infection as they do not have 
pre-existing BKPyV-specific antibodies, although individuals exposed to BKPyV may 
not develop BKPyV infection following transplantation (Beimler et al., 2007). Patients 
that have produced antibodies against BKPyV are still at risk of PVAN as host cellular 
immunity plays a pivotal role in BKPyV control (Comoli et al., 2013). Studies have 
reported that less secreted interferon-γ (IFN-γ) was detected in patients diagnosed 
with PVAN, as they contain fewer BKPyV-specific lymphocytes. This level of secretion 
was around 10 times less than the observed levels during infection with other viruses 
associated with transplantation, such as Epstein-Barr virus (EBV). These data 
suggest that BKPyV immunity is decreased, which following could lead to increased 
rate of developing PVAN (Comoli et al., 2004).  
Immunosuppressive drugs are required following a transplantation to prevent allograft 
rejection by the host immune system. To date, strong immunomodulatory drugs such 
as tacrolimus (Tac) and mycophenolate mofetil (MMF) are administered and the 
reduced rate of renal graft rejection has been inversely correlated with increased 
incidence of BKPyV reactivation and infection (Scadden et al., 2017). Tac is a 
calcineurin inhibitor, which interferes with T cell activation, whereas MMF is an anti-
proliferative agent that interferes with T cell proliferation, downstream of the 
interleukin-2-receptor activation (Ginevri et al., 2007; Brennan et al., 2005; Halloran, 
2004). Most of the reported cases received immunosuppressive combinations 
containing Tac or MMF. However, studies have shown that there is an increased rate 
of developing PVAN using a combination of Tac-MMF-corticosteroids or cyclosporin 
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(Brennan et al., 2005). Hence, no specific immunosuppressive drug can be 
exclusively related to PVAN. 
Furthermore, HLA matching is being considered as another critical risk factor of 
developing PVAN. Studies have identified that there is ineffective clearance of BKPyV 
due to MHC mismatching using a mouse model (Scadden et al., 2017). Other clinical 
studies have also supported that increased HLA mismatch may lead to PVAN (Hirsch 
et al., 2002; Masutani et al., 2013; Awadalla et al., 2004). There are also several other 
risk factors that might increase the risk of developing PVAN, such as male gender, 
age older than 50 years, white ethnicity, diabetes mellitus or whether the organ was 
sourced from a deceased donor (Mengel et al., 2003; Dharnidharka et al., 2009; 
Dharnidharka et al., 2009; Vasudev et al., 2005). 
 
1.3.2 Clinical manifestation of PVAN 
The median time for PVAN diagnosis is within the first-year post-transplantation 
(Nickeleit et al., 2000; Drachenberg et al., 1999), however approximately 25% of the 
reported clinical cases have been diagnosed at later stages (Costa and Cavallo, 
2012). Varying degrees of renal dysfunction and stages of PVAN might be identified, 
whereas even normal serum creatinine levels might be detected in early stages 
(Krishna and Prasad, 2011). The stereotypical progression of PVAN is thoroughly 
characterized and is as follows (Ramos et al., 2009). Most of the cases are initially 
asymptomatic with a persistent and significant viruria, as indicated by detectable urine 
viral load > 105 BKPyV copies/ml or by urine cytology. Viremia usually follows BKPyV 
viruria within the next few weeks (Ramos et al., 2009). The significant and sustained 
BKPyV viremia indicates the uncontrolled viral replication in patients, which potentially 
results in parenchymal injury. Progression of PVAN ultimately leads to deterioration 
of renal graft function and kidney failure (Ramos et al., 2009). Interstitial nephritis and 
ureteric stenosis with ureteric obstruction, hydronephrosis and urinary tract infections 
may be developed during PVAN as well (Hariharan, 2006).  
There are several histologic features which are observed in patients diagnosed with 
PVAN, including viral inclusion bodies which are detected in epithelial cells of the 
urothelium. The virus is usually detected by immunohistochemical staining with an 
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antibody that detects the SV40 TAg, and effectively cross-reacts with BKPyV TAg 
(Nickeleit et al., 1999; Costa and Cavallo, 2012). There are three distinct histological 
patterns of PVAN. In pattern A, which includes the early stage of the disease, 
cytopathic alterations with little to no inflammation sign or tubular atrophy are 
observed. Cytopathic changes with inflammation, tubular atrophy and fibrosis indicate 
pattern B of PVAN. Finally, extensive tubular atrophy, interstitial nephritis and chronic 
inflammatory infiltrate are present in the end-stage of PVAN, which is described as 
pattern C. Thus, the degree of damage reflects the degree of renal graft dysfunction 
and outcome (Scadden et al., 2017; Costa and Cavallo, 2012; Drachenberg et al., 
2004). 
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Figure 1. 3 Renal biopsy sample. Renal biopsy with preserved tubular morphology, without significant 
damage or inflammation. PVAN confirmed by positive SV40 staining which is shown in dark purple 
colour. Adapted from Scadden et al., (2017). 
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1.3.3 Diagnosis of PVAN 
BKPyV is first detected in the urine after its reactivation, and then follows viremia 
several weeks later. However, there are some rare cases reported, which identify 
patients with viremia without developing viruria. Studies have shown that screening 
for BKPyV has higher positive predictive rates for PVAN (50-60%) compared with 
BKPyV viruria, therefore specific screening for BKPyV is more preferred (Bechert et 
al., 2010). Table 1.2 presents the different screening methods that are currently used 
(Sawinski and Goral, 2015). 
Real-time PCR can be used to diagnose PVAN in individuals by detecting BKPyV in 
plasma. Studies have shown that this screening method is very specific and sensitive 
reaching 90% and 100%, respectively. Positive predictive values for PVAN is 
approximately 50%, whereas negative predictive rate is 100% (Hirsch et al., 2002; 
Viscount et al., 2007). Currently, this is the most preferred screening test and a 
suggested BKPyV viral load more than 4log copies/ml is strongly correlated with 
diagnosis of PVAN on renal biopsy (Hirsch et al., 2005; Scadden et al., 2017). 
BKPyV can also be detected in the urine of approximately 30% of kidney transplant 
recipients (Wiseman, 2009). There are two distinct methods for screening urine 
samples: BKPyV detection by cytology and quantification of BKPyV DNA by real-time 
PCR reaction. “Decoy cells” are infected tubular epithelial cells with BKPyV and can 
be detected in urine samples. These cells have a characteristic morphology and are 
easily recognizable as they have a basophilic nucleus containing viral inclusion 
bodies (Wiseman, 2009). Although, studies have highlighted that screening methods 
for urine BKPyV based on PCR reaction are more sensitive compared to urine 
cytology for diagnosis of PVAN. The detection of decoy cells shows only 25% 
sensitivity and approximately 84% specificity for PVAN in comparison with urine 
BKPyV PCR which reaches 100% sensitivity and 78% specificity, respectively 
(Viscount et al., 2007; Costa and Cavallo, 2012).  
Icosahedral BKPyV viral aggregates (“Haufen”) were first investigated by Singh et al., 
(2009) in urine samples of renal transplant recipients diagnosed with PVAN using 
negative staining electron microscopy. These aggregates are originated from lysed 
BKPyV infected renal cells. It was reported that 21 renal transplant recipients 
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diagnosed with PVAN by biopsy were also positive for Haufen aggregates in their 
urine, suggesting that Haufen are highly related with PVAN. These findings suggest 
that detection of Haufen might serve as a noninvasive screening method for diagnosis 
of PVAN in the future (Kuypers, 2012; Sawinski and Goral, 2015). 
Another biomarker for native renal disease is urine mRNA profiles. Studies have 
proposed that BKPyV VP1 mRNA molecules derived from urinary cells can be used 
for PVAN diagnosis (Singh et al., 2009). An approximate 6.5x 105 VP1 mRNA/ng RNA 
is the threshold value indicating PVAN, as it was suggested by Dadhania et al., (2010) 
by studying patients diagnosed with PVAN by renal biopsy. A very recent study 
revealed that BKPyV miRNA molecules are highly abundant in urinary exosomes of 
patients diagnosed with PVAN and can be quantified using standard PCR methods. 
The diagnostic power of BKPyV miRNA is comparable to those of plasma and urine 
BKPyV viral load, suggesting that urinary exosomal miRNA could be used as a 
biomarker for the diagnosis of PVAN (Kim et al., 2017). 
Renal biopsy remains the gold standard for PVAN diagnosis and is obligatory in 
transplant recipients with a level of BKPyV viral load over than 4log copies/ml 
regardless of levels of serum creatinine (Sawinski and Goral, 2015). Renal biopsy as 
a screening method is challenging due to the fact that a negative renal biopsy cannot 
eliminate PVAN at early stages with 100% certainty. Although, the level of renal 
fibrosis and tubular atrophy appears to be the most predictive of renal graft clinical 
outcome (Masutani et al., 2012). Importantly, tubular cytopathic alterations and 
interstitial nephritis that are developed during PVAN can be focal or isolated solely to 
the medulla and missed on one third of renal biopsies if only a single core is tested 
(Drachenberg et al., 2004; Sawinski and Goral, 2015). Therefore, at least two cores 
including medulla should be extensively examined. In some reported cases, there is 
high suspicion of PVAN, although there are no cytopathic alterations on renal 
histology. For that reason, immunohistochemistry against BKPyV or cross-reacting 
SV40 TAg is suggested (Howell et al., 1999). 
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Table 1. 2 Screening methods for PVAN diagnosis. Four distinct methods that are currently used for 
PVAN diagnosis are represented and positive/negative predictive values, sensitivity and specificity of 
each method are also summarized. Adapted from Sawinski and Goral, (2015). 
 
 
 
Screening 
method 
Positive 
predictive value 
(%) 
Negative 
predictive value 
(%) 
Sensitivity (%) Specificity (%) 
Decoy cells  
(Hirsch et al., 
2002) 
29 100 25 84 
Haufen 
aggregates  
(Singh et al., 
2009) 
97 100 100 99 
BKPyV urine 
PCR  
(Hirsch et al., 
2002; Nickeleit 
et al., 2000; 
Kuppachi et al., 
2013) 
40 100 100 78 
BKPyV serum 
PCR 
(Hirsch et al., 
2002; Nickeleit 
et al., 2000; 
Kuppachi et al., 
2013) 
50-60 100 100 88 
BKPyV miRNA 
(urinary 
exosome) (Kim 
et al., 2017) 
- - 100 98.5 
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1.3.4 Therapeutic interventions for PVAN 
There are more than 100,000 patients in the USA in the waiting list for renal 
transplantation and in 2014 there were only 17,000 donor kidneys available for 
transplantation. Today there are approximately 5,000 people in the UK, waiting for a 
renal transplantation and around 3,000 donor kidneys are reported each year. 
Currently, there is no specific anti-viral therapy to treat PVAN and knowing that the 
level of immunosuppression is the main risk factor for the development of PVAN, the 
management of BKPyV infections is currently relied on reduction of 
immunosuppressive treatments (Mazalrey et al., 2015). Although, this may lead to 
acute allograft rejection (Johnston et al., 2010). Reduction of immunosuppressive 
drugs is applied in patients diagnosed with PVAN, histologically, as a curative 
treatment. It can also be applied in patients who are positive for BKPyV viremia, but 
not diagnosed with PVAN yet, as a pre-emptive treatment. Studies have proposed 
that pre-emptive treatment can be applied in patients with BKPyV plasma viral load 
higher than 104 DNA copies/ml (Hirsch et al., 2013). These therapeutic approaches 
include reduction or discontinuation of corticotherapy and the dose of other 
immunosuppressive drugs are reduced by 50% or switching to less potent drugs 
including Azathioprine, Sirolimus or Leflunomide and Cyclosporine A (Mazalrey et al., 
2015; Hirsch et al., 2013; Alméras et al., 2008; Saad et al., 2008; Trofe et al., 2004). 
Despite the lack of specific clinical treatment against BKPyV, there are some 
additional treatments which are used as adjuvant therapies alongside the 
immunosuppressive drugs and are based on their anti-viral activity in vitro (Lamarche 
et al., 2016; Ambalathingal et al., 2017). 
The acyclic deoxycytidine monophosphate analogue Cidofovir was first described for 
its anti-viral activity against cytomegalovirus (CMV), which impairs virus DNA 
replication (Mazalrey et al., 2015). Previous studies have reported that inhibition of 
BKPyV replication was observed in vitro upon Cidofovir treatment, although the drug 
shows significant cytotoxic effects (Bernhoff et al., 2008). Importantly, side effects of 
Cidofovir are observed in in vivo studies revealing significant nephrotoxicity (Kuypers 
et al., 2008). Brincidofovir (CMX001), is a lipid-conjugated derivative of Cidofovir and 
is internalized by cells similar to lysophosphatidylcholine. Following, cellular 
internalization Cidofovir is liberated from Brinicidofovir and become active after its 
phosphorylation. It is highlighted that Brincidofovir shows a greater anti-viral function 
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compared to Cidofovir in urothelial and human primary kidney epithelial cells and has 
a lower incidence of nephrotoxicity (Rinaldo et al., 2010; Marty et al., 2013; Tylden et 
al., 2015).  
The immunosuppressive drug Leflunomide is used as a treatment for rheumatoid 
arthritis (Mazalrey et al., 2015). This drug acts by blocking protein kinase activity and 
the synthesis of pyrimidines (Elder et al., 1997). Recent studies have established that 
Leflunomide can also be administered in renal transplant recipients to prevent chronic 
graft rejection and due to its low nephrotoxicity. It impedes BKPyV replication in vitro 
and reduces TAg expression (Bernhoff et al., 2010). Encouraging results have been 
seen in in vivo studies (Williams et al., 2005), although further validation by clinical 
studies is required (Mazalrey et al., 2015).  
Fluoroquinolones are antibiotics that target bacterial topoisomerases, however they 
can also have an activity against polyomaviruses (Sharma et al., 2011). It is known 
that Quinolones inhibit BKPyV replication in human renal proximal epithelial cells, due 
to the blockade of TAg as helicase as well as DNA topoisomerase (Sharma et al., 
2011). Studies have also identified that Fluoroquinolones impair SV40 replication in 
monkey kidney cells (Josephson et al., 2006). Initial non-randomized studies show 
encouraging reductions in BKPyV viral load of patients diagnosed with PVAN upon a 
combination treatment of Ciprofloxacin and Leflunomide (Zaman et al., 2014). 
Whereas, two more recent randomized controlled studies reported that Levofloxacin 
was not effective as either a curative (Knoll et al., 2014) or pre-emptive (Lee et al., 
2014) PVAN therapy. 
The mTOR inhibitor, Sirolimus, is used as an immunosuppressive drug due to its 
ability to impede IL-2 dependent T cell proliferation and its impact on TReg generation 
and T cell metabolic programming (Lo et al., 2014). However, Sirolimus can also 
decrease BKPyV TAg expression but not DNA replication in in vitro studies (Liacini et 
al., 2010a). 
Intravenous immunoglobulins have also been used as an adjuvant therapy for PVAN. 
Previous studies have proposed that immunoglobulins are capable of blocking BKPyV 
replication in human primary kidney cells (Randhawa et al., 2010; Randhawa et al., 
2015). Although, due to the high levels of existing and specific antibodies against 
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BKPyV in patients diagnosed with PVAN, intravenous immunoglobulins are not 
sufficient to control BKPyV replication. Furthermore, the efficacy of immunoglobulins 
is not fully understood as they are administered in combination with 
immunosuppressive drugs; therefore, further investigation by clinical trials is required 
(Mazalrey et al., 2015).  
Clinical trials are currently performed including treatments with BD03 from SL 
VAXIGEN. BD03 is a DNA vaccine that consists of 3 plasmid DNA molecules 
encoding for CMV and BKPyV antigens. It is expected to express antigen specific T-
cell immune response, and ultimately prevent activation of both viruses. Kidney 
transplant patients are receiving BD03 intramuscularly by electroporator three times 
on 6 weeks and 2 weeks prior to renal transplantation and up to 4 weeks after. The 
study completion date is eastimated in July 2019 (Clinicaltrials.gov, 2018). 
 
1.4 BK Polyomavirus (BKPyV) 
1.4.1 Epidemiology and transmission of BKPyV 
Epidemiology studies have reported that primary BKPyV infection occurs during 
childhood at a median age of 4-5 years (Shah et al., 1973; Knowles, 2001). It is 
identified that seroprevalence is lowest at the early age of 6 months after the loss of 
maternal antibodies and reaches to approximately 75% among adults (range 46-
94%), worldwide (Ambalathingal et al., 2017; Knowles, 2001). The natural route of 
virus transmission might be a respiratory route as viral DNA is present in tonsillar 
tissue (Goudsmit et al., 1982; Knowles, 2006). Additionally, there are other routes of 
transmission, including blood transfusion, urino-oral, fecal-oral and transplacental 
(Abend, et al., 2009). 
It is established that BKPyV persists for a lifelong infection and disseminates to the 
urinary tract (Heritage et al., 1981). Studies have shown that BKPyV DNA has been 
detected not only in the ureter, bladder and renal epithelial cells, but also in peripheral 
blood mononuclear cells, proposing that BKPyV might hijack host cell immune system 
to spread from the primary site of infection to its site of persistence (Chatterjee et al., 
2000). However, it is still poorly understood whether BKPyV enters a true state of viral 
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latency or maintain a minimal level of replication (Bennett et al., 2012). Doerries 
(2006) reported that BKPyV may be re-activated and detected in the urine of healthy 
individuals, periodically, which supports the evidence of an urino-oral infectious 
transmission route.  
Moreover, there are four distinct BKPyV genotypes: I, II, III and IV which present 
sequence variation in VP1 protein and correspond to specific serotypes, as well (Jin 
et al., 1993; Pastrana et al., 2013). Hemagglutination inhibition assays revealed that 
genotypes I, II, III and IV correspond to BK, SB, AS and IV serotypes, respectively 
(Knowles et al., 1989). Epidemiological studies have identified a correlation between 
geographical areas and BKPyV genotypes and subgroups within genotypes. BKPyV 
genotype I is the predominant and within this genotype, subgroup I/b-2 is mainly 
detected in European and American populations, although subgroup I/c-2 is primarily 
observed in Asian populations (Zhong et al., 2009). It still remains unclear whether 
there is any correlation between genotypes and clinical disease (Bennett et al., 2012). 
 
1.4.2 Cellular tropism of BKPyV 
Several different cell lines can be productively infected, in vitro, by BKPyV including 
simian and human kidney epithelial cells, endothelial cells, foetal neuronal cell lines, 
human fibroblasts and epithelial cells from salivary glands (Jeffers et al., 2009). 
Furthermore, BKPyV genomic DNA has been isolated, in vivo, from many different 
tissues such as salivary glands, the urothelium and renal epithelia, however kidney 
epithelial cells appear as the main reservoir of BKPyV persistent infection (Mazalrey 
et al., 2015). In addition, previous studies have identified the presence of BKPyV DNA 
in lymphocytes of both healthy and unhealthy individuals (Dolei et al., 2000; Azzi et 
al., 1996), supporting the evidences which show BKPyV receptors on the surface of 
lymphocytes (Possati et al., 1983). It is established that JCPyV can enter B-
lymphocytes so as to be transmitted to glial cells and not in order to be actively 
replicated. These findings proposed a model for JCPyV transportation across the 
blood-brain barrier of the human host (Chapagain and Nerurkar, 2010). Even though, 
the role of lymphocytes in a successful BKPyV infection has not been fully identified, 
a similar mechanism of transmigration in human hosts might occur in the case of 
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BKPyV. BKPyV might enter B-lymphocytes to transport from the initial site of infection 
to distant target tissues including renal epithelial cells and the urothelium. However, 
there is no experimental evidence indicating that BKPyV actively replicates in 
lymphocytes or that a cell-to-cell transmigration including lymphocytes has been 
identified (Mazalrey et al., 2015).   
 
1.5 Molecular Virology of BK Polyomavirus (BKPyV) 
1.5.1 Structure and Genome Organization 
BKPyV is a non-enveloped virus containing a double-stranded DNA genome, which 
is super-coiled with the host cell histone proteins H2A, H2B, H3 and H4 generating a 
minichromosome (Mazalrey et al., 2015; Fang et al., 2010; Wright and Di Mayorca, 
1975). It is established that infectious BKPyV particles have a diameter of 
approximately 45 nm and a density of 1.34 g/ml (Hurdiss et al., 2016; Seehafer et al., 
1975; Wright and Di Mayorca, 1975). 
Current resolutions of cryo-electron microscopy (EM) BKPyV virion structures range 
from 8 to 25 Å (Hurdiss et al., 2016; Li et al., 2003; Nilsson et al., 2005; Shen et al., 
2011; Li et al., 2015). A recent study solved the solution structures of native BKPyV 
virions and virus-like particles (VLPs) using single particle cryo-EM with a direct 
electron-detecting camera (Hurdiss et al., 2016). BKPyV virions and VLPs were 
detected at a resolution of 7.6 Å and 9.1 Å, respectively (Figure 1.4A). A more recent 
study determined the structure of BKPyV at a resolution of 3.8 Å (Figure 1.4B), using 
high-resolution cryo-EM and presenting the highest-resolution EM structure solved 
for any other human polyomaviruses to date (Hurdiss et al., 2018). These high-
resolution structures allowed the visualization of secondary structural motifs, including 
β sheets and α helices (Hurdiss et al., 2016). Moreover, differences between human 
pathogens and those that infect murine and simian hosts, including differences in how 
both disulphide bonds and C-terminal arms stabilize the capsid can be highlighted 
(Hurdiss et al., 2018).  
Previous studies of SV40 (Stehle et al., 1996) and murine polyomavirus (MPyV) 
(Stehle and Harrison, 1996) proved that both native virions and VLPs are isometric 
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particles. A more recent study reported that BKPyV virions and VLPs are isometric 
particles as well (Hurdiss et al., 2016). It is known that BKPyV capsids are composed 
of 360 molecules of VP1 forming 72 pentamers arranged in a T = 7d icosahedral 
symmetry stabilized by intra- and inter-pentameric disulphide bonds and Ca2+ cations 
(Nilsson et al., 2005). Furthermore, studies have demonstrated that there are six 
distinct conformations of VP1 in the BKPyV shell (Figure 1.4C) (Hurdiss et al., 2016; 
Hurdiss et al., 2018).  The pentamers are tied together using C-terminal arms, with 
each pentamer of VP1 interacting with five such arms to and from adjacent pentamers 
(Hurdiss et al., 2016). In addition to these pentamers found in the outer surface of 
BKPyV capsid, VP2 and VP3, the two other structural proteins, reside in the inner part 
of BKPyV virions (Hurdiss et al., 2016). Electron microscopy studies have also 
reported that there are bridges between VP2/VP3 proteins and the encapsidated 
double-stranded genomic DNA with packaged histone proteins (Figure 1.4D) (Hurdiss 
et al., 2016). Moreover, it is identified that there are bridges between the VP1 capsid 
and encapsidated double-stranded DNA situated beneath the N-termini of each of the 
six VP1 quasi-equivalent conformers (Hurdiss et al., 2016). 
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Figure 1. 4 Cryo-electron microscopy structures of native BKPyV virions and VLPs. A. External view of 
BKPyV native virion (left) (7.6 Å) and VLP (right) (9.1 Å) is presented at contour levels of 0.022 and 
0.009, respectively (Hurdiss et al., 2016). B. Isosurface representation of the 3.8 Å structure of BKPyV 
(Hurdiss et al., 2018). C. The architecture of a polyomavirus capsid showing how the T = 7d capsid is 
consisted of 72 pentamers of VP1, and an identical VP1 polypeptide is identified in six distinct quasi-
equivalent conformations in the capsid shell (1, red; 2, yellow; 3, green; 4, cyan; 5, blue and 6, gray) 
(Hurdiss et al., 2018). D. Enlarged view of a pyramidal density below each single VP1 penton. Strands 
of double-stranded DNA wrapped around a human histone octamer are represented. The density within 
6 Å of the fitted co-ordinates for SV40 VP1 is coloured grey. Density for VP2 and VP3 is coloured 
blue/green and for packaged double stranded DNA yellow/pink. Scales bars shown (Hurdiss et al., 2016).  
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The BKPyV genome is approximately 5,000 bp in size and replicates bidirectionally 
from a unique origin. It is composed of two regions, that are highly conserved, and 
coding for early and late proteins, located adjacent a non-coding control region 
(NCCR) of approximately 400 bp (Figure 1.5) (Helle et al., 2017). Large tumour 
antigen (TAg), small tumour antigen (tAg) and the truncated TAg (truncTAg) are 
encoded by the early genes and expressed by alternative splicing soon after infection 
of host cells and prior to genome replication. The late structural proteins VP1, VP2 
and VP3 and the non-structural protein, agnoprotein, are encoded by the late genes 
and expressed after the initiation of genome replication (Helle et al., 2017).  
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Figure 1. 5 Schematic representation of the BK Polyomavirus (BKPyV) genome. BKPyV genome is a 
double-stranded DNA molecule of approximately 5,000 bp and is organized in three main regions: the 
early region (on the left) encodes for the tumour antigens (TAg, tAg, trucTAg), the late region (on the 
right) expresses structural (VP1, VP2 and VP3) and non-structural (agnoprotein) proteins and the non-
coding control region (NCCR). Transcription of both early and late genes occurs in opposing directions. 
Solid arrows represent exons and dashed lines represent introns. The viral miRNA is transcribed from 
the late transcript. The archetype form of the NCCR (WW strain) is shown as a sequence of blocks 
(OPQRS) with the number of base pairs in each domain. Adapted from Mazalrey et al., (2015).  
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1.5.2 Non-coding control region (NCCR) 
The archetypal strains of BKPyV are predominately found in the urine of human 
individuals and are thought to be the transmissible form of the virus (Rubinstein et al., 
1987; Yogo et al., 2008). The NCCR of BKPyV archetypes consists of five distinct 
sequence regions starting from the O domain which is 142 bp in length and includes 
the origin of BKPyV genome replication and TATA-box. Then follows the P block of 
68 bp, the Q block which is 39 bp in length, the R block of 63 bp and the S block of 
63 bp in length is the last block. TATA-like elements and other regulatory regions that 
facilitate both early and late genes expression are contained in the PQRS blocks 
(Cubitt, 2006; Bethge et al., 2015; Bethge et al., 2016). In silico studies have reported 
approximately 30 different transcription factor binding sites, which might be contained 
in the NCCR (Bethge et al., 2015; Moens et al., 1995; Johnsen et al., 1995). There is 
evidence that Sp1 play a major role in regulation of early and late gene expression 
(Bethge et al., 2015; Bethge et al., 2016). It is identified that the number of binding 
sites, the strand orientation and the affinity of Sp1 transcription factor is critical for the 
bidirectional balance of early and late genes expression. Other studies have also 
highlighted the importance of NF-κB, NF1 and Ets-1 (Bethge et al., 2015; Gorrill and 
Khalili, 2005). Additionally, oestrogen-responsive elements, phorbol ester-, 
glucocorticoid/progesterone-, and cAMP can also control BKPyV transcription and 
replication (Moens et al., 1990; Moens et al., 1994).   
The NCCR varies considerably amongst different BKPyV isolates, even though 
protein coding sequences are highly conserved in most BKPyV strains. Therefore, 
the NCCR variety isolated from human kidneys is often associated with clinical 
complications (Cubitt, 2006). Duplications or triplications of P block are the most 
common re-arrangement of NCCRs observed, although variations of the neighboring 
O and Q blocks have been identified as well. Moreover, other variations such as 
deletions can occur within the P, Q, R and S blocks, however part or even the whole 
R block might be deleted in some cases. Studies have shown that most known 
variants tend to retain P and S blocks, suggesting the importance of these sequences 
(Moens and Van Ghelue, 2005). Nonetheless, all these important variations in the 
NCCR sequence lead to the creation or deletion of transcription factor binding sites 
(Bethge et al., 2015; Markowitz et al., 1990). Previous studies have established that 
a relatively weak early gene expression and a strong late gene expression are 
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benefited by the archetypal NCCR sequence, although the opposite phenomenon is 
observed in re-arranged NCCR forms regardless of deletions or insertions (Markowitz 
et al., 1990; Gosert et al., 2008).  
The architecture of NCCR might indicate the oncogenic potential and the cell tropism 
of BKPyV, in vitro (Johnsen et al., 1995). The ability amongst polyomaviruses to adapt 
to different environments might be reflected by the NCCR architecture. Additionally, 
a progressive number of re-arrangements of the BKPyV NCCR might be observed 
with the disease progression (Helle et al., 2017). It is determined that an increased 
BKPyV replication and cytopathology were detected in renal transplant recipients 
positive for BKPyV with a re-arranged NCCR form (Gosert et al., 2008). BKPyV with 
both archetypal or re-arranged form of NCCR can be isolated from patients who suffer 
from PVAN, whereas archetypal BKPyV is often detected in the urine for an unknown 
reason. Contrary, re-arranged forms of BKPyV are often isolated from plasma 
samples and are correlated with higher values of plasma viral loads (Gosert et al., 
2008). Moreover, it is identified that both the archetype and the re-arranged NCCR 
form of BKPyV have been detected not only in PVAN sufferers, but also in 
cerebrospinal fluid from neurological patients with suspected JCPyV infection 
(Barcena-Panero et al., 2012).  
The archetypal form of BKPyV replicates poorly in cell culture systems compared with 
the re-arranged strains (Helle et al., 2017). As such, these re-arrangements of the 
NCCR sequence might be critical for the virus adaptation which in turn are important 
for efficient growth in various cell types in cell culture (Moens and Van Ghelue, 2005). 
Other studies have also supported this hypothesis indicating that the NCCR sequence 
has a major impact on virus replication in vitro (Broekema et al., 2010). Furthermore, 
NCCR sequencing following viral amplification in vitro reveals duplications and/or 
deletions, that are not observed in NCCR sequences directly extracted from human 
urine samples (Rubinstein et al., 1987; Markowitz et al., 1990). A weak TAg protein 
expression from the archetypal BKPyV might be a limiting factor for the virus 
propagation as TAg overexpression is able to rescue genome replication (Broekema 
and Imperiale, 2012).  
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1.5.3 BKPyV proteins 
1.5.3.1 Early proteins 
TAg, tAg and truncTAg are expressed by the early region of the BKPyV genome 
through alternative splicing. After the removal of the first intron, the first and the 
second exons generate the TAg, which is a protein of approximately 80 kDa. 
Alternatively, retention of the first intron reveals the presence of a stop codon, allowing 
generation of tAg, which is translated into a protein of around 20 kDa. Therefore, TAg 
and tAg share the same first 82 amino acids but have unique carboxyl regions (Helle 
et al., 2017). Studies have also identified the expression of a third translation product, 
the truncTAg protein of approximately 17 kDa (Abend et al., 2009). truncTAg is 
generated from alternative splicing and the removal of a second intron from the mRNA 
product encoding for TAg. Therefore, truncTAg and TAg share the first 133 amino 
acids, but the additional slice leads to translation from a different reading frame, 
adding three new amino acids before reaching a stop codon (Abend et al., 2009).  
A nuclear localization signal (NLS) is contained in both TAg and truncTAg and as a 
result both proteins are detected in the nucleus (Helle et al., 2017). Studies have 
shown that both proteins contain a J domain in their N-terminus which exhibits high 
homology with members of the DnaJ family, the molecular chaperone proteins, which 
interacts with the heat shock cognate 70 co-chaperone (Hsc70) and plays a critical 
role in viral replication (Kelley and Georgopoulos, 1997; An et al., 2012; DeCaprio 
and Garcea, 2013). Another conserved LXCXE motif is contained in both TAg and 
truncTAg and this facilitates their interaction with pRb and the p107 and p130 family 
members (Harris et al., 1996; Harris et al., 1998). This interaction displaces pRb from 
the E2F transcription factor, transactivating genes associated with the S phase 
progression and DNA synthesis resulting in cell cycle progression and viral genome 
replication (Harris et al., 1996; Harris et al., 1998; An et al., 2012; DeCaprio and 
Garcea, 2013). 
The region of TAg that is unique compared to truncTAg, contains a Zinc-binding 
domain, an ATPase domain and a DNA-binding domain (DBD) providing a DNA 
helicase activity to TAg, which is critical for BKPyV genome replication (An et al., 
2012; DeCaprio and Garcea, 2013). The sequence GRGGC is present in the origin 
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of replication within the NCCR and is recognized specifically by the DBD of TAg. In 
addition, the interaction between DBD and the Replication Protein A (RPA) is critical 
for efficient viral amplification. The active helicase consists of TAg hexamers, formed 
by the Zinc-binding domain, and the energy that is required for helicase function is 
provided through the ATPase domain. Studies have also reported that the helicase 
domain can bind to the p53 tumour suppressor to block cell cycle arrest and apoptosis 
(An et al., 2012; DeCaprio and Garcea, 2013; Harris et al., 1996; Nakshatri et al., 
1988). 
In contrast to TAg, tAg can localize to both the cytoplasm and the nucleus. In 
additional to the N-terminal J domain, tAg contains a unique C-terminal region 
containing two zinc-fingers. Through this region, tAg inactivates proteins phosphatase 
2A and this supports cell cycle progression (An et al., 2012; DeCaprio and Garcea, 
2013). All these functions of both TAg and tAg implicating them in cell cycle events 
are primarily responsible for the potential cell transformation by BKPyV. There is 
evidence identifying BKPyV as a potential co-factor involved in human prostate 
cancers (Tognon and Provenzano, 2015). Furthermore, a recent study highlighted 
that BKPyV integrated into the human chromosomal DNA in a kidney graft tumour, 
showing strong TAg protein expression, interference of late genes expression and 
blockade of genome amplification (Kenan et al., 2015). Although, BKPyV is still 
characterized as potential carcinogenic to humans due to inadequate evidence (Helle 
et al., 2017). 
 
1.5.3.2 Structural late proteins 
The BKPyV structural proteins VP1, VP2 and VP3 are essential during the viral life 
cycle as they form the virus capsid necessary for virus entry and egress (Helle et al., 
2017). VP1 is the major capsid protein composed of 362 amino acids and 
approximately 42 kDa in mass. It is divided into five distinct loops, BC, DE, EF, GH 
and HI that bridge the strands of the protein (Teunissen et al., 2013). Pentamers of 
VP1 are located at the exterior of the capsid and it is demonstrated that VP1 loops 
play critical roles in capsid assembly (Dugan et al., 2007). BKPyV capsid has a quasi-
symmetry and is formed by 72 pentons of VP1 (Hurdiss et al., 2018). It is highlighted 
31 
 
that VP1 pentamers are composed of five β-barrel-shaped VP1 monomers that form 
a ring and are tightly linked through loops that interact with the frameworks of β-
strands (Hurdiss et al., 2016; Hurdiss et al., 2018). Moreover, it is identified that the 
N-terminal of VP1 protein is located in the interior of the virion and binds to the 
encapsidated viral DNA genome (Hurdiss et al., 2016). The C-termini of each VP1 
undergoing exchange with neighboring pentons to stabilize the capsid shell, adopting 
six distinct conformations that allow a single VP1 sequence to adopt all of the 
positions in a T = 7d lattice (Hurdiss et al., 2016; Hurdiss et al., 2018) (Figure 1.4). 
This is also supported by evidences stating that VP1 monomers lacking C-terminal 
region cannot form stable virus-like particles even though capsomers are formed 
(Teunissen et al., 2013).  
Studies have also shown that VP1 plays an essential role in viral attachment to host 
cell receptors of target cells. Site directed mutagenesis analysis revealed that there 
are key residues of VP1 protein sequence that are essential for several processes 
during the BKPyV life cycle including viral infectivity, binding to host cell receptor, 
entry, and assembly (Dugan et al., 2007; Neu et al., 2013). Studies have also reported 
that phosphorylation of Ser-80 of VP1 has been determined crucial for BKPyV 
propagation (Chen et al., 2011). Moreover, a shallow groove between BC and HI 
loops of BKPyV VP1 protein is predicted to be the receptor-binding site (Figure 1.6) 
(Jin et al., 1993; Dugan et al., 2007). Also, the epitopes which are responsible for the 
variation of the different BKPyV serotypes are located on BC loop (Jin et al., 1993). 
The VP1 subtyping region is located between amino acids 61 and 83 and is used as 
a tool to distinguish the different serotypes (Jin et al., 1993). A recent study by Morel 
et al., (2017) generated an algorithm to facilitate the recognition and confirmation of 
the 12 different BKPyV subtypes/subgroups based on a 100 bp-region located on 
VP1 sequence and called the BKPyV typing and grouping region.  
VP2 and VP3 are the minor capsid proteins and are approximately 38 kDa and 27 
kDa in mass, respectively. The same late mRNA transcript expresses both VP2 and 
VP3 protein and as a result, the C-terminal region of both proteins is common. The 
initiating AUG codon of VP3 is in-frame with the downstream initiating VP2 AUG 
codon, therefore VP3 is an N-truncated isoform of VP2 (Figure 1.5) (Schowalter and 
Buck, 2013). In related polyomaviruses such as SV40 and JCPyV, the VP2 N-
terminus is modified by the addition of myristic acid. Whilst BKPyV VP2 shares the 
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consensus myristoylation sequence including the critical glycine at residue 2, mass 
spectrometry studies have thus far failed to detect this modification (Fang et al., 
2010). Three important features reside in the common C-terminal region shared by 
VP2 and VP3 including a DNA-binding region, an NLS and the VP1-binding region 
(Henriksen et al., 2016). A single copy of either protein interacts with each VP1 
pentamer through hydrophobic interactions (Hurdiss et al., 2016). In addition, viral 
assembly or virion stability are not affected by the absence of both minor capsid 
proteins (Hurdiss et al., 2016; Teunissen et al., 2013). Stable VLPs consisted of VP1 
only, were able to transduce cell lines suggesting that the absence of either VP2 or 
VP3 did not impact on BKPyV capsid formation (Hurdiss et al., 2016). Contrary 
mutations in one amino acid of BKPyV VP2 (amino acid 229) and/or VP3 (amino acid 
110) negatively affect the viral replication cycle at a stage prior to DNA replication, as 
that impact was not noticed upon DNA transfection in RPTE cells (Henriksen et al., 
2016). Moreover, it is demonstrated that mutations of start codons of the BKPyV minor 
capsid proteins together or alone cause a reduction of infectivity by approximately 
99% in comparison with the wild-type (Henriksen et al., 2016). Similar results were 
also observed in experiments utilizing BKPyV pseudoviruses or mouse polyomavirus 
and SV40, JCPyV mutants lacking either VP2 or VP3 or both VP2/VP3, although the 
mechanism by which the minor capsid proteins facilitate virus infection remains 
controversial (Bagchi et al., 2015; Schowalter et al., 2012; Daniels et al., 2006; 
Gasparovic et al., 2006; Mannová et al., 2002).   
Daniels et al., (2006) suggested that SV40 minor capsid proteins promote the escape 
of the virus from the endoplasmic reticulum (ER). Other studies suggested that VP3 
is critical for ER escape, whereas the VP2 role is to direct transportation of the virus 
to the ER (Inoue and Tsai, 2011). Contrary, it is proposed that SV40 VP2 and VP3 
are critical for the nuclear import of the viral genome, and the virus escape occurs 
without the benefit of the minor capsid proteins (Nakanishi et al., 2007). In 2008, 
Merkel cell polyomavirus (MCPyV) was discovered and associated with Merkel cell 
carcinoma (Feng et al., 2008). MCPyV lacks VP3 protein, although both VP1 and VP2 
proteins are expressed (Schowalter and Buck, 2013). Studies utilizing both MCPyV 
and BKPyV pseudoviruses revealed the importance of minor capsid proteins on 
pseudovirion transduction (Schowalter and Buck, 2013). It is reported that VP2 is 
dispensable for MCPyV infectious entry in some cell types including UACC-62 cells 
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and SK-MEL-2 cells (melanoma cell lines), whereas it is required for the transduction 
of HEK293TT cells (embryonic kidney cells), NCI/ADR-RES cells (ovarian cancer 
line) and A549 cells (lung cancer line) (Schowalter and Buck, 2013). However, BKPyV 
pseudovirions transduction was significantly higher in the presence of all the structural 
proteins, highlighting the importance of the minor capsid proteins (Schowalter and 
Buck, 2013).  
Post-translational modifications of the structural proteins might be essential for 
different functions (Fang et al., 2010; Ponder et al., 1977). Key phosphorylated 
residues of polyomavirus VP1 have been detected at Ser-66, Thr-63 and Thr-156 (Li 
and Garcea, 1994; Li et al., 1995). Studies have demonstrated that mutations at that 
positions negatively affect the replication cycle of polyomaviruses (Li and Garcea, 
1994; Li et al., 1995).  Other studies have stated that specific post-translational 
modifications of both VP1 and VP2 might be crucial for BKPyV propagation (Chen et 
al., 2011). BKPyV VP1 is phosphorylated at Ser-80, Ser-133 and Ser-327, BKPyV 
VP2 at Ser-223 and Ser-254 and BKPyV VP3 at Ser-129, respectively. However, only 
the phosphorylation of Ser-80 of VP1 and Ser-254 of VP2, respectively, have been 
reported as crucial for BKPyV propagation since mutations at these specific positions 
led to inhibition of the replication cycle. Nevertheless, the mechanism of how 
phosphorylation of structural proteins contributes to regulation of BKPyV replication 
is still not clear (Chen et al., 2011).   
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Figure 1. 6 Crystal structure of a BKPyV VP1-GD3 oligosaccharide complex. Structure of a BKPyV VP1 
pentamer is shown in complex with GD3 oligosaccharide. One of the five VP1 monomer is represented 
in green. Monosaccharides are shown in orange and the other monomers in white. Adapted from Neu et 
al., (2013). 
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1.5.3.3 Non-structural late protein 
The agnoprotein is a small non-structural late protein. It possesses a highly basic 
amino acid composition with dominant Arg (R) and Lys (K) residues, which are 
detected in the amino and carboxy regions of the protein (Figure 1.7A) and is 
approximately 8 kDa in mass (Rinaldo et al., 1998; Leuenberger et al., 2007). The 
subcellular localization of agnoprotein is primarily in the cytoplasm during the later 
stages of the virus life cycle, although, is also detected in the perinuclear area and a 
small fraction is located in the nucleus (Rinaldo et al., 1998; Johannessen et al., 
2008). The central part of BKPyV agnoprotein contains a stretch of hydrophobic 
residues, including Ile, Leu and Phe and is predicted to form an α-helix (Figure 1.7A) 
(Gerits and Moens, 2012). This region is implicated in the formation of stable dimers 
and oligomers whose function is still not understood (Saribas et al., 2011; Saribas et 
al., 2016). The agnoproteins of BKPyV, JCPyV and SV40 share a high degree of 
homology, within the N-terminal region of the peptide (up to 83% identity between 
BKPyV and JCPyV) (Figure 1.7B) (Royle et al., 2015; Rinaldo et al., 1998). The crystal 
structure of agnoprotein has not been solved, however Coric et al., (2017) generated 
a nuclear magnetic resonance structure of JCPyV agnoprotein as Figure 1.7C shows, 
identifying the a-helical structure at the N-terminal and central regions. It also known 
that the SV40 Ri257 variant agnoprotein contains a hydrophobic region in the N-
terminal region, whilst an additional hydrophobic region is detected in the unique C-
terminal region (Gerits and Moens, 2012).  
Previous studies have identified that BKPyV and JCPyV agnoproteins undergo post-
translational modification such as phosphorylation on multiple serine and threonine 
residues (Ser-7, Ser-11, Thr-21 and Ser-64) (Figure 1.7A) (Johannessen et al., 2008; 
Sariyer et al., 2006). Studies have shown that both Ser-7 and Ser-11 are also 
detected in SV40, SV40 Ri257 variant and SA12 agnoprotein, whereas Thr-21 is 
conserved in SA12 agnoprotein, but replaced by Ser-21 in SV40 agnoprotein (Gerits 
and Moens, 2012). Single and/or double replacement of the key phosphorylation 
residues with Ala in JCPyV agnoprotein resulted to mutant viruses that failed to 
propagate (Sariyer et al., 2006). Similar results were also observed when Ser-11 
replaced with Ala in BKPyV agnoprotein (Johannessen et al., 2008), highlighting the 
importance of the phosphorylation sites to viral multiplication. Moreover, studies have 
indicated that phosphorylation not only impacts on viral propagation, but also on the 
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stability of the protein (Johannessen et al., 2008; Sariyer et al., 2006). Single T21A, 
double S7A/S11A, and triple S7A/S11A/T21A mutations cause an increase of 
expression levels of the mutant agnoprotein compared to the wild-type JCPyV 
agnoprotein, whereas BKPyV S11A agnoprotein was less stable than the wild-type 
protein (Johannessen et al., 2008; Sariyer et al., 2006). In addition to this, residue-
specific phosphorylation might control agnoprotein degradation. Phosphorylation of 
Ser-7 and Thr-21 may trigger JCPyV degradation (Sariyer et al., 2006). Hunter (2007) 
stated that phosphorylation can trigger a substrate’s ubiquitination and degradation 
by the proteasome. In silico studies have predicted that agnoprotein of different 
polyomaviruses contains putative lysine residues for ubiquitination, however it is not 
known whether phosphorylation of agnoprotein results in its subsequent degradation 
(Lee et al., 2011).  
Phosphorylation might also affect the subcellular localization of agnoprotein (Gerits 
and Moens, 2012). A putative Leu-rich nuclear export signal (NES) and a region of 
basic amino acids, which may represent a nuclear localization signal (NLS) are 
contained in BKPyV, JCPyV, SV40 and SA12 agnoproteins (Fu et al., 2011; Lange et 
al., 2007). Subcellular localization of a protein might be controlled by phosphorylation 
due to conformational changes that expose NLS or NES (Whitmarsh and Davis, 
2000). Studies have identified that JCPyV agnoprotein retained in the nucleus upon 
treatment with H89, a cAMP-dependent protein kinase/protein kinase A (PKA) (Okada 
et al., 2001). Other studies have demonstrated that there is a co-localization of BKPyV 
agnoprotein and lipid droplets and residues at positions 20-42 are required for this 
co-localization (Unterstab et al., 2010). Lipid droplets are highly dynamic organelles 
in a donut-like structures, consist of a hydrophobic core formed of neutral lipids 
(Unterstab et al., 2010), and they can travel along microtubules and interact with 
cellular organelles (Liu et al., 2007; Zehmer et al., 2009). Studies have identified that 
mutations within the hydrophobic domain, inhibited the lipid droplets targeting, 
whereas switching the Ser-11 phosphorylation site to aspartic acid or alanine did not 
affect the lipid droplets co-localization (Unterstab et al., 2010). At present, the role of 
agnoprotein in the context of lipid droplets remains speculative.  
BKPyV lacking agnoprotein, could infect Vero cells, however reduced propagation 
was observed compared to the wild-type BKPyV (Johannessen et al., 2008). A recent 
study in human renal epithelial cells demonstrated that BKPyV without agnoprotein 
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expression fails to release from host cells and does not propagate in culture to similar 
levels as wild-type virus. Although, they also proved that agnoprotein does not play a 
critical role in native virion infectivity or morphogenesis (Panou et al., 2018). Both 
studies confirmed that agnoprotein plays an important role in BKPyV life cycle. 
Moreover, BKPyV strains containing a deletion within NCCR and also lacking the 5’-
end of the agnoprotein peptide cannot release infectious viral progeny. However, 
rescue assays with agnoprotein exogenously added showed that production and 
release of infectious virions were recovered (Myhre et al., 2010). Additionally, there 
is evidence suggesting that JCPyV agnoprotein destabilizes the nuclear envelope to 
facilitate native virion nuclear release (Okada et al., 2005). For this, the N-terminal 
region of JCPyV agnoprotein interacts with Heterochromatin Protein 1α (HP1α) and 
due to this interaction, the lamin B receptor cannot interact with HP1α (Okada et al., 
2005). Interestingly, despite the high homology between JCPyV and BKPyV 
agnoprotein, BKPyV agnoprotein does not cause gross destabilization of the nuclear 
membrane in human primary renal epithelial cells. Immunofluorescence microscopy 
revealed that Lamin B localization was unaffected in both wild-type containing cells 
and cells lacking agnoprotein (Panou et al., 2018).  
Several host cellular proteins interact with agnoprotein to favour BKPyV infection, 
including p50, p75 and p100 (Rinaldo et al., 1998). Johannessen et al., (2011) 
demonstrated an interaction between the N-terminal region of BKPyV agnoprotein 
and the α-soluble N-ethylmaleimide-sensitive fusion attachment protein (α-SNAP) 
using a yeast two-hybrid assay. α-SNAP (33 kDa in mass) is required for the 
disassembly of vesicles during secretion (Johannessen et al., 2011). Similar findings 
were also confirmed recently by Panou et al., (2018). In this study, interaction 
between α-SNAP and BKPyV agnoprotein was confirmed using glutathione S-
transferase pull down assays with recombinant agnoprotein and cell lysates from 
primary renal epithelial cells. The necessity of α-SNAP for a successful BKPyV egress 
was also shown in this study (Panou et al., 2018). Moreover, BKPyV DNA 
amplification is inhibited due to the interaction between the proliferating cell nuclear 
antigen (PCNA-35 kDa in mass) and agnoprotein (Gerits et al., 2015). Agnoprotein is 
also involved in DNA repair after DNA damage as it can control the DNA damage-
induced cell cycle by binding directly to the DNA repair enzyme Ku70 (Darbinyan et 
al., 2004). Studies have additionally highlighted that agnoprotein can negatively 
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control both early and late gene translation (Gosert et al., 2008). These findings 
agreed with the observation that both late and early proteins expression was 
increased in cells lacking BKPyV agnoprotein (Johannessen et al., 2008; Panou et 
al., 2018). Thus, agnoprotein appears to be a multifunctional protein associated with 
viral transcription, replication, assembly and release, although its role remains 
enigmatic in many processes.  
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Figure 1. 7 Primary and NMR structure of JCPyV agnoprotein. A. Schematic representation of primary 
structure of JCPyV agnoprotein. The Leu/Ile/Phe-rich domain is highlighted. Phosphorylation sites at key 
residues (Ser-7, Ser-11 and Thr-21) are also indicated. P stands for phosphorylation (Saribas et al., 
2013). B. Conserved sequences of BKPyV, JCPyV and SV40 agnoproteins. Residues are presented 
using amino acid single letter codes. Conserved residues are displayed in red through to unconserved 
residues in blue. * represents a residue conserved in all three agnoproteins’ sequences (Royle et al., 
2015). C. NMR structure of JCPyV agnoprotein is shown. Two α-helices were shown between Leu-6 and 
Lys-13 and from Arg-24 to Phe-39. α-helices are represented in green. Two more unstructured regions 
were also shown between Val-14 and Lys-23 and from Cys-40 to Thr-71. These two domains are 
represented in red. In some NMR structures a third α-helix is formed between Glu-43 and Ser-45 (Coric 
et al., 2017). 
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1.5.3.4 Putative VP4 protein 
A very late protein named as VP4 is encoded by SV40 and is generated from a 
downstream AUG start codon located within the sequence of VP2. Consequently, all 
VP2, VP3 and VP4 proteins share a common C-terminal sequence (Daniels et al., 
2007). It is proposed that VP4 is implicated in SV40-mediated cell lysis and the egress 
of viral progeny. Interestingly, a corresponding VP4 open reading frame was detected 
in the BKPyV genome (Daniels et al., 2007). A more recent study confirmed that 
BKPyV genome contains the putative VP4 and two even smaller proteins, the putative 
VP5 and VP6 which all share a common C-terminal region (Figure 1.8) (Henriksen et 
al., 2016). The role of BKPyV VP5 and VP6 is still not identified. However, Henriksen 
et al., (2016) failed to detect VP4 in BKPyV infected cells by mass spectrometry and 
in further experiments were unable to demonstrate a role for VP4 in SV40 (Henriksen 
et al., 2016). Thus, the role of VP4 in SV40 infection is still not clear.  
 
 
Figure 1. 8 Schematic representation of BKPyV minor capsid proteins. BKPyV VP2 and VP3 and the 
putative proteins are shown. Highlighted regions and motifs are derived from the UntiProtKB database 
and the VP4 hydrophobic domain is represented by similarity to SV40 VP4. Adapted from Henriksen et 
al., (2016).  
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1.5.4 BKPyV microRNA molecules 
JCPyV, BKPyV and SV40 genome encode a pre-miRNA hairpin, which can generate 
two distinct miRNAs, the 3p-miRNA and 5p-miRNA that are complementary to mRNA 
molecules transcribed from the viral early genes (Seo et al., 2008). Initially, it was 
suggested that these miRNAs control expression of early genes at later stages of viral 
infection due to cleavage of the complementary early viral mRNA molecules. That, 
subsequently, could decrease the sensitivity of SV40 infected cells to cytotoxic T cells 
(Sullivan et al., 2005). Although, further studies demonstrated that these miRNAs 
regulate the expression of early mRNA transcripts before genome amplification 
(Broekema and Imperiale, 2013). The sequences in the NCCR control the miRNA 
expression in a trend similar to late mRNA transcripts. As a result, early mRNAs in 
archetype viruses are weakly expressed and targeted for degradation by the robustly 
translated miRNAs. As a consequence, DNA amplification is limited in archetype 
viruses. In contrast, high levels of early mRNA transcripts cannot be sufficiently 
degraded in re-arranged strains as miRNAs are weakly expressed (Helle et al., 2017). 
The miRNAs can also target cellular genes, in particular the stress-induced ligand 
ULBP3 is recognized by the killer receptor NKG2D and can be targeted by both 
BKPyV and JCPyV 3p-miRNA (Bauman et al., 2011). Viral miRNA induced down-
regulation of ULBP3 leads to decreased NKG2D-mediated eradication of virus-
infected cells by natural killer cells. This might explain a potential mechanism of viral 
latency and how BKPyV escapes the host immune system. Thus, miRNA molecules 
might be of great importance for viral persistence (Broekema and Imperiale, 2013). 
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1.6 BK Polyomavirus (BKPyV) life cycle 
An infectious native BKPyV virion needs to attach to the host cell receptor to initiate 
the virus life cycle. This interaction leads to internalization of the virus into the host 
cell to exploit the host cell machinery for its favour. BKPyV navigates through the 
cytoplasm exploiting host cell factors en route the nucleus. Once BKPyV reaches the 
nucleus transcription of early genes, genome replication and transcription of late 
genes occur. Finally, infectious viral particles are assembled, and newly generated 
viral progeny are released from host cells to infect neighboring ones. 
 
1.6.1 BKPyV-host cell receptor attachment 
BKPyV infection initiates with the binding of VP1 pentamers to host cell receptor 
molecules. Polysialylated gangliosides are the candidates host cellular receptors for 
BKPyV (Sinibaldi et al., 1990; Low et al., 2006). Gangliosides are glycosphingolipids 
and are abundantly found in host cell membranes. The carbohydrate moiety ceramide 
is a component of gangliosides, which consists of two arms with one or more sialic 
acid residues (Groux-Degroote et al., 2017). Gangliosides are also defined as GM, 
GD and GT describing the mono-, di- and trisialogangliosides, respectively. Sialic 
acids that are found on gangliosides are usually located in α(2, 3)-binding to 
galactosyl residues or in α(2, 8)-binding to other sialic acids. The conserved α(2, 8)-
disialic acid motif located on the right arm of b-series gangliosides is the critical and 
minimal binding epitope for BKPyV, with the variable left arm contributing some 
additional contacts (Neu et al., 2013). GD3, GD2, GD1b and GT1b are b-series 
gangliosides that interact with BKPyV, whereas a-series gangliosides such as GM1 
cannot interact with native BKPyV virions (Neu et al., 2013; Low et al., 2006) (Figure 
1.9). A very recent study using high-resolution cryo-EM determined the structure of 
native BKPyV virions bound to the ganglioside GT1b at a 3.4 Å resolution, which is 
the highest resolution of a polyomavirus with the host cell receptor bound up to date 
(Hurdiss et al., 2018) (Figure 1.10). The binding mode of GT1b is similar to GD3, an 
oligosaccharide that lacks the left arm. This study revealed bridges between Asp-59 
and Lys-83 of BKPyV VP1 and the GT1b receptor (Hurdiss et al., 2018), which was 
previously shown in other studies (Neu et al., 2013). It is also indicated that α(2, 3)-
43 
 
linked sialic acid is crucial for BKPyV as its enzymatic removal from cells results in 
blockade of BKPyV infection (Dugan et al., 2005). They also reported that inhibition 
of N-linked glycosylation reduces BKPyV infection, however that is not observed after 
inhibition of O-linked glycosylation. Therefore, N-linked glycoprotein consisted of an 
α(2, 3)-linked sialic acid might be an essential host cellular co-receptor for BKPyV 
(Dugan et al., 2005). 
Genotype BKPyV-Ia uses GT1b or GD1b oligosaccharides as an entry receptor (Low 
et al., 2006). A study was performed to examine whether all BKPyV genotypes require 
gangliosides for internalization (Pastrana et al., 2013), utilizing murine GM95 cells 
which lack gangliosides (Ichikawa et al., 1994). Cells were transduced with 
pseudovirions of each BKPyV variant in the presence or not of exogenous GT1b 
ganglioside. It is demonstrated that only BKPyV-Ic, -II and -III variants were highly 
responsive to ganglioside supplementation. BKPyV-Ib2 show a modest increase of 
the transduction, while exogenous GT1b supplementation had no impact on BKPyV-
IV (IVb1 and IVc2) variant (Pastrana et al., 2013). Therefore, BKPyV-IV transduces 
the murine GM59 cells through a ganglioside-independent internalization pathway. 
Similar experiments performed in other cell lines, including A549 and ART (ovarian 
cancer cell line NCI/ADR-RES stably transfected with SV40 TAg) cells with GM3 
synthase knocked down. Knockdown of GM3 synthase cause inhibition of BKPyV-IV 
transduction, suggesting that gangliosides were required for an infectious entry of 
BKPyV-IV in A549 and ART cells (Pastrana et al., 2013). Thus, BKPyV-IV follows 
different entry pathways in different cell lines showing distinct cellular tropisms.  
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Figure 1. 9 BKPyV binds to GD1b and GT1b. Schematic representation of GM1, GD1b and GT1b 
gangliosides. Ceramide (Cer) is presented in yellow; Glucose (Glc) in green; Galactose (Gal) in grey; N- 
acetyl- galactosamine (GalNAc) in blue; Sialic acid (SA) in pink. Adapted from Low et al., (2006). 
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Figure 1. 10 The structure of BKPyV: GT1b host cell receptor molecule. A. Representation of the 3.4 Å structure of BKPyV native virion, in complex with GT1b shown 
in magenta. B. Representation of a single 5-fold pentamer of the BKPyV: GT1b complex. C. Enlarged view of the GT1b containing the atomic model for the disialic 
motif of the GT1b right arm. Adapted from Hurdiss et al., (2018).
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1.6.2 Internalization of BKPyV 
BKPyV enters host cells after the initial binding to cellular receptors. BKPyV 
internalization into Vero cells occurs in a manner independent of clathrin-coated-pit 
assembly but through a caveolae-mediated endocytosis (Eash et al., 2004). 
Dominant-negative mutants of caveolin 1 and Eps15 were used to deconstruct 
caveolin and clathrin-dependent endocytosis, respectively. Similar findings were 
observed in RPTE cells suggesting that BKPyV is internationalized into the most 
physiologically relevant cell line by a caveolae-mediated endocytic pathway 
(Moriyama et al., 2007; Moriyama and Sorokin, 2008). Time-of-addition assays also 
revealed that infectious BKPyV particles are localized in a neutralizing compartment 
between 2-4 hours post-infection (Eash et al., 2004) and co-localization of caveolin 1 
with BKPyV peaked approximately 4 hours after infection (Moriyama et al., 2007).  
Caveolae- and clathrin-mediated endocytosis are two major well-characterized 
pathways that form small endocytic vesicles, however there are other alternative 
endocytic pathways that are not dependent on caveolin or clathrin-coated pit (Figure 
1.11) (Mayor and Pagano, 2007). Caveolin 1, 2 and 3 belong to a cholesterol binding 
proteins family with caveolin 1 and 2 abundantly expressed in cells including epithelial 
cells, and caveolin 3 in muscle cells (Murata et al., 1995). Studies have demonstrated 
that only caveolin 1 is required for caveolae formation (Drab et al., 2001; Razani et 
al., 2002). Previous studies have identified that BKPyV, SV40 and murine 
polyomavirus use caveolae-mediated endocytosis to enter host cells (Pelkmans et 
al., 2001; Richterova et al., 2001). However, JCPyV internalizes host cells via a 
clathrin-mediated endocytic pathway (Pho et al., 2000). The clathrin protein complex 
is composed of three light and three heavy chains (Fotin et al., 2004). Clathrin 
complexes are not able of interacting with plasma membrane directly, therefore 
adaptor proteins are essential to recruit clathrin complexes on the membrane. Then, 
the clathrin coated pit with the help of dynamin forms clathrin-coated vesicles 
(Hinrichsen et al., 2003). 
A recent study re-examined the BKPyV entry process in RPTE cells (Zhao et al., 
2016). Silencing of clathrin heavy chain, caveolin 1 and 2 and UDP-Glucose 
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Ceramide Glucosyltransferase (UGCG) using siRNA molecules revealed that BKPyV 
requires gangliosides, although enters RPTE cells in a caveolin- and clathrin-
independent endocytic pathway (Zhao et al., 2016). There have been identified 
several caveolin- and clathrin-independent endocytic pathways that could be utilized 
by BKPyV for an infectious entry implicating RhoA GTPases (Lamaze et al., 2001), a 
Cdc42-based actin machinery (Chadda et al., 2007), ADP-ribosylation factor (ARF) 6 
(Radhakrishna and Donaldson, 1997) and flotillin (Glebov et al., 2006). Taken 
together that polyomaviruses enter tight fitting vesicles following endocytosis (Damm 
et al., 2005; Drachenberg et al., 2003) and actin is not essential for a BKPyV infectious 
entry (Eash and Atwood, 2005), Zhao et al., (2016) suggested that BKPyV is more 
likely to enter RPTE cells by a yet undefined endocytic pathway, since most of the 
previously mentioned pathways require actin polymerization. 
It is also possible that BKPyV uses a lipid-dependent endocytic pathway in which 
cholesterol and gangliosides might be required (Zhao et al., 2016). In vitro studies 
have demonstrated that caveolae-like vesicles, named giant unilamellar vesicles, can 
be formed by artificial liposomes with gangliosides and cholesterol alone (Bacia et al., 
2005). Ewers et al., (2010) indicated that SV40 was able to cause invaginations on 
the surface of these vesicles, highlighting that polyomavirus successful entry might 
be mediated via a protein-independent pathway. In that case, tight fitting vesicles 
could be structured by direct interactions between the VP1 major capsid protein and 
gangliosides, with cholesterol facilitating the stabilization of the vesicle membrane 
invagination (Zhao et al., 2016). The distinct BKPyV endocytosis process is still 
controversial, thus further studies are required. 
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Figure 1. 11 Endocytic pathways followed into host cells. A. Virus internalization by the host cell via 
caveolae, which are specialized lipid rafts that form flask-shaped invaginations of the plasma membrane. 
Caveolins form the structural backbone of caveolae. Internalized viruses bound to their host cell receptor 
are transported to the early endosome. B. Clathrin-mediated endocytosis is triggered by the binding of 
the virion to host cell receptors. This induces the binding of an adaptor protein to the receptor cytoplasmic 
tail, which allows clathrin to multimerize to form characteristic invaginations or Clathrin-coated pit (CCP). 
Membrane scission proteins pinch off the CCP from the host membrane thereby releasing the Clathrin-
coated vesicle (CCV). Following the vesicle delivers its viral content to early endosomes. C. Several 
pathways that do not use a caveolin or clathrin coat are hijacked by viruses to enter host cells. These 
pathways can be further defined by their dependency to various molecules such as cholesterol, small 
GTPases and non-caveolar lipid rafts (Gasteiger et al., 2003). 
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1.6.3 Trafficking of BKPyV through the Endoplasmic Reticulum 
Following endocytosis, BKPyV might enter the endosomes of host cells (Zhao and 
Imperiale, 2017). BKPyV native and infectious virions traffic to smooth tubular 
structures adjacent to rough endoplasmic reticulum (ER) based on findings using 
transmission electron microscopy (Drachenberg et al., 2003). Pharmacological 
experiments demonstrated that BKPyV relies on an intact microtubule network and 
not on an intact actin cytoskeleton in both Vero and RPTE cells (Eash and Atwood, 
2005; Moriyama and Sorokin, 2008; Jiang et al., 2009). Microtubules are cytoskeletal 
filaments composed of α- and β-tubulin dimers and their function is to define 
intracellular structure for the maintenance of cell shape and motility, intracellular 
transport of vesicles, molecules and granules between organelles (Moriyama and 
Sorokin, 2008). Microtubule dynamics consist of growing and shrinking of tubulin 
dimers at microtubule ends (Moriyama and Sorokin, 2008). Studies have shown that 
BKPyV can move along the microtubules, but their dynamics are not essential for the 
virus transportation in Vero cells (Eash et al., 2004; Eash and Atwood, 2005). Studies 
performed pharmacological analysis using nocodazole and colchicine as microtubule 
disrupting agents and paclitaxel as microtubule dynamics disrupting agents to identify 
their requirement on BKPyV transportation in RPTE cells. Findings revealed that 
BKPyV transportation is relied on intact microtubules and on microtubule dynamics in 
RPTE cells (Moriyama and Sorokin, 2008). Additionally, studies have identified that 
BKPyV intracellular transportation is dynein-independent. These discrepancies might 
be observed as BKPyV transportation was investigated in different cell lines in these 
studies. Another factor that is associated with intracellular transportation of vesicles 
is the motor proteins, dynein and kinesin, which facilitate cargo transportation along 
microtubules (Moriyama and Sorokin, 2008). Dynein is a minus-end microtubule 
motor protein attached to the microtubule organizing centre (MTOC) and is identified 
to transport several viruses including adenovirus, herpes simplex virus, rabies virus 
and vaccinia virus (Greber and Way, 2006; Leopold and Pfister, 2006; Radtke et al., 
2006). Studies have demonstrated that there was no correlation between BKPyV 
transportation and dynein activity (Moriyama and Sorokin, 2008). Similar findings 
were observed with JCPyV and SV40 (Ashok and Atwood, 2003), indicating that 
members of Polyomaviridae might be transported along microtubules independently 
of dynein function. 
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During endocytosis a pH-dependent step occurs at a very early stage of BKPyV life 
cycle, during the first 2 hours post-infection. This was identified using lysosomotropic 
agents such as ammonium chloride and chloroquine, indicating that acidification and 
maturation of endosomes are critical for a successful BKPyV infection in RPTE cells 
(Eash et al., 2004; Jiang et al., 2009). Following to this, BKPyV co-localizes with 
caveolin 1 at 4 hours post-infection, suggesting that BKPyV is found in caveosome, a 
pH-neutral compartment at this stage of the life cycle (Moriyama et al., 2007). 
Treatments with brefeldin A (BFA) and Retro-2cycl, two agents that inhibit retrograde 
transport to the ER, showed a decrease of BKPyV protein expression. However, co-
localization of BKPyV with markers of the Golgi apparatus was not observed. Taken 
together these findings proposed that BKPyV traffics through the ER, although 
bypasses the Golgi apparatus in its natural host cells (Low et al., 2006; Moriyama et 
al., 2007; Moriyama and Sorokin, 2008; Jiang et al., 2009; Nelson et al., 2013). Co-
localization of BKPyV with markers of ER and time-of-addition experiments using 
brefeldin A showed that BKPyV reaches ER approximately 8-10 hours after infection 
(Moriyama and Sorokin, 2008; Jiang et al., 2009). Similar findings were observed with 
other polyomaviruses including SV40 and murine polyomavirus (Bernacchi et al., 
2004; Gilbert et al., 2003; Norkin et al., 2002; Tagawa et al., 2005), however the 
course of BKPyV infection in RPTE cells is relatively slow. Studies have shown that 
SV40 is co-localized with caveolin 1 at 0.5 hours post-infection and is detected at the 
perinuclear region approximately 4 hours after infection in CV-1 cells (Pelkmans et 
al., 2001). Whereas, murine polyomavirus is co-localized with caveolin 1 at 0.5 hours 
post-infection, is transported along microtubules at 2 to 4 hours and reaches the ER 
at 4 hours after infection in rat glioma cells (Gilbert and Benjamin, 2004). 
A recent study using a whole human genome siRNA screen identified key host cell 
factors that are associated with BKPyV late-endosome-to-ER transportation in RPTE 
cells (Zhao and Imperiale, 2017). Rab18, ZW10, RINT1 and syntaxin 18 were 
identified as critical host factors for a successful BKPyV infection in RPTE cells (Zhao 
and Imperiale, 2017). Rab18 has been linked in vesicular transportation between the 
ER and the Golgi apparatus and lipid droplets homeostasis (Dejgaard et al., 2008; Liu 
and Storrie, 2012). Studies have shown that Rab18 is primarily detected on the 
membranes of cis-Golgi apparatus and ER (Dejgaard et al., 2008). Moreover, Rab18 
can be detected on the surface of other organelles including the endosomes, the 
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lysosomes and lipid droplets (Zhang et al., 2016; Zhang et al., 2017). Affinity 
chromatography and mass spectrometry analyses revealed that Rab18 interacts with 
RINT1, ZW10 and syntaxin 18 (Gillingham et al., 2014). It is also established that 
RINT1 and ZW10 interact through each other N-terminal region and with NAG protein 
construct the NRZ complex. Syntaxin 18, a t-SNARE protein, located on the ER 
membrane binds to the NRZ complex indirectly (Tagaya et al., 2014; Hirose et al., 
2004; Çivril et al., 2010). Zhao and Imperiale (2017) identified that silencing of Rab18 
cause BKPyV accumulation in the late endosomes, suggesting that Rab18 mediates 
late-endosome-to-ER transportation of BKPyV and transportation along microtubules 
together with the virus-containing vesicles. After the NRZ complex located on the ER 
surface captures and tethers vesicles to the ER surface, a yet-to-be-identified v-
SNARE interacts with syntaxin 18 on the vesicles and in turn this complex promotes 
vesicle fusion to the ER membrane allowing entry of BKPyV into ER (Figure 1.12) 
(Zhao and Imperiale, 2017). More details of the Rab18-mediated pathway are still not 
known, thus further studies are required to fully define the BKPyV retrograde 
endocytic pathway. 
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Figure 1. 12 Schematic representation of BKPyV vesicular transportation. BKPyV internalizes a vesicle 
from the membrane of the endosome. Rab18 located on the membrane of endosomes, interacts with 
ZW10 kinetochore protein and RAD50 interactor 1 (RINT1), which are members of the NRZ complex, 
forming a Rab18/NRZ/syntaxin (STX18) complex at the ER surface. STX18 functions as a t-SNARE on 
the ER membrane, where the NRZ components work as a tether to assist with retrograde vesicle 
docking. Another yet-to-be-identified v-SNARE protein, located on endosomal membranes, interacts with 
STX18 to facilitate the vesicle fusion to the ER membrane and the release of BKPyV virions into the ER 
of infected RPTE cells. Adapted from Zhao and Imperiale (2017). 
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1.6.4 Release from the ER and nuclear entry 
Viruses must penetrate host cell membranes in order to reach the nucleus, where 
replication and assembly of viral progeny occurs (Inoue et al., 2015). The non-
enveloped viruses have a distinct mechanism by which viruses penetrate the host cell 
membrane. In that case, non-enveloped virus is transported to the site for penetration 
and undergoes conformational changes mediated by host cell factors and 
environments including a low-pH microenvironment, reductases, proteases and 
chaperones (Inoue et al., 2015). These changes might, in turn, expose hydrophobic 
domains of the native virions or release small lytic peptides that were not exposed 
before (Chandran et al., 2002; Walczak and Tsai, 2011). Then, this hydrophobic viral 
intermediate disrupts the integrity of the lipid bilayer facilitating its cross of the 
membrane, which in some cases is mediated by host cellular machineries (Walczak 
et al., 2014).  
A distinct feature of polyomaviruses is the trafficking through the ER during the entry 
process. Blockade of BKPyV transportation to the ER impacts on VP1 cleavage and 
disulphide bond isomerization (Jiang et al., 2009). Studies have shown that an ER 
reductase, ERdj5, acts synergistically with Protein Disulphide Isomerase (PDI) to 
decrease the disulphide bonds in SV40 capsids (Inoue et al., 2015). Based on these 
findings, it is likely that BKPyV exploits the disulphide isomerases, reductases and 
chaperones localized in the ER for further uncoating of the capsid and viral ER-to-
cytosol trafficking (Helle et al., 2017). Studies have also demonstrated that ERdj5 
cooperates with PDI to promote structural alterations to SV40, which are required for 
SV40 to interact with the ER membrane protein BAP31 (Inoue et al., 2015). This 
interaction in turn promotes SV40 ER-to-cytosol translocation (Inoue et al., 2015). A 
summarized model describing how ERdj5 and PDI mediate SV40 penetration of the 
ER membrane is shown in Figure 1.13 (Inoue et al., 2015).  
The ER-associated protein degradation (ERAD) pathway and proteasome have been 
strongly linked with BKPyV trafficking into the cytoplasm from the ER compartment 
(Dupzyk and Tsai, 2016). Under normal circumstances, the ERAD pathway is 
required for transportation of misfolded protein out of the ER compartment for 
degradation by the proteasome. This process implicates several proteins including 
membrane J-protein, membrane proteins of Derlin families, Hsp70 and Hsp110. 
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Inhibition of the ERAD machinery and proteasome, using pharmacological 
compounds impeded BKPyV infection and as a result partially uncoated BKPyV 
virions with exposed VP2/VP3 proteins accumulated in the ER of infected RPTE cells 
(Bennett et al., 2013). Time-of-addition experiments using epoxomicin, a potent 
blocker of the chymotrypsin-like activity of the proteasome (Meng et al., 1999) 
revealed that BKPyV no longer required proteasome function after approximately 18 
hours post-infection. This suggested that BKPyV traffics through the ER between 8 to 
16 hours post-infection (Bennett et al., 2013), which is also in agreement with previous 
studies in the same cell line (Jiang et al., 2009). The role of ERAD pathway was also 
examined independently from the proteasome function by using Eeyarestatin I 
(Bennett et al., 2013). Eeyarestatin I inhibits the AAA-ATPase p97, which is upstream 
of the proteasome as a component of the ERAD pathway and provides the driving 
energy for extraction of ERAD substrates from the ER (Wang et al., 2008; Wolf and 
Stolz, 2012). Similar inhibition kinetics were observed with Eeyarestatin I and 
epoxomicin, suggesting that proteasome acts as part of the ERAD pathway to allow 
BKPyV to exit from the ER (Bennett et al., 2013). Interestingly, VP1 monomers can 
enter the cytoplasm from the ER irrespective of the inhibition of ERAD machinery and 
proteasome function (Bennett et al., 2013). Bennett et al., (2013) proposed that some 
infectious viral particles might be trapped within the ER when ERAD is blocked, even 
though VP1 monomers can still enter cytosol. Before membrane penetration, the ER-
resident Hsp70 Bip is recruited to maintain the hydrophobic BKPyV intermediate in a 
soluble state (Inoue and Tsai, 2015; Goodwin et al., 2011). Studies have also 
identified that Grp170, a Nuclear Exchange Factor (NEF), by converting ADP-BiP to 
ATP-BiP, the release of ER-localized BKPyV is triggered (Inoue and Tsai, 2015). It is 
also known that Derlin-1, an ER membrane component interacts with VP1 and is 
implicated in the ER-to-cytoplasm trafficking, however the exact contribution to the 
process is not clear (Jiang et al., 2009). Then, a cytosolic complex composed of SGTA 
proteins and Hsp105 might be recruited for BKPyV translocation to the cytoplasm 
(Ravindran et al., 2015; Walczak et al., 2014).  
There is conflicting evidence for the nuclear entry mechanism of polyomaviruses. 
Partial uncoating might give the virus a smaller shape enough for active transport 
through the nuclear pore complex (Panté and Kann, 2002). It is demonstrated that 
there is direct interaction between the SV40 chromosome and importins α and β in 
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the cytosol indicating that SV40 uses the canonical nuclear import pathway for its 
entry (Nakanishi et al., 2002; Nakanishi et al., 2007). The nuclear localization signal 
(NLS) of a protein is recognized and bound to the adaptor proteins, importins α and 
β. NLS of SV40 VP2 and VP3, located in their C-terminus interact with the importins 
showing that SV40 transported through the nuclear pore complex and via the 
canonical nuclear import machinery (Nakanishi et al., 2002; Nakanishi et al., 2007). 
However, other studies have reported that SV40 infection cause a breakdown of the 
nuclear lamina and in turn disruption of the nuclear envelope permitting SV40 to pass 
from the ER directly into the nucleus (Butin-Israeli et al., 2011). 
BKPyV capsid proteins have extensive homology with the SV40 proteins. Bennett et 
al., (2015) identified that a Lysine located in the C-terminal region of VP2/VP3 is 
critical for the nuclear localization of the minor capsid proteins. The significance of 
NLS involves the classical importin α/β 1 pathway for nuclear entry. Inhibition of 
BKPyV infection was observed after knocking down of importin 1 and in the presence 
of ivermectin, a nuclear import inhibitor, supporting the hypothesis that BKPyV enters 
the host nucleus using the NLS of the minor capsids (Bennett et al., 2015). Ivermectin 
is known to target specifically only the importin α/β 1-mediated pathway and not 
others importin β- or transportin-mediated pathways (Wagstaff et al., 2012). Importin 
α recognizes the NLS and then importin β interacts with the NLS-importin α complex 
to mediate transport through the nuclear pore (Yoneda et al., 1999).  
Studies have proposed alternative entry pathways existing along with nuclear import 
through the nuclear pore. Bennett et al., (2015) demonstrated that mutation in BKPyV 
VP2/VP3 NLS resulted in attenuated infectivity. Butin-Israeli et al., (2011) proposed 
that cytosolic viral particle may enter the nucleus during mitosis, when nuclear 
envelope breaks down. In addition, BKPyV might utilize an alternative NLS from 
VP2/VP3 NLS. Studies have shown that VP1 contains an NLS, although is considered 
to be hidden within the partially disassembled particle (Ishii et al., 1996; Moreland and 
Garcea, 1991). Treatment with ivermectin blocked the wild-type virus to similar level 
as the mutant, therefore the mutant virus still uses the canonical nuclear import 
pathway indicating the use of another viral NLS potentially (Bennett et al., 2015). 
Thus, BKPyV internalizes host nucleus via the nuclear pore complex, but another 
pathway of entry might exist as well.  
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Figure 1. 13 Schematic representation of ERdj5- and PDI-dependent conformational changes of SV40. 
After reaching the ER, SV40 is delivered to subdomains containing BAP31, called foci (Step 1). ERdj5 
decreases disulphide bonds of SV40, while PDI is likely to unfold the viral particle. These two processes 
mediate conformational changes generating a hydrophobic viral core particle (Step 2). The altered 
hydrophobic virus binds to BAP31, where positioned to cross the ER membrane to reach the cytosol 
(Step 3). Adapted from Inoue et al., (2015). 
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1.6.5 BKPyV Gene expression and Genome replication 
Polyomavirus replication has been extensively studied in the context of SV40, which 
is closely related to BKPyV. The BKPyV genome enters the host nucleus, early viral 
genes generate early mRNA molecules. Following this, early proteins are produced 
in the cytoplasm and TAg, containing the NLS, traffics into the nucleus. Both SV40 
and BKPyV TAg regulate cell cycle progression and halts the process of apoptosis 
due to its interactions with the pRb and p53 tumour suppressors (Figure 1.14A). This 
interaction leads to an inability to sequester E2F transcription factors which ultimately 
results in G1/S-phase transition and activation of the host cell DNA machinery, which 
is required for BKPyV genome amplification (Helle et al., 2017). The mitogen-
activated protein (MAP) kinases are critical in several processes and include the 
extracellular signal related kinases ERK-1 and ERK-2 (Seamone et al., 2010). 
Signaling via ERK1/2 is a crucial element that promotes transition to S-phase and 
cellular proliferation (Liu et al., 2004; Mansour et al., 1994). The activation of ERK1/2 
signaling pathway leads to upregulation of cyclin D1, which in turn phosphorylates 
pRb and triggers G1/S-phase transition (Lavoie et al., 1996). Studies demonstrated 
that MAP kinase signaling increases BKPyV genome replication in vitro (Seamone et 
al., 2010). It is also identified that BKPyV, did not promote ERK1/2 phosphorylation 
or cyclin D1 expression in vitro (Seamone et al., 2010). However, the inhibition of 
cyclin D1 function decreased BKPyV genomic replication, suggesting that ERK1/2 
signaling pathway acts synergistically with TAg (Seamone et al., 2010). Another 
signaling pathway that plays an important role in BKPyV replication is the protein 
kinase Akt (Akt)/mammalian target of rapamycin (mTOR) pathway (Tikhanovich and 
Nasheuer, 2010). Akt is a serine/threonine kinase, also known as protein kinase B, 
and is activated by cytokines, mitogens and growth factors (Fayard et al., 2010). The 
mTOR signaling pathway is downstream of Akt and regulates protein synthesis, cell 
growth and division. There are two mTOR complexes; mTOR complex 1 (mTORC1),  
which regulates initiation of translation and mTOR complex 2 (mTORC2), which 
controls cytoskeletal changes and is also known as a 3’-phoshoinositide-dependent 
kinase-2 (PDK2) phosphorylating Akt (Bhaskar and Hay, 2007). Tikhanovich and 
Nasheuer, (2010) identified that BKPyV infection leads to activation of the Akt/mTOR 
signaling pathway in RPTE cells. Whereas, inhibition of mTORC1 after treatment with 
Sirolimus led to decrease of BKPyV TAg expression. Moreover, blockade of PKD1 
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and Akt phosphorylation was observed upon treatment with Leflunomide, which 
ultimately led to decrease of BKPyV TAg expression and genomic replication (Figure 
1.14B). 
Moreover, cell cycle progression is also controlled by tAg through the blockade of 
protein phosphatase 2A enzyme activity. This interaction results in increased cyclins 
D and A, and downregulation of p27, factors in the control of cell cycle progression 
into the G1/S-phase (Bennett et al., 2012) (Figure 1.14C). The multifunctional BKPyV 
TAg is required for viral genome amplification, as a viral DNA polymerase is not 
encoded. It is known that the host cell supplies all of the other factors that are essential 
for genome replication (Helle et al., 2017). Viral genome amplification is initiated by 
TAg due to its ability to bind to GRGGC motifs within the origin of replication, forming 
two distinct hexamers, which show a helicase function and exhibit an orientation 
head-to-head. Then, the double-stranded genomic DNA is separated by TAg double 
hexamer and replication protein A (RPA) is recruited to bind to single-stranded DNA 
molecules. Topoisomerase I is also present to promote the separation of genomic 
DNA. Furthermore, DNA polymerase α-primase generated short RNA primers, which 
are elongated by the enzyme complex of DNA polymerase. RPA, replication factor C, 
proliferating cell nuclear antigen (PCNA), DNA polymerase α-primase and DNA 
polymerase δ are then recruited in order to complete the leading and lagging single-
strand of genomic DNA (Tikhanovich and Nasheuer, 2010; Tikhanovich et al., 2011).  
Studies have also identified that BKPyV disrutps the expression of several host genes 
(Grinde et al., 2007; Abend et al., 2010). Particularly, BKPyV infected cells are 
protected from BKPyV-induced host DNA damage response due to activation of the 
cellular DNA damage response through ataxia telangiectasia mutated (ATM) and 
Rad3-related (ATR) kinases by viral genome replication (Jiang et al., 2012; Verhalen 
et al., 2015). Severe DNA damage is observed during BKPyV infection in the absence 
of ATM and/or ATR kinase. In addition, BKPyV replication causes a dramatic re-
structuring of Promyelocytic Leukemia Nuclear Bodies (PML-NBs) as a decrease in 
PML-NBs number and an increase in size were observed (Jiang et al., 2011). It is of 
great importance that PML-NBs are localized adjacent to BKPyV DNA foci during later 
stages of a successful infection and this re-organization might reveal a mechanism of 
inactivation of PML-NBs intrinsic antiviral activities which is utilized by BKPyV. Late 
proteins expression occurs following genome replication and is facilitated by the 
60 
 
activation of transcription from the late promoter and controlled by TAg (Helle et al., 
2017). 
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Figure 1. 14 Schematic representation of signaling pathways involved in BKPyV life cycle. A. BKPyV, JCPyV and SV40 TAg interacts with p53 leading to inactivation 
of p53 and downregulation of p21 that eventually impacts on the release of E2F. E2F is liberated from pRb:E2F by the interaction of TAg with pRb resulting to the 
transition of G1 to S phase of the cell cycle. Adapted from (Reiss and Khalili, 2003). B. Growth factors and mitogens activate the Akt/mTOR signaling pathway 
through the PDK1 phosphorylation of Akt. Akt indirectly activates mTOR. mTOR exists in two protein complexes, mTORC1 which phosphorylated p70 and 4-EBP1 
to initiate protein translation and mTORC2 which phosphorylates Akt. This in turn activates Akt. mTOR also blocks PP2A. mTORC1 is inhibited by Sirolimus and 
Leflunomide blocks PDK1 and Akt (Liacini et al., 2010). C. BKPyV inactivates the activity of PP2A leading to upregulation of Cyclin A and D and downregulation of 
p27, which in turn result in cell cycle progression. Adapted from Bennett et al., (2012). 
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1.6.6 BKPyV assembly and progeny release 
Following the synthesis of late proteins in the cytoplasm, newly generated proteins 
are translocated into the nucleus for virion assembly. NLS contained in VP1 is critical 
for protein import into the nucleus and for VP1-VP2 and VP1-VP3 complexes, 
respectively (Bennett et al., 2015). Interactions between VP1 and chaperone proteins 
located in the cytoplasm might inhibit assembly of pre-mature virions. Studies have 
shown that production of progeny virions can be detected in host RPTE cells’ nucleus 
approximately 2 days after infection (Low et al., 2004). Renal biopsies from patients 
diagnosed with PVAN contain approximately 6000 BKPyV progeny virions per 
infected cell (Hirsch and Steiger, 2003). 
The mechanism of BKPyV release is not fully understood, although non-enveloped 
viruses, such as BKPyV, might be released through passive lysis. Τhere is recent 
evidence for a range of non-enveloped viruses suggesting that passive lysis might 
not always be the case. It is identified that poliovirus promotes the formation of 
autophagosome-like vesicles that are associated with viral egress (Taylor et al., 
2009). Parvovirus Minute Virus of Mice (MVM) has been shown to be released 
through late endosomal or lysosomal vesicles (Bär et al., 2008). Interestingly, a recent 
study suggested that a non-lytic egress of BKPyV from infected RPTE cells occurs 
(Evans et al., 2015). This route of release is impaired by treatment with 4, 4’–
diisothiocyano-2, 2’–stilbenedisulfonic acid (DIDS). DIDS is an anion channel 
inhibitory agent that impacts on cellular secretion pathways (Evans et al., 2015). 
Treatment with DIDS traps BKPyV virions in acidic compartments of lysosomal or late 
endosomal-origin compartments (Evans et al., 2015). Currently, the target of DIDS 
responsible for virion egress is not clear. However, previous studies have 
demonstrated that a lytic replication cycle occurs in BKPyV infected RPTE cells (Low 
et al., 2004). Moreover, cytopathic effects are observed in SV40 infected cells and 
not in BKPyV infected cells (Henriksen et al., 2016). As it is previously mentioned 
(Section 1.5.3.3), agnoprotein plays a critical role in viral progeny egress. The 
mechanism of BKPyV release is controversial and there are conflicting evidences, 
thus further studies are required to fully define it. 
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A schematic representation (Figure 1.15) of BKPyV life cycle is shown, below, 
summarizing the most critical stages as described.  
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Figure 1. 15 Schematic representation of BKPyV life cycle. (1) BKPyV infectious virions attach to host 
cell receptor, and especially GD1b, GT1b and/or N-linked glycoprotein with an α-(2, 3)-linked sialic acid. 
(2) BKPyV is internalized into the host cells during the first 4 hours post-adsorption potentially through a 
caveolin- or clathrin-indepedent endocytic pathway. (3) Then the virus traffics to the endoplasmic 
reticulum (ER), where is detected around 10 hours after infection. (4) In the ER, BKPyV is partially 
uncoated exposing VP2/VP3 proteins from the viral capsid. ER-associated protein degradation (ERAD) 
machinery is involved in the release of partially uncoated BKPyV. (5) The NLS of VP2/VP3 and the 
importin α/β1 import pathway are linked with the transportation of BKPyV genome into the nucleus. (6) 
Early genes expression occurs approximately 24 hours after infection. (7) BKPyV genome replication is 
initiated after the early proteins translocation into the nucleus to facilitate the process. (8) Late genes are 
translated. (9) Self-assembly of VP1, VP2 and VP3 proteins into the nucleus occurs to form capsids. 
Genomic DNA is encapsidated into the newly synthesized capsid. (10) Viral progeny is released mainly 
by cell lysis or (11) A potential non-lytic egress of virions might occur (Helle et al., 2017).
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1.7 Renal Ion Channels 
Ion channels are transmembrane proteins that create a pore to permit the influx and 
efflux of ions by passive diffusion. Most ion channels are susceptible to 
conformational changes when they switch from the closed to open states. Opening of 
the channel permits the passage of ions across the membrane (Jentsch et al., 2004). 
Voltage, post-translational modifications like phosphorylation and the binding of 
specific ligands including neurotransmitters or intracellular Ca2+ are all factors that 
regulate the opening and closing of ion channels. Most ion channels have a function 
as protein complexes of either homologous or identical subunits that act 
synergistically to form the pore. These are often involved with other channel-specific 
subunits that are structurally unrelated and might control the function of ion channels 
(Jentsch et al., 2004).  
Ion channels in renal epithelial cells are associated with the maintenance of cell 
volume and ion composition not only of the epithelial cells but also of the entire 
organism. Maintaining the balance of ion composition is dependent on transepithelial 
ion transportation, a mechanism that implicates ion channels at the basolateral and/or 
apical cell membranes (Palmer and Sackin, 1988). Potassium (K+) channels can 
regulate a broad spectrum of cellular processes, including neurotransmitter release, 
insulin secretion, cell volume regulation, T-cell stimulation and heart rate. Also, by 
controlling K+ secretion and maintaining the right levels of K+ into cells, several cellular 
processes can be activated or inhibited (Giebisch, 2001). There have been identified 
two different broad classes of K+ channels based on transmembrane topology 
including: the six-transmembrane-helix voltage-gated (Kv) and the two-
transmembrane-helix inward-rectifier (Kir) subgroups (Miller, 2000). Renal epithelial 
sodium (Na+) channel (ENaC) regulates the Na+ reabsorption via the distal nephron 
in kidneys. Blood volume, blood pressure and Na+ balance are all controlled by ENaC. 
In contrast, dysregulation of ENaC leads to essential hypertension, the main cause of 
cardiovascular mortality and morbidity. ENaC is composed of three partly 
homologous subunits (Sagnella and Swift, 2006; Warnock and Rossier, 2005). In 
addition, calcium (Ca2+) channels have significant tubular and vascular effects on 
renal cells. Renal blood flow, electrolyte excretion and increase of glomerular filtration 
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rates are included in these renal effects (Chan and Schrier, 1990). Voltage-gated Ca2+ 
channel subtypes, including N-, T-, L- and P/Q-type, can be found in kidneys. Studies 
have shown that blockade of these channels creates diverse actions on renal 
microcirculation (Hayashi et al., 2007). Furthermore, several chloride (Cl-) channels 
are involved in a various range of renal physiological procedures, including cell 
volume regulation, transepithelial Cl- transport, vesicular acidification and regulation 
of the excitability of neurons (Nilius and Droogmans, 2003). There are several distinct 
Cl- subfamilies: the Glycine receptors; the transmitter-gated GABA; the voltage-
sensitive ClC subfamily; the Ca2+-activated channels; the high-(maxi) conductance 
channels; the cystic fibrosis transmembrane conductance regulators (CFTR) and the 
volume-regulated channels (Verkman and Galietta, 2009). Most of the subfamilies are 
well defined, although the role of glycine receptors and GABA remains poorly 
characterized (Devuyst and Guggino, 2002). 
 
1.8 CFTR ion channels  
1.8.1 CFTR localization 
One of the major roles of mammalian kidneys is to maintain the concentration of 
extracellular sodium chloride, which in turn controls blood pressure and extracellular 
fluid volume (Morales et al., 2000). Chloride anions (Cl-) are re-absorbed along the 
nephron and are the predominantly glomerular infiltrate. Transportation of Cl- occurs 
through several transmembrane proteins, the ion channels (Morales et al., 2000). 
Many Cl- channels have been extensively studied and some of them have been 
directly linked with severe clinical complications (Jentsch, 1994; Lehmann-Horn and 
Jurkat-Rott, 1999; Sasaki et al., 1994). Cystic fibrosis (CF) is a lethal autosomal 
recessive genetic disorder, which is caused by mutations within the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene. The cftr gene expresses an 
integral membrane protein, which is a member of the ABC transporter family and 
localized in a variety of epithelia such as the renal tubules (Riordan, 1993).  
CFTR is abundantly expressed in kidneys of both rats and humans and is greater 
expressed in renal cortex and outer renal medulla kidney areas in comparison with 
other areas (Morales et al., 1996). Particularly, CFTR protein was detected at the 
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apical surface of both distal and proximal tubules of rat kidneys, although there was 
no expression in the outer medullary collecting ducts (Crawford et al., 1991). In human 
kidneys, CFTR protein is detectable in several areas, including distal and proximal 
tubular cells, collecting duct, the thin limbs of Henle’s loop and the branching ureteric 
bud (Crawford et al., 1991; Morales et al., 1996; Devuyst et al., 1996). Studies have 
demonstrated that despite the fact that CFTR is a plasma membrane ion channel, in 
proximal tubular cells, CFTR is localized in intracellular organelles along the endocytic 
and secretory pathways. CFTR might regulate pH by importing Cl- into endocytic 
vesicles equilibrating H+ accumulation (Bradbury, 1999).  
 
1.8.2 CFTR as an intracellular chloride channel 
Regulation and maintenance of an acidic environment within intracellular organelles 
controlled by CFTR ion channels is controversial (Bradbury, 1999; Edwards and Kahl, 
2010). It is identified that living cells have developed mechanisms to control the pH 
inside organelles and within the cytoplasm. Several studies performing biochemical 
and functional analyses have identified acidic intracellular compartments, such as 
secretory granules, endosomes, lysosomes and some compartments of the Golgi 
apparatus (Bradbury, 1999).  
Lipophilic weak bases and fluorescent dextrans have been utilized to study and 
measure vacuolar acidification (Anderson et al., 1991; Maxfield, 1982; Mellman et al., 
1986). Internal pH of endosomes has been estimated between 5.0 and 6.0. However, 
this range might vary as probes such as FITC-dextran is transported from less to more 
acidified endosomes after initial internalization (Geisow and Evans, 1984; Tycko and 
Maxfield, 1982; Haggie and Verkman, 2009). Moreover, the lysosomal acidic 
environment ranges between 4.6-5.0 (Haggie and Verkman, 2009; Tycko and 
Maxfield, 1982). 
Proton pumps (H+-ATPases) are strongly associated with vesicular acidification as 
they not only create a ΔpH across the organelle membrane, but also cause a distinct 
membrane potential ΔΨ because of the proton transportation (Bradbury, 1999; 
Forgac, 2007). H+-ATPases create a membrane potential and inhibition of further 
proton transportation and creation of ΔpH occur if the proton permeability of the 
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subcellular membrane organelle is low. Whereas, the presence of CFTR localized 
within the membrane of intracellular organelles permits Cl- transportation into the 
organelles, functioning to collapse the membrane potential and promote vesicular 
acidification (Figure 1.16) (Bradbury, 1999; Tamir et al., 1994; Jouret et al., 2007). 
Lysosomes and endosomes in different cell types may contain K+ conductance in 
order to facilitate acidification (Galloway et al., 1983; Harikumar and Reeves, 1983; 
Hover et al., 2018).  
Findings suggested that Cl- conductance can regulate vesicular pH, although protein 
kinases have been identified to regulate subcellular Cl- transportation and 
consequently acidification process as well (Bradbury, 1999). Endosomal Cl- channels 
are regulated in a tissue and organelle-specific manner. Cl- channels of endosomes 
contained in renal cells are controlled by protein kinase A and a decrease in 
endosome acidification was observed upon treatment with phosphatases that 
counteract the function of PKA (Reenstra et al., 1992).  
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Figure 1. 16 Schematic representation of organelle acidification mechanism. Vesicular proton pumps are 
localized in the subcellular membrane and generate a membrane potential (ΔΨ) and a pH gradient 
inhibiting proton transportation and acidification (left). Chloride ion channels, such as CFTR, collapse 
subcellular membrane potential and permit organelle acidification (right). Adapted from Bradbury, (1999). 
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1.8.3 Structure and function of the CFTR ion channel 
CFTR belongs to the ABC transporter family and works as an ion channel and not as 
an active transporter like other members of the family (Bear et al., 1992). Sulfonylurea 
receptor (SUR) is also member of the ABC family and does not function as an active 
transporter (Souza-Menezes and Morales, 2009). 
The human cftr gene is localized within chromosome 7 (7q31.2) and encodes for a 
protein of approximately 1,480 amino acids (Knowlton et al., 1985; Morales et al., 
1999). Studies have demonstrated that CFTR consists of an intracellular N-terminal 
arm, six transmembrane-spanning domains (TMD1), which are linked with a 
nucleotide-binding domain (NBD1) containing sequences for ATP binding (Morales et 
al., 1999). NBD1 is followed by a regulatory domain (R), which contains sequences 
capable of being phosphorylated by PKA and PKC (Chen and Hwang, 2008). This is 
followed by a second set of six transmembrane-spanning domains (TMD2) and a 
nucleotide-binding domain (NBD2) (Figure 1.17) (Souza-Menezes and Morales, 
2009). A recent study revealed the molecular structure of the human CFTR ion 
channel (Figure 1.18) (Liu et al., 2017).  
The main trigger for CFTR activity in vivo is its phosphorylation by PKA and PKC 
(Sheppard and Welsh, 1999). Studies have reported that CFTR opening rate is 
increased by the addition of PKA in the presence of MgATP and burst duration is also 
increased under phosphorylating conditions, suggesting that phosphorylation sites 
control CFTR channel closing (Mathews et al., 1998; Wang et al., 2000). Five distinct 
Ser (Ser-700, Ser-737, Ser-768, Ser-795 and Ser-813) residues are phosphorylated 
by PKA in the R domain in vivo (Hegedűs et al., 2009) and specifically Ser-737 and 
Ser-768 are argued to be inhibitory on the basis of the observation that their disruption 
increases CFTR channel activity (King et al., 2009). In contrast, unphosphorylated R 
domain blocks CFTR channel opening (Hwang and Kirk, 2013), although the 
mechanism of how phosphorylation impacts on this inhibition is still unclear. 
Similar to other ABC transporters, the NBDs of CFTR are able to form a dimmer 
(Vergani et al., 2005). Moreover, there are two distinct binding pockets for ATP (ABP). 
ABP1 contains the Walker A and B consensus sequences of NBD1 and the signature 
sequence of NBD2, whereas ABP2 consists of the signature sequence of NBD1 and 
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Walker A and B motifs contained within NBD2 (Chen and Hwang, 2008). Binding of 
ATP to NBDs causes the close interaction of the two NBDs and the locking of two 
ATPs in the NBD1 and NBD2 interface (Gadsby et al., 2006). Due to this interaction, 
the signal transmission occurs through cytoplasmic-linking domains, and the channel 
gate opens (Gadsby et al., 2006). The channel remains open until hydrolysis of one 
of the ATPs, which results in the separation of NBD1 and NBD2 interface (Gadsby et 
al., 2006). Closure of the ion channel gate abolishes Cl- flux until binding of ATP to 
the NBDs of CFTR occurs again (Gadsby et al., 2006) (Figure 1.19).  
CFTR is critical not only for Cl- transportation but also for regulation of other 
transporters, which might be crucial for epithelia and strongly associated with 
transportation of several ions. Stimulation of an outward rectifying Cl- channel, ORCC, 
and blockade of the epithelial Na+ channels, ENaC, occur due to CFTR function 
(Fulmer et al., 1995; Schwiebert et al., 1998; Kunzelmann et al., 2001).  
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Figure 1. 17 Schematic representation of CFTR ion channel located in the plasma membrane. CFTR 
consists of two distinct sets of transmembrane-spanning domains, TMD1 and TMD2; two distinct 
nucleotide-binding domains, NBD1 and NBD2; a regulatory domain, R; a N-terminal domain, N and a 
carboxy-terminal domain, C (Souza-Menezes and Morales, 2009). 
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Figure 1. 18 Structure of human CFTR ion channel in a dephosphorylated and ATP-free confirmation 
state. Electron microscopy structure of human CFTR are represented with the EM densities shown in 
red corresponding to unstructured areas within the R domain or the R insertion of NBD1. Dashed lines 
represent unresolved structures (Liu et al., 2017).  
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Figure 1. 19 CFTR channel gating. A simplified diagram presenting dominant gating transitions from Step 
1 to Step 4, including the engagement and disengagement of the two TMDs and NBDs. Adapted from 
Hwang and Kirk, (2013). 
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1.8.4 CFTR and regulation of ROMK ion channel activity in kidneys 
The renal outer medullary potassium (ROMK) ion channel is critical for restoration of 
K+ levels in the lumen of thick ascending limbs of Henle’s loop (TAL) and K+ excretion 
in the cortical collecting duct (CCD) of human kidneys (Wang et al., 1997) (Figure 
1.20). ROMK is a member of the inward-rectifier K+ channels or Kir. All members of 
this ion channel subfamily share common features, including two transmembrane 
domains, the cytoplasmic N- and C-terminal regions and a conserved selectivity filter 
for K+ (Welling and Ho, 2009).  
Restoration of K+ across the apical membrane of TAL is crucial for NaCl reabsorption, 
which consequently results in accumulation of solutes in the renal medulla (Hebert 
and Andreoli, 1984; Greger, 1985). Three distinct significant processes are 
associated with K+ restoration in kidneys. K+ recycling causes hyperpolarization of cell 
membrane, which following leads to Cl- dissemination across the basolateral 
membrane. Furthermore, transepithelial Na+ reabsorption is regulated by K+ 
restoration due to the generated lumen-positive potential. Moreover, K+ are provided 
to Na-K-Cl co-transporter because of K+ recycling (Giebisch, 1998; Souza-Menezes 
and Morales, 2009). It has been identified that K+ transportation across the apical 
membrane of the CCD is controlled by ROMK ion channel (Wang, 1999).  
Previous studies have shown that inhibition of the ABC transporter family member 
SUR by the pharmacological agent Glibenclamide results in inhibition of ROMK2, an 
isoform of ROMK (Inagaki et al., 1995). Based on these findings, an accessory protein 
might be important for the function of ROMK2. According to Aguilar-Bryan et al., 
(1998) both subtypes of SUR, SUR1 and SUR2, interact with ROMK2 although there 
is no expression of SUR1 or SUR2 in kidneys. Fuller and Benos, (1992) suggested 
that CFTR is abundantly expressed in kidney epithelial cells and might form a renal 
low-conductance ATP-sensitive K+ channel with the ROMK ion channel. It is also 
demonstrated that the presence of Glibenclamide impedes the function of ROMK2, 
when ROMK2 is co-expressed with CFTR (McNicholas et al. 1996). Further 
investigations revealed that NBD1 of CFTR ion channel is critical for the interaction 
between ROMK2 and CFTR (McNicholas et al., 1997). Additional studies have 
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demonstrated that ROMK1 was not sensitive to Mg-ATP, whereas in the presence of 
CFTR, the ion channel sensitivity to ATP changed (Ruknudin et al., 1998). These 
findings proposed that CFTR might be critical in human kidneys, where ROMK ion 
channels are also expressed (Souza-Menezes and Morales, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 20 Structure of a human nephron. Schematic representation of a human nephron showing its 
different parts (Pocock and Richards, 2006).   
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1.8.5 CFTR ion channel inhibitory compounds 
Open channel blockers were the first CFTR inhibitory compounds (Schultz et al., 
1999; Hwang and Sheppard, 1999). These compounds act physically by entering the 
open pore of the channel and temporally blocking of Cl- flow (Linsdell, 2014). Inhibitors 
that share this common mechanism of CFTR ion channel inhibition are sulfonylureas 
including Glibenclamide, diphenylamine-2-carboxylate (DPC) and 5-nitro-2-(3-
phenylpropyl-amino) benzoate (NPPB) (Figure 1.21) (Verkman et al., 2013). 
Glibenclamide is one of the most widely utilized compound for Cl- inhibition and is 
identified as an antidiabetic drug, which targets ATP-sensitive K+ channels in 
pancreatic islet beta cells (Verkman et al., 2013).  
Biophysical analysis of these compounds revealed details about the mechanism of 
their action. Each inhibitor binds to sites inside the pore only from the cytoplasmic end 
causing a voltage-dependent blockade, which is stronger in more hyperpolarized 
voltages. However, the channel inhibition is affected by the extracellular Cl- 
concentration. At low extracellular Cl- concentration, the ion channel inhibition is 
stronger, whereas at higher Cl- is weaker (Linsdell, 2014). Previous studies have also 
suggested that CFTR might possess an asymmetric structure since inhibitors reach 
the pore of the channel only from the cytoplasmic side. The narrow extracellular 
entrance does not permit the entry of larger compounds, although the inner side is 
accessible for substances from the cytoplasm (Hwang and Sheppard, 1999; Linsdell 
and Hanrahan, 1996).  
Other studies have identified novel inhibitors with a more potent effect on CFTR 
(Figure 1.19) (Verkman and Galietta, 2009). Thiazolidinone, CFTR172, blocks CFTR 
ion channel from the cytoplasmic side at a sub-micromolar level (Ma et al., 2002) and 
in a voltage-independent manner (Taddei et al., 2004; Kopeikin et al., 2010). 
Furthermore glycine hydrazides, such as GlyH-101, impact on CFTR ion channel in 
a voltage-dependent manner from the extracellular environment and at a low 
micromolar concentration (Muanprasat et al., 2004). These two recent identified 
compounds cause inhibition of CFTR ion channel by a different mechanism in 
comparison with the open channel blockers (Linsdell, 2014). In particular, CFTR172 
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binds to the open ion channel preferentially, which results in conformational changes 
of CFTR (Kopeikin et al., 2010). GlyH-101 works as an open channel blocker, 
although reaches the ion channel pore from the extracellular side through the narrow 
entrance blocking Cl- flow (Muanprasat et al., 2004; Norimatsu et al., 2012). The 
pyrimido-pyrrolo-quinoxalinediones (PPQs) are also small molecule CFTR inhibitors 
and a primary screening identified PPQ-102 as the most potent among 347 
commercially available PPQ analogs (Verkman et al., 2013). Unlike GlyH-101, PPQ-
102 is uncharged at physiological pH and therefore acts in a voltage-independent 
manner (Verkman et al., 2013). A more potent CFTR modulator, compared to PPQ-
102, is BP0-27 exhibiting greater metabolic stability and aqueous solubility even 
though it acts in voltage-independent trend similarly to PPQ-102 (Verkman et al., 
2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 21 Chemical structures of CFTR inhibitory compounds. Structure of the open channel blockers, 
DPC, NPPB and Glibenclamide are shown. Structure of more recent and potent inhibitors such as 
CFTR172, GlyH-101, PPQ-102 and BPO-127 are represented (Verkman et al., 2013). 
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1.9 Viral modulation of host ion channels 
All viruses exploit host cell factors and machineries to fulfill their life cycles. It is 
established that several viruses generate their ion channels to monitor ion 
homeostasis throughout the different stages of their life cycles (Royle et al., 2015; 
Sze and Tan, 2015). However, many viruses do not generate a viroporin and/or 
manipulate host cell ion channels to regulate host ionic environment. Studies have 
shown that host cell ion channels are exploited by different viruses and at different 
stages of their life cycles (Hover et al., 2017). 
 
1.9.1 Host ion channels and virus trafficking 
Ion channels are implicated in the process of virus trafficking into the host cells and 
during the virus and host membrane fusion processes. It is known that Ebola virus 
(EBOV) and Marburg virus enter host cells through micropinocytosis (Gehring et al., 
2014).  Studies have demonstrated that host Ca2+  channels play a critical role for 
filoviruses cell entry since treatment with Ca2+ inhibitory compounds, such as 
verapamil, cause blockade of virus entry (Gehring et al., 2014). Two types of Ca2+ 
family, TPC1 and TPC2 are associated with EBOV entry and release from the 
endocytic network. Moreover, similar findings were observed for Marburg virus life 
cycle, suggesting a shared regulatory mechanism for filoviruses (Sakurai et al., 2015).   
Recent work has identified that K+ channels control events after the initial entry of 
Bunyamwera virus (BUNV) (Hover et al., 2016). K+ channels were critical for the 
BUNV during the early stages of infection prior to viral RNA synthesis and blockade 
of this ion channel family was detrimental to BUNV (Hover et al., 2016). Further 
analysis revealed that the two-pore K+ channels (K2P) are required for the BUNV life 
cycle (Hover et al., 2016) and particularly are important within endosomal 
compartments (Hover et al., 2018). In addition, the requirement of K+ channels for a 
successful life cycle was also observed in other bunyaviruses, such as Hazara virus 
and Schmallenberg virus, indicating a common regulatory mechanism shared 
amongst the members of this family (Hover et al., 2016). 
81 
 
It is also demonstrated that there is a requirement of host Cl- channels during herpes 
simplex virus 1 (HSV-1) entry process. HSV-1 promotes Cl- flow and in the presence 
of specific inhibitory compounds, such as NPPB and tamoxifen, blockade of HSV-1 
virion binding, penetration into the host cell and nuclear translocation were observed 
(Zheng et al., 2014). 
 
1.9.2 Host ion channels and virus persistence 
Previous work has identified that the Hepatitis C virus (HCV) non-structural protein, 
NS5A, is able to block the liver-expressed voltage-gated K+ channel 2.1 (Kv2.1) 
(Mankouri et al., 2009). Phosphorylation and activation of Kv2.1 are promoted by 
oxidative stress leading to an outward K+ current that cause apoptotic induction 
(Redman et al., 2007). An increase in reactive oxygen species has been identified in 
HCV infected hepatocytes, thus the virus would appear capable of promoting such 
channel activity. To avoid this, NS5A blocks the oxidative-stress-mediated 
phosphorylation of Kv2.1 and linked apoptotic signaling (Mankouri et al., 2009). 
Moreover, the suppression of p38 MAPK signaling is involved in the mechanism of 
Kv2.1 inhibition (Mankouri et al., 2009). It was also demonstrated that stress-mediated 
neuronal cell death is blocked by NS5A through the impediment of Kv2.1 functionality 
via Src-mediated phosphorylation (Redman et al., 2007). Consequently, these 
findings suggested that Kv2.1 activation is disturbed by HCV to avoid apoptosis and 
permit virus survival and persistence (Norris et al., 2012). Additionally, HCV causes 
an increase of intracellular Cl- flow, which can be blocked by specific pharmacological 
compounds (Igloi et al., 2015). Three members of Cl- channel family, ClC-1, ClC-5 
and ClC- 7 are required for HCV replication by an unknown mechanism (Igloi et al., 
2015). 
Studies have indicated that HIV-1 is able to modify K+ concentration indirectly (Choi 
et al., 2008) and further analysis revealed that large-conductance Ca2+-dependent K+ 
host channels (BKCa) are blocked by Nef protein, although this modulation is still 
unclear (Herrmann et al., 2010; Kort and Jalonen, 1998). HIV-1 virion particles release 
is regulated by K+ channel functionality through the impact of HIV-1 gp120 and viral 
protein U (Vpu). Direct interaction of Gp120 with the cytoplasmic C-terminus of the 
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ether-a-go-go K+ channel (hERG) and its subsequently inhibition results in enhanced 
virus particle release, whereas it can be impeded by hERG overexpression 
(Herrmann et al., 2010). Moreover, resting membrane potential is manipulated by 
HIV-Vpu through obstruction of leak K+ channels (Hsu et al., 2010; Strebel, 2004). 
Previous studies revealed that HIV-1 release is blocked by the expression of the acid-
sensitive K2P channel, TASK-1 via an unknown mechanism (Hsu et al., 2004). HIV 
release is facilitated due to the formation of inactive Vpu and TASK-1 heterodimers, 
which subsequently cause an inhibition of TASK-1 currents and destabilization of 
membrane potential to facilitate virus assembly (Hsu et al., 2004).  
Furthermore, studies have shown that eight different host ion channels from K+, Na+, 
Cl- and Ca2+ families are downregulated by monkeypox virus, although the distinct 
impact of this downregulation on virus life cycle is still uncharacterized (Alkhalil et al., 
2010). Previous work has also demonstrated that Epstein-Barr virus causes an 
increase of the Orai1 channel expression, modifying Ca2+ homeostasis due to the 
initiation of Ca2+ flow into ER stores. These results indicated that intracellular host ion 
channels might be modulated by viruses (Dellis et al., 2011). It is also established that 
human T-cell leukaemia virus type 1 might stimulate an inward K+ current for as yet 
unknown viral processes (Biasiotto et al., 2010).  
 
1.9.3 Viral modulation of host ion channels in excitable cells 
Chronic viral infection of the central nervous system might result in severe clinical 
complications, likely promoted by viral modulation of ion channels. Studies have 
shown that mumps virus is able to reduce the magnitude and frequency of action 
potentials, which might be associated with the blockade of voltage-gated Na+ (Nav) 
channel (Stauffer and Ziegler, 1989). In contrast, varicella-zoster virus promotes 
increase of Nav currents mediated by the Nav1.6 and Nav1.7 members of this family, 
which might lead to neuropathic pain (Kennedy et al., 2013). Rabies virus (RABV) is 
also strongly linked with complications of central nervous system. Studies have 
shown that a reduction of inwardly-rectifying K+ (Kir) and Nav was observed in RABV 
infected cells, which ultimately results in alterations of action potential firing (Iwata et 
al., 1999). Moreover, it is identified that RABV prohibits the inhibition of Ca2+ currents 
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in the presence of noradrenaline, an important mediator of Ca2+ entry that signals 
neurotransmitter release (Rosenblum et al., 1991). These findings suggested that 
alterations of K+, Na+ and Ca2+ currents might facilitate virus pathogenesis although 
resulting in lethal consequences to the host (Iwata et al., 1999).  
Previous work has also demonstrated that there are distinct interactions between 
coxsackievirus B3 (CVB3) and hERG1 channels, L-type Ca2+ channels and KvLQT1 
(Kv7.1) channels during infection (Steinke et al., 2013). Further analysis in mice 
revealed that CVB3 replicated in higher titres in the heart of Kir6.1-deficient mice, 
indicating that ATP-sensitive K+ channel deregulation might play a crucial role in 
innate anti-viral immunity in the heart. Therefore, ion channel alterations promoted by 
CVB3 might impact on the arrhythmia observed in CVB3 patients and may be required 
for virus persistence as well (Steinke et al., 2013). Thus, host cell ion channel activity 
appears to be a key virus-host interaction during several viruses’ life cycle and since 
some of these ion channel modulators are currently clinically available, further studies 
may reveal intriguing insights into their potential anti-viral therapeutic.  
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1.10  Aims and Objectives 
Preliminary data from our group had proposed that inhibition of host cell K+ channels, 
using specific inhibitory compounds, could impair the BKPyV life cycle by a 
mechanism which was uncharacterized. The main aim of this research project was to 
validate the preliminary data and to investigate whether host ion channels could be 
potential anti-viral drugs against BKPyV. To this end the objectives of this project 
were: 
 
1. To establish a primary renal proximal epithelial cell culture model for the study 
of the BKPyV life cycle. 
 
2. To perform and establish a high-throughput technique for BKPyV titration.  
 
3. To validate and characterize the impact of host cell ion channels on BKPyV 
life cycle. 
 
4. To identify at which stage of BKPyV life cycle there is a potential requirement 
of host ion channels. 
 
5. To investigate whether the same ion channel is required by other 
polyomaviruses. 
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 Materials and Methods 
2.1 Bacterial cell culture 
2.1.1 Preparation of competent bacteria cells 
NEB5α bacteria cells were prepared to become chemically competent. SOB-media 
(10 mM NaCl, 0.5% yeast extract, 2% peptone, 2.5 mM KCl, pH 7.5) was used for the 
growth of single bacterial colonies. Single colonies were grown at 18oC to reach an 
optical density at 600 nm (OD600) of approximately 0.6. Cultures were incubated on 
ice and then centrifuged at 2500 x g for 10 minutes to harvest bacterial cells. The 
harvested bacterial cells were then washed in transformation buffer containing 15 mM 
CaCl2, 10 mM PIPES, 55 mM MnCl2, 250 mM KCl, pH 6.7. Following this, the bacterial 
cells were resuspended in cold transformation buffer containing 7% dimethyl 
sulphoxide (DMSO). Prepared aliquots of competent bacteria cells were placed at -
80oC for long-term storage.  
 
2.1.2 Transformation of plasmid DNA into bacteria 
Competent bacteria NEB5α cells were used in all transformation experiments. An 
aliquot of bacteria was thawed on ice and 1.5 ml tubes were pre-chilled. Thawed 
bacteria (50 μl) were mixed with 1 μl of DNA and incubated in the pre-chilled tubes 
on ice for 30 minutes. The mixture was next heat shocked at 42oC for 45 seconds and 
placed back on ice to recover for 2 minutes. LB-Broth (200 μl) was added to the 
bacterial mixture, which was then incubated at 37oC and 180 rpm for 1 hour. The 
bacterial culture was spread on agar plates in the presence of the appropriate 
antibiotics (100 µg/ml) and incubated at 37oC overnight. 
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2.1.3 Preparation of plasmid DNA 
2.1.3.1 Small scale bacterial culture 
Small scale bacterial cultures were set up to a final volume of 5 ml LB-Broth media. 
In 50 ml universal falcon tubes 5 ml of LB-Broth containing the appropriate antibiotics 
(100 µg/ml) was inoculated with a scrape from a glycerol stock or a single colony from 
a cultured agar plate. Bacterial inoculum was incubated in an orbital shaker at 180 
rpm and 37oC from 4 hours to overnight incubation depending on the experiment and 
the use of the bacterial culture. 
 
2.1.3.2 Large scale bacterial culture 
Large scale bacterial cultures were set up to a final volume of 100 ml LB-Broth media. 
In 500 ml sterile conical flasks, 100ml of sterile LB-Broth media containing the 
appropriate antibiotics (100 µg/ml) was inoculated with 5 ml of overnight bacterial 
culture. Bacterial culture was incubated in an orbital shaker at 180 rpm and 37oC 
overnight. Following, bacterial culture centrifuged at 4,000 x g for 15 minutes at 4oC 
to pellet bacterial cells. Plasmid DNA extraction was performed according to 
manufacturer’s instructions (Qiagen, Germany). Plasmid DNA was eluted by adding 
100-800 μl nuclease-free water and quantified using the Nanodrop (Thermo Fisher 
Scientific, USA).  
 
2.2 Mammalian cell culture 
2.2.1 Growing, maintaining and passaging mammalian cells 
African green monkey kidney (Vero) cells (kindly provided by Dr Holly Shelton-The 
Pirbright Institute, UK) were cultured and seeded in Dulbecco’s Modified Eagle 
Medium (DMEM) (Sigma Aldrich, USA) supplemented with 1% (v/v) 
Penicillin/Streptomycin and 10% (v/v) Foetal bovine serum (FBS). Vero cells were 
grown in T75 cm2 flasks in the tissue culture incubator at 37oC and 5% CO2 
(Ammerman et al., 2008). To passage Vero cells, growth media was decanted, and 
87 
 
the cells washed with Phosphate Buffered Saline (PBS). Cells were trypsinised to 
remove them from the flask and passaged at 1:10 dilution in fresh complete media.  
Human foetal glial (SVG-A) cells (kindly provided by Dr Walter Atwood-Brown 
University, USA) were cultured and seeded in Dulbecco’s Modified Eagle Medium 
(DMEM) (Sigma Aldrich, USA) supplemented with 1% (v/v) Penicillin/Streptomycin, 
1% (v/v) non-essential amino acids (Life Technologies, USA) and 10% (v/v) Foetal 
bovine serum (FBS). SVG-A cells were grown in T75 cm2 flasks in the tissue culture 
incubator at 37oC and 5% CO2. To passage SVG-A cells, growth media was 
decanted, and cells were washed with Phosphate Buffered Saline (PBS). Cells were 
trypsinised to remove them from the flask and passaged at 1:8 dilution in fresh 
complete media. 
Human embryonic kidney (HEK293TT) cells (HEK293T are HEK293 cells stably 
transfected with SV40 genome and they express tAg and low amount of TAg. 
HEK293TT are HEK293T cells that are stably transfected with SV40 TAg cDNA and 
they express high levels of TAg) (kindly provided by Dr Chris Buck- NIH, USA) were 
cultured and seeded in Dulbecco’s Modified Medium (DMEM) (Sigma Aldrich, USA) 
supplemented with 1% (v/v) Penicillin/Streptomycin and 10% Foetal bovine serum 
(FBS) (Russell et al., 1977). HEK293TT cells were grown in T75 cm2 flasks in the 
tissue culture incubator at 37oC and 5% CO2. To passage HEK293TT cells, growth 
media were decanted and washed with Phosphate Buffered Saline (PBS). Cells were 
trypsinised to remove them from the flask and passaged at 1:10 dilution in fresh 
complete media. 
Primary Human Renal Proximal Tubular Epithelial cells (RPTE) were obtained from 
Lonza and cultured in REBM Medium (Lonza, UK). Essential supplements including 
FBS, insulin, gentamicin sulphate, epidermal growth factor, epinephrine, 
hydrocortisone, triiodothyonine and transferrin (purchased as a kit-Lonza, UK) were 
added to the media before use. RPTE cells were seeded onto a T175 flask and 
manipulated according to the supplier’s instructions. To allow a flask to become 
confluent the media was changed every 3 days due to the low amount of FBS. After 
each passage, 1 x 106 RPTE cells per ml in 1 ml fresh media were frozen down as 
aliquots (Taub, 1997).  
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2.2.2 Cell counting 
Mammalian cells were counted using a haemocytometer. Cell suspension (10 μl) was 
mixed with 10 μl of Trypan Blue solution (Sigma Aldrich, USA) and applied to the 
haemocytometer slide. The average cell count from each set of corner squares was 
taken and multiplied by 2 x 104 to represent the number of cells per ml. 
 
2.2.3 Freezing and thawing mammalian cells 
Following cell harvesting, 5 x 105-106/ml cells were resuspended in 1 ml of complete 
fresh media in the presence of 10% (v/v) DMSO. Cell solutions were added to 
cryovials and placed in a freezer container (Mr Frosty) containing isopropanol and 
incubated at -80oC overnight. The following day, cells were transferred to liquid 
nitrogen for long-term storage. 
Frozen cells were thawed at 37oC and transferred to a universal falcon tube. 
Approximately 10 ml of fresh complete media was added to cells. This suspension 
centrifuged at 1,100 rpm at 4oC for 5 minutes to pellet the cells. The supernatant was 
carefully discarded, and cells were resuspended in 2 ml of fresh complete growth 
media. Resuspended cells were transferred to a T75 cm2 flask and 8 ml of fresh 
growth media was added. Flasks were placed in the tissue culture incubator at 37oC 
and 5% CO2. 
 
2.2.4 Transient transfections with NanoJuice 
Vero cells were seeded into 6-well dishes (Sarstedt, Germany) at a density of 2 x 105 
cells/ml and incubated overnight. Plasmid DNA (0.5 μg) was added per reaction to 
each well. The transfection mixture was prepared in 1.5 ml tubes and for each 
reaction, 50 μl of Opti-MEM was added to 1 µl of NanoJuice Core transfection reagent 
and 1.5 µl of NanoJuice Transfection Booster (Merck Millipore, USA) and mixed 
thoroughly before a 15 minute-incubation at room temperature. Next, DNA was 
added, and the transfection mixture was incubated for 15 minutes at 
roomtemperature. The transfection mixture (50 μl) was then added to each well of 
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cells (in complete growth media). Growth media was replaced with fresh 16 hours 
post-transfection (Panou et al., 2018). Transfected cells were incubated for further 
48-72 hours depending on the specific experimental procedure. 
 
2.2.5 Transfecting siRNA into RPTE cells 
RPTE cells were seeded into 6-well dishes (Sarstedt, Germany) at a density of 2 x 
105 cells/ml and incubated overnight. RPTE cells were transfected with a pool of 4 
different Flexitube siRNA (Table 2.1) (Qiagen, Germany) molecules specifically 
targeted to CFTR, and an AllStars negative control siRNA (Qiagen, Germany). Each 
of the 4 different Flexitube siRNA (100 nM each) and 10 µl of Santa Cruz siRNA 
Transfection Reagent (Santa Cruz, USA) were dissolved in 100 µl of Opti-MEM in 2 
different 1.5 ml tubes, respectively. This was then incubated at room temperature for 
5 minutes. Next, the 2 solutions were combined, mixed gently and incubated for 30-
45 minutes at room temperature. Approximately 800 µl of complete fresh media was 
added to the transfection mixture. Cells were washed once with 1 ml of Opti-MEM 
before the transfection mixture was added. The siRNA transfection mixture was 
removed from cells around 6-8 hours post-transfection and replaced with 2 ml of fresh 
media. Cells were incubated for 48 hours prior to analysis. 
 
Table 2. 1 CFTR-specific FlexiTube siRNA sequences 
 
  
Product name siRNA sequence 
Hs_CFTR_5 ATCGCGATTTATCTAGGCATA 
Hs_CFTR_4 TCGATATATTACTGTCCACAA 
Hs_CFTR_2 ATGGCCAACTCTCGAAAGTTA 
Hs_CFTR_1 CTCGAAAGTTATGATTATTGA 
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2.2.6 Use of ion channel modulators 
All the inhibitors used in this study were diluted to a final working concentration in 2 
ml of complete fresh media (Table 2.2). Mixtures of fresh media and inhibitory 
compounds were mixed thoroughly and added directly to cells. Treated cells were 
incubated for 24-72 hours based on the experimental procedure. 
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Table 2. 2 List of modulatory compounds. The table indicates the ion channel family and sub-family 
targeted and the diluent used. 
Compound Ion channel 
family 
Compound 
modulates 
Diluent 
Tetraethylammonium 
(TEA) 
K+ Non-selective K+ 
channel blocker 
H2O 
Potassium Chloride 
(KCl) 
K+ Increases 
extracellular K+ 
H2O 
Quinidine K+ Reduces both Na+ 
and K+ channel 
currents 
DMSO 
Barium Chloride 
(BaCl2) 
K+ Blocker of inward 
rectifier K+ channels 
H2O 
4-Aminopyridine (4AP) K+ Non-selective 
voltage-gated K+ 
channel blocker 
H2O 
Glibenclamide K+ Blocker of ATP-
sensitive K+ 
channels 
DMSO 
Tolbutamide K+ Blocker of ATP-
sensitive K+ 
channels 
DMSO 
Apamin K+ Blocker of Ca+2-
activated K+ 
channels 
Acidic buffer pH 4.8 
5-Hydroxydecanoate 
(5HD) 
K+ Blocker of 
mitochondrial ATP-
sensitive Κ+ 
channels 
H2O 
U-37883A K+ Blocker of ATP-
sensitive Κ+ 
channels (specificity 
to Kir6.1-type) 
H2O 
Diazoxide K+ Activator of ATP-
sensitive K+ 
channels 
DMSO 
Pinacidil K+ Activator of ATP-
sensitive K+ 
channels 
DMSO 
VU591 K+ Blocker of ROMK 
channels 
DMSO 
CFTR172 Cl- Blocker of CFTR ion 
channels 
DMSO 
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2.2.7 Cell viability (MTT) assay 
Cells were seeded into 96-well dishes at a density of 103 cells/ml and incubated 
overnight. The next day, cells were treated with ion channel modulators and incubated 
for the period that the drugs’ effect was being assessed. Vero and RPTE cells were 
incubated for 48 hours, HEK293TT cells for 72 hours and SVG-A cells were incubated 
for 5 days. On the day of the assay, MTT Mw414 was dissolved in serum free media 
at 1 mg/ml concentration. Growth media was removed from wells and 100 μl of MTT 
solution was added per well. Cells were then incubated at 37oC for 30 minutes and 
plates were covered in aluminium foil. After the incubation, the MTT solution was 
discarded and replaced with 100 μl DMSO. Plates were then placed on a shaking 
rocker for 5 minutes (60 rpm) to dissolve the purple precipitate and optical densities 
were read at 570 nm on a plate reader (Riss et al., 2004).  
 
2.2.8 Resting membrane potential assay 
Cells were seeded into 6-well dishes at a density of 2 x 105 cells/ml and incubated 
overnight. The next day, cells were treated with inhibitory compounds to a final 
working concentration in 2 ml of complete fresh media and incubated for the required 
length of time (Vero/RPTE cells-48 hours; HEK293TT cells-72 hours and SVG-A 
cells-5 days). Cells were then incubated with 20 µM of DiBAC4(3) (Sigma-Aldrich, 
USA) in 2 ml of fresh complete media for 30 minutes at 37oC and protected from light 
(Hover et al., 2016). The DiBAC4(3) dye was removed and cells were washed once 
with 2 ml of 1 x PBS before being scraped into 500 μl of PBS for analysis by flow 
Cytometry.  
 
2.2.9 Flow cytometry analysis of live cells 
Cell suspensions of cells treated with ion channel modulators and DiBAC4(3) were 
analysed on an LSRFortessa (BD Biosciences, USA) flow cytometer using the 
accompanied (FACSDiva Version 6.2) software. All cell populations were gated to 
contain only live cells. The mean green fluorescence was determined for 100,000 live 
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cells per sample and the experiments were repeated three independent times. The 
resulting data were entered into an Excel file to conduct a statistical analysis.  
 
2.2.10 Harvesting and lysing cells 
Three different lysis buffers were used in our experiments, dictated by the nature of 
the experimental protocol. 
Cells were cultured in 6-well dishes for the appropriate incubation time at 37oC. 
Growth media was removed, and cells were washed with 1 ml of PBS and trypsinized 
with 1 ml of 1 x Trypsin (Lonza, UK), to remove the cells from the dish. To neutralise 
the 1 x Trypsin, 1 ml of growth media was added, and the cell suspension transferred 
to 1.5 ml tubes. The cell pellet was collected by centrifugation at 13,000 rpm for 5 
minutes and the supernatant discarded, prior to washing the cell pellet with 0.5 ml of 
PBS. This was repeated, and the cell pellet placed at -80oC for long-term storage. 
Cell lysis was conducted using a Triton lysis buffer (10 mM Tris (pH 7.6); 10 mM 
sodium phosphate; 130 mM NaCl; 1% Triton X-100, 20 mM N-ethylmaleimide) 
containing 1 x Protease inhibitor cocktail EDTA-free (Roche, Switzerland) (Hurdiss et 
al., 2016). Approximately 100 µl of lysis buffer was added to cell pellets and the cells 
were gently resuspended. Cell lysates were sonicated (20 seconds on, 20 seconds 
off) 3 times, then incubated on ice for 1 hour and subsequently centrifuged at 13,000 
rpm for 5 minutes. Alternatively, for harsher lysis conditions, cells were lysed using 
100 µl of RIPA buffer for containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% 
NPEO (Nonylphenol ethoxylates), 0.5% Sodium deoxycholate, 0.1% SDS and 1 x 
Protease inhibitor cocktail EDTA-free. Cells were gently resuspended in lysis buffer 
and sonicated (20 seconds on and 20 seconds off) 3 times. Then, cells were 
incubated on ice for 1 hour and centrifuged at 13,000 rpm for 5 minutes. Another lysis 
buffer that was used in this study was E1A lysis buffer containing 50 mM HEPES pH 
7.0, 250 mM NaCl, 0.1% NP-40, 1 mM EDTA, 1 mM DTT and 1 x Protease inhibitor 
cocktail EDTA-free (Jiang et al., 2009). Approximately 100 µl of E1A lysis buffer was 
added to lyse the cells. Cell lysates were sonicated (20 seconds on, 20 seconds off) 
3 times. Then, cells were incubated on ice for 1 hour and centrifuged at 13,000 rpm 
for 5 minutes. Cell lysates were contained in the supernatant.  
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2.3 Preparation of viral genomes 
2.3.1 Preparation of BKPyV, JCPyV and SV40 genomes 
Plasmid vectors containing the viral genomes were digested with 10 units of restriction 
enzymes (Table 2.3) in a 50 μl reaction buffer containing 1 x buffer 4 (NEB, USA) and 
double distilled water to final volume. Reactions were incubated at 37o C for 2 hours; 
after 1 hour another 10 units of restriction enzymes (NEB, USA) was added to the 
mixture. Once digested, re-ligations of the linear genomes at a concentration of 10 
ng/μl were carried out with 1 μl of T4 DNA Ligase (NEB, USA) in 100 μl of 10 x T4 
Ligation Buffer (NEB, USA) and double distilled water to a final volume of 1 ml (to 
reduce the probability of concatemer formation). Ligation mixtures were incubated at 
16oC overnight and subsequently purified. Both digested and ligated samples were 
analysed by agarose gel electrophoresis.  
 
Table 2. 3 List of viral genomes. The name of each plasmid containing the viral genome, the amount of 
DNA and the restriction enzyme used in each enzymatic restriction reaction are listed. 
 
Plasmid Amount of maxi-
prepped DNA 
Restriction enzyme Source 
pGem7 BKPyV Dunlop 
(re-arranged form-lab 
strain) 
10 μg BamHI-HF Kindly provided by 
Professor Michael 
Imperiale, University of 
Michigan, USA 
pBR322 JCPyV Mad-1 10 μg EcoRI-HF Kindly provided by 
Professor Michael 
Imperiale, University of 
Michigan, USA 
pUC SV40 4 μg KpnI-HF Kindly provided by 
Professor Daniel 
DiMaio, Yale University, 
USA 
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2.3.2 DNA purification and quantification 
A commercially available PCR Purification Kit (Qiagen, Germany) was used to purify 
ligated DNA products, based on the protocol’s instructions. Briefly, 3-parts of Buffer 
PB were added to 1-part of DNA solution (3 ml of Buffer PB was added to 1 ml of DNA 
solution). Approximately 650 μl of sample was loaded onto a silica column inside a 
provided 2 ml collection tube, which following was centrifuged at 13,000 rpm for 60 
seconds. The flow-through was discarded. That step was repeated to wash the whole 
sample volume. A further wash was conducted by adding 750 μl of Buffer PE to the 
silica column. Samples were centrifuged at 13,000 rpm for 60 seconds and flow-
through was discarded. Another centrifugation at 13,000 rpm for 60 seconds was 
carried out to remove any remaining wash Buffer PE. Following this, the silica column 
was removed from the 2 ml collection tube and transferred to a new sterile 1.5 ml 
tube. Nuclease-free distilled water (30 μl) was added to the silica column to elute DNA 
samples. Nuclease-free distilled water was left in the column for 60 seconds at room 
temperature to increase the concentration of DNA sample after the purification. 
Samples were centrifuged at 13,000 rpm for 60 seconds to elute DNA from the silica 
column. Eluted DNA was quantified using a Nanodrop spectrophotometer (Thermo 
Fisher Scientific, USA) through the Nanodrop 1000 computer software. Double 
distilled water (1.5 μl) was used as a blank and 1 µl of sample was measured. Each 
DNA concentration was calculated by measuring the optical density at 260 nm 
wavelength relative to the double distilled water control. 
Alternatively, an ethanol precipitation was carried out to purify ligated DNA products. 
For this, 2.5 ml of 100% ethanol and 100 μl of 3 M sodium acetate pH 5.2 were added 
to each ligation reaction. Samples were placed at -80oC for 1 hour, then centrifuged 
at 2,500 rpm for 30 minutes and the cell pellets were washed with 70% ethanol. A 
second centrifugation step followed at 2,500 rpm for 5 minutes. The supernatants 
were discarded, and the DNA pellets were allowed to dry briefly and resuspended in 
200 μl of double distilled water.  
 
96 
 
2.3.3 Agarose gel electrophoresis 
Agarose gels (1% w/v in 1 x TAE buffer) containing, 1 x SYBRsafe Gel Stain 
(Invitrogen, USA) were used to analyse 8 µl of each sample (3 μl of genomic DNA; 3 
μl of double distilled water; 2 μl of loading dye (NEB, USA)). HyperLadder I (NEB, 
USA) (200-10,000 bp) (6 μl) was also loaded onto the agarose gels and served as a 
molecular weight marker. Agarose gels were run for approximately 40 minutes at 80 
V and DNA bands were visualized using the Syngene gel imager. 
 
2.4 Generation of viral stocks  
2.4.1 Generation of BKPyV stocks 
Vero cells were seeded into 2 T75 cm2 flasks (Sarstedt, Germany) at a density of 1 x 
106 cells/ml and incubated overnight. The following day, cells were transfected with 
BKPyV genomes and 800 μl of Opti-MEM, 8 μl of Core reagent and 12 μl of Booster 
(NanoJuice transfection kit) were required for each flask. All the reagents were mixed 
thoroughly and incubated at room temperature for 5 minutes. Then, 4 μg of ligated 
BKPyV DNA genome was added to transfection mixture and incubated for 15 minutes 
at room temperature. Approximately 800 μl of this mixture was next distributed to each 
flask in complete growth media at an even distribution. The following morning, media 
was replaced with fresh and cells were incubated for 10 days at 37oC. Transfected 
Vero cells were harvested by scraping the cells into the growth media of each flask 
and stored at -80oC. 
The frozen harvested cell suspension from BKPyV transfected Vero cells thawed out 
using a sequential freeze-thaw protocol. Briefly, the suspension exposed to liquid N2 
and a 40oC water bath for 3 times, which bursts the infected cells. The lysate was 
then added to naïve Vero cells in T75 cm2 flasks for 2 hours at 37oC rocking the flask 
every 30 minutes to ensure even coverage. After this period, suspensions were 
removed and replaced with fresh complete growth media. Cells were incubated for 14 
days without adding any fresh growth media and prior to harvesting by scraping the 
cells into the growth media of each flask. Samples were placed at -80oC for long-term 
storage (Figure 2.1) (Hurdiss et al., 2016). 
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Figure 2. 1 Schematic representation of the preparation of BKPyV virus stock. Vero cells were 
transfected with 4 µg of ligated BKPyV genomes and incubated overnight at 37oC. Media was replaced 
with fresh and transfected Vero cells were incubated for 10 days at 37oC. Cell suspension was harvested 
and used to further infect naïve Vero cells for 2 hours at 37oC. Infected Vero cells were incubated for 14 
days at 37oC, then cell suspension was harvested and purified. 
 
2.4.2 Generation of JCPyV stocks 
SVG-A cells were seeded into 2 T75 cm2 flasks (Sarstedt, Germany) at a density of 1 
x 106 cells/ml and incubated overnight. The following day, cells were transfected with 
JCPyV genomes. Approximately 400 μl of Opti-MEM with 8 μg of ligated JCPyV DNA 
genome and 400 μl of Opti-MEM with 16 μl of Lipofectamine 2000 (Invitrogen, USA) 
were mixed and incubated for 5 minutes, separately, for each flask.  Then, both 
mixtures were combined in one and incubated for 20 minutes at room temperature. 
Approximately 800 μl of transfection mixture was distributed to each flask at an even 
distribution containing complete growth media. The following morning, media was 
replaced with fresh and cells were incubated for 20 days at 37oC. Transfected SVG-
A cells were harvested by scraping them into the media of each flask and stored at -
80oC.  
 
 
Time, days  10 
Harvesting 
media/cells 
 0  14 
Harvesting 
media/cells- Virus 
purification 
 
0 
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2.4.3 Generation of SV40 stocks 
Vero cells were seeded into 2 T75 cm2 flasks (Sarstedt, Germany) at a density of 1 x 
106 cells/ml and incubated overnight. The following day, cells were transfected with 
SV40 genomes and 800 μl of Opti-MEM, 8 μl of Core reagent and 12 μl of Booster 
(NanoJuice transfection kit) were required for each flask. All the reagents were mixed 
thoroughly and incubated at room temperature for 5 minutes. Then, 4 μg of ligated 
SV40 DNA genomes was added to this mixture and incubated for 15 minutes at room 
temperature. Approximately 800 μl of the transfection mixture was distributed to each 
flask in complete growth media at an even distribution. The following morning, media 
containing the transfection mixture was replaced with fresh and cells were incubated 
for 7 days prior harvesting by scraping them into the media of each flask. Samples 
were placed at -80oC for long-term storage. 
 
2.4.4 Purification of BKPyV stocks 
Cell suspensions were collected from infected Vero cells and centrifuged at 8,000 x 
g for 30 minutes. The supernatants were saved on ice and cell pellets resuspended 
in 10 ml of Buffer A (10 mM HEPES, pH 7.9; 1 mM CaCl2; 1 mM MgCl2; 5 mM KCl; 
water) and sonicated in a water bath for 5 minutes. The pH of the resuspended 
samples was adjusted to 6.0 with 0.5 M HEPES pH 5.4 and 10 U of neuraminidase 
from Clostridium perfringens (C. welchii) (Sigma Aldrich, USA) was added prior to a 
1 hour-incubation time at 37oC. Neuraminidase cleaves the sialic acid groups from 
host cell glycoproteins for the virus to be released from host cells. The pH of the 
samples was next adjusted to 7.4 with 0.5 M HEPES pH 8 and the samples were 
heated to 40oC for 5 minutes prior to centrifugation at 16,000 x g for 5 minutes. 
Supernatants were placed on ice, whilst cell pellets were resuspended in 10 ml of 
Buffer A and 100 μl of sodium deoxycholate (Sigma Aldrich, USA) was added to the 
mixture. Samples were incubated at 37oC for 15 minutes with occasional vortexing 
within the incubation time before a 5 minute-centrifugation at 16,000 x g; supernatants 
were placed on ice. After the last centrifugation, all the supernatants that were 
collected during the process, were combined and added over a layer of 4 ml of 20% 
sucrose. Samples were centrifuged at 25,000 rpm (85,500 x g) for 3 hours and then 
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the pellets (containing the virus) were resuspended in 10 ml of Buffer A and sonicated 
for 5 minutes. Samples were then centrifuged at 4,000 rpm for 5 minutes to pellet the 
insoluble fraction, collect the supernatant and place it over a preformed CsCl (Sigma 
Aldrich, USA) gradient (3 ml of light (1.2 g/cm3) CsCl; then added 3 ml of heavy (1.4 
g/cm3) CsCl underneath). All the samples were centrifuged at 35,000 rpm (155,000 x 
g) for 16 hours at 15oC and subsequently dialyzed against 1 L of Buffer A overnight 
at 4oC. All the solutions were made up in Buffer A (Light CsCl solution: 1.2 g/cm3; 
Heavy CsCl solution: 1.4 g/cm3; 20% sucrose: 10 g/50 ml) (Jiang et al., 2009). 
 
2.4.5 Titration of purified BKPyV or crude BKPyV, SV40 and JCPyV 
Cells (RPTE, Vero and SVG-A, respectively) were seeded into 96-well dishes 
(Sarstedt, Germany) at a density of 2 x 103 cells/ml and incubated overnight. 
Approximately 90 μl (for the purified virus titration) or 50 μl (for the crude virus titration) 
of Opti-MEM was mixed with 10 μl of purified BKPyV or 50 μl crude cell suspension 
containing virus, into the first well of the 96-well dish, respectively. All the other wells 
of the same row across the plate contained 50 μl of Opti-MEM.  Then, two-fold serial 
dilutions into the existing Opti-MEM of each well across the plate were carried out. 
The final volume into each well was 50 μl totally. Cells were incubated with the purified 
or crude virus for 2 hours at 37oC, then one wash with 1 x PBS was performed and 
100 μl of complete growth media was added to each well. Infected cells were 
incubated for 48 hours before the detection of viral proteins using the IncuCyte ZOOM 
equipment (Stewart et al., 2015).  
 
2.4.6 Immunofluorescence and use of the IncuCyte ZOOM for determination 
of virus titres 
Infected cells on 96-well plates were washed once with 1 x PBS for 5 minutes and 
fixed with 4% paraformaldehyde for 10 minutes at room temperature. Then followed 
extensive washes with 1 x PBS and the cell monolayer was permeabilized with 0.1% 
Triton-X100 in PBS (v/v) for 15 minutes. Next, cells were washed once with 1 x PBS 
and blocked with 1% BSA (Sigma Aldrich, USA) in PBS for 30 minutes. Another wash 
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with 1 x PBS was followed and primary anti-VP1 (1:250) antibody was added to cells 
and incubated overnight at 4oC. The following day cells were washed with 1 x PBS 
twice and anti-mouse alexa fluor 488-conjugated secondary (1:250) antibody 
(Thermo Fisher Scientific, USA) was added for 1 hour at 37oC. Approximately 4 
washes with 1 x PBS were carried out and cells were stored in 1 x PBS prior to 
visualization. After the immunofluorescence staining, the 96-well plates were imaged 
with the IncuCyte ZOOM machine (Essen Bioscience, USA) and the appropriate 
IncuCyte software was utilized to calculate the mean confluence from non-
overlapping bright phase images of each well. Following, the number of positive-
infected cells per well was calculated and based on these results, viral titres were 
calculated as well. All the titres were represented as infectious units per ml (IU/ml) 
(Stewart et al., 2015). 
 
2.5 Infection of cells using viral stocks 
2.5.1 Infection of cells with virus stocks 
 Cells were seeded into 6-well dishes (Sarstedt, Germany) at a density of 2 x 105 
cells/ml and incubated overnight.  The following day cells at approximately 70% 
confluency were infected with virus stock at an MOI of 0.5 or 5 (dependent on the 
experiment). Virus was diluted in 2 ml of Opti-MEM or the appropriate amount of crude 
media of infected virus added to cells for approximately 2 hours at 37oC. For a 
synchronised infection of cells, virus was diluted in 2 ml of Opti-MEM and added to 
cells for 2 hours at 4oC to allow virus attachment to host cell receptors. Once the virus 
was removed, infected cells were washed once with 1 ml of 1 x PBS and 2 ml of fresh 
media was added. Infected cells were incubated for further 24-72 hours dependent 
on the specific experiment (Figure 2.2). 
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Figure 2. 2 Schematic representation of the methodology of cells’ infection. Cells were infected with 
purified or crude virus stock at an MOI of 0.5 or 5 and incubated for 2 hours at 37oC. Once the virus was 
removed, fresh media was added to cells and further incubated for 24 up to 72 hours. 
 
2.5.2 Time-of-addition experiments using inhibitory compounds 
RPTE cells were seeded into 6-well dishes at a density of 2 x 105 cells/ml and 
incubated overnight. The following day cells at approximately 70% confluency were 
infected with virus stock. BKPyV stock (MOI of 0.5) was diluted in 2 ml of Opti-MEM 
and added on cells for approximately 2 hours at 4oC. Once the virus was removed, 
infected cells were washed once with 1 ml of 1 x PBS. All the inhibitors that used in 
this experiment were diluted to a final working concentration in 2 ml of complete fresh 
media and added to infected RPTE cells at indicated time-points as described below: 
0, 1, 2, 4, 6, 8, 10, 12 and 24 hours post-infection, respectively. A treatment was 
carried out 1-hour pre-infection and during the incubation time of infection. Once the 
virus-inhibitory compound mixture was removed, cells were washed twice with 2 ml 
of 0.5% Trypsin in 1 x PBS to wash off any residual of the ion channel modulators in 
Further analysis 
2h incubation 
Cells 
Remove virus and 
replace with media  
24-72h incubation 
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the wells and 2 ml of fresh media was added. Infected and treated RPTE cells were 
incubated for a total 48 hour-incubation time.  
 
2.5.3 Infection assays using media from infected cells 
RPTE cells were grown and infected as it is described in Section 2.5.2 and incubated 
for a total 48 hour-incubation time. Following this period, cell pellets were harvested 
for further analysis and media of each treatment was collected and placed at -80oC 
for long-term storage.  
RPTE cells were seeded into 96-well dishes at a density of 2 x 103 cells/ml and 
incubated overnight. The following day cells at approximately 70% confluency were 
infected with 100 µl of media that was collected and incubated for a 48 hour-
incubation period and further analysed using the IncuCyte ZOOM equipment (Figure 
2.3). 
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Figure 2. 3 Schematic representation of infection assay. Cells were infected with purified or crude virus 
stock at an MOI of 0.5 and incubated for 2 hours at 37oC. Once the virus was removed, fresh media was 
added to cells and further incubated for 48 hours in the presence of modulatory compounds. Media 
samples were used to further infect naïve RPTE cells prior a 48-hour incubation time. Infected RPTE 
cells were analysed by the IncuCyte ZOOM equipment. 
 
RPTE cells 
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2.6 Production of Virus-like particles (VLPs) 
2.6.1 Transfection of HEK293TT cells 
HEK293TT cells (1 x 106 cells/ml) were seeded into T75 cm2 flasks (Sarstedt, 
Germany) so that they were at 60% confluency by the next day. The following day, 
38 μg of DNA (19 μg of maxi-prepped plasmid (pIaw, expressing VP1-kindly provided 
by Dr Chris Buck, NIH, USA) and 19 μg of GFP-C1 (Addgene, USA) plasmid) were 
mixed with 2 ml of Opti-MEM. In separate tubes, 85 μl of Lipofectamine 2000 
(Invitrogen, USA) were mixed with 2 ml of Opti-MEM and incubated separately at 
room temperature for 5 minutes. Then the 2 mixtures were combined and incubated 
for an additional 20-minute incubation time. The resulting lipid/DNA complexes were 
added directly to the pre-plated HEK293TT cells and incubated overnight at 37oC. 
The next morning, the lipid/DNA complexes were removed, and fresh media was 
added to the upper surface of the flask to avoid any dislodging cells. Upon media 
change, flasks were returned to the incubator for an additional 30-hour incubation 
time. A total incubation period of 48 hours will have passed after the initial addition of 
the lipid/DNA transfection mixtures (Buck et al., 2004).  
 
2.6.2 Harvesting and maturation of generated VLPs 
Cells were collected by trypsinization 48 hours post-transfection. Floating cells were 
collected from the culture by centrifugation as well. Cell pellets were resuspended in 
up to 10 ml of complete growth media and transferred to conical tubes and the flask 
was rinsed with 4 ml of fresh media to collect any residual cells. Supernatants were 
discarded, and cell pellets were resuspended in the residual fluid by gently agitating 
the conical tubes and transferred into siliconized screw-cap tubes. The original tubes 
were rinsed with 0.5 ml DPBS/0.8 M salt (20 ml of 10 x PBS; 25 ml of 5 M NaCl; 90 
μl of 2 M CaCl2; 50 μl of 2 M MgCl2; 420 μl of 1 M KCl; 153.5 ml of double distilled 
water) and combined with the suspended cells. Then, cells were centrifuged in the 
siliconized tubes and supernatants were discarded. Instead of counting cells, an 
estimation of the volume of the cell pellet was performed and 1.2 pellet volume of 
DPBS/0.8 M salt was added to the siliconized tube to resuspend the cell pellet. Next, 
2 U/ml of neuraminidase from Clostridium perfringens (C. welchii) (Sigma Aldrich, 
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USA) was added to the suspended cells and tubes were mixed briefly by vortexing 
prior to a 30-minute incubation time at 37oC. To lyse the cells, 1/20th of a volume of 
10% Triton X-100 was also added to the mixture. Following, 0.2% benzonase and 
1/40th volume of 1 M ammonium sulfate pH 9 (final concentration of 25 mM) were 
added to cell suspension for an overnight incubation at 37oC for VLPs maturation 
(Buck et al., 2004). 
 
2.6.3 Purification and collection of VLPs 
The next morning, 0.17 volumes of 5 M NaCl was added to the cell lysates and 
incubated for 10 minutes on ice. Salt lysates were clarified by centrifugation at 5,000 
x g for 5 minutes at 4oC and the clarified supernatants were transferred into fresh 
siliconized screw-cap tubes. Pellet materials were re-extracted by re-suspending 
them into two pellet volumes of DPBS/0.8 M NaCl. Another centrifugation step 
followed at 5,000 x g for 5 minutes and the second clarified supernatants were 
transferred into the same tubes with the first supernatants, respectively. A third 
centrifugation step was carried out to re-clarify the pooled supernatants at 5,000 x g 
for 5 minutes. The double-clarified supernatants were layered onto an Optiprep 
(Sigma Aldrich, USA) gradient to purify the VLPs and samples were centrifuged at 
16oC at 50,000 rpm (234,000 x g) for 3.5 hours in an SW55Ti rotor. Acceleration and 
deceleration were set to minimum. The Optiprep gradient was made up as described 
below using the following buffers: Optiprep (60% wt/vol iodixanol solution); 50 ml 46% 
Optiprep in PBS/0.8 M salt (38.3 ml of 60% Optiprep; 5 ml of 10 x PBS; 6.5 ml of 5 M 
NaCl; 23 μl of 2 M CaCl2; 13 μl of 2 M MgCl2; 100 μl of 1M KCl); 27% Optiprep in 
PBS/0.8 M salt (9.3 ml of DPBS/0.8 M salt and 13.2 ml of 46% Optiprep in PBS/0.8 
M salt); 33% Optiprep in PBS/0.8 M salt (6.4 ml of DPBS/0.8 M salt and 16.1 ml of 
46% Optiprep in PBS/0.8 M salt); 39% Optiprep in PBS/0.8 M salt (3.4 ml of DPBS/0.8 
M salt and 19 ml of 46% Optiprep in PBS/0.8 M salt). Optiprep gradients were placed 
in thin polyallomer (Beckman Coulter, USA) 5 ml tubes by underlaying 27%, then 33% 
and then 39% Optiprep gradients at approximately 1.4 ml steps using a 3 ml syringe 
fitted with a long needle. The Optiprep gradients were allowed to set between 1 to 4 
hours before adding the double-clarified supernatants on the top. After the 
centrifugation, gradient fractions were collected by puncturing the bottom of the tube 
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slightly of centre with a syringe needle (25-26-gauge needles). Drip fractions were 
collected into siliconized microcentrifuge tubes (the first 750 μl as one fraction and 6 
to 8 drop fractions up to fraction 10; the top 2 ml of the gradient were discarded) (Buck 
et al., 2004).   
 
2.7 Protein Biochemistry 
2.7.1 Bicinchoninic acid assay for protein quantification 
The bicinchoninic acid (BCA) assay (Thermo Fisher Scientific, USA) was used for 
protein quantification of cell lysates according to manufacturer’s instructions. Diluted 
albumin standards (BSA) at known concentrations were made up in the appropriate 
diluent (0 μg/ml-2 μg/ml). To make up the working solution, 50-parts of BCA Reagent 
1 and 1-part of BCA Reagent 2 were mixed and 5 μl of each BSA standard and each 
sample was added to wells on a 96-well plate. Also, 50 μl of the working solution was 
added to each well for a 15-minute incubation time at room temperature. The plate 
was read at 562 nm on a PowerWave XS2 Microplate Spectrophotometer (BioTek, 
UK) and the optical densities of each of the standards were used to create a standard 
curve using the accompanying software (Gen5 1.07.5, BioTek, UK). The optical 
densities of each sample were then plotted against this standard curve to calculate 
protein concentrations.  
 
2.7.2 Bradford assay for protein quantification 
The Bradford assay (Sigma-Aldrich, USA) was used for protein quantification of cell 
lysates according to manufacturer’s instructions. Diluted albumin standards (BSA) at 
known concentrations were made up in the appropriate diluent (0 μg/ml-2 μg/ml). 
Approximately 5 μl of each BSA standard and each sample were added to wells on a 
96-well plate. Also, 100 μl of the working solution was added to each well for 15 
minutes at room temperature. Then, the plate was read at 595 nm on a PowerWave 
XS2 Microplate Spectrophotometer (BioTek, UK) and the optical densities of each of 
the standards were used to create a standard curve using the accompanying software 
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(Gen5 1.07.5, BioTek, UK). The optical densities of each sample were plotted against 
this standard curve to calculate protein concentrations.  
 
2.7.3 Preparation of SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins from cell lysates were separated according to molecular weight using a 
minigel system (BioRAD, USA). SDS-polyacrylamide (8%, 10%, 12.5% and 15%) 
gels were prepared according to required protein resolution and allowed to set an 
appropriate amount of time (separating gel: 8%, 10%, 12.5%, 15% Acrylamide, 0.1% 
SDS, 375 mM Tris/HCl pH 8.8, 0.1% APS and 0.01% TEMED). Stacking gels were 
allowed to set above the separating gels with a 10-well comb (BioRAD, USA) inserted. 
SDS-polyacrylamide gels were inserted into a Mini-PROTEAN Tetra System 
(BioRAD, USA) and 30 µl of protein samples with 10 µl of lithium dodecyl sulphate 
(LDS) sample buffer (Invitrogen, USA) and 0.1% β-mercaptoethanol were loaded. 
Approximately 5 µl of Blue Protein Standard Blue Range Protein Marker (NEB, USA) 
or Color Protein Standard Broad Range Protein Marker (NEB, USA) was used as a 
marker for protein molecular weight. SDS-polyacrylamide gel electrophoresis was 
conducted at 120 V for approximately 80 minutes until the protein loading dye reached 
the bottom of the gel. 1 x SDS running buffer contains 250 mM Tris Base, 1.92 M 
Glycine and 34.7 mM SDS. 
 
2.7.4 Western Blot Analysis 
Proteins separated on the SDS-polyacrylamide gel were transferred onto HybondTM-
C Extra mixed ester nitrocellulose membranes (Amersham BioSciences, UK) on a 
wet transfer XCell IITM Blot Module (Invitrogen, USA) or on a semi-dry Turbo-Blot 
Transfer Blot (BioRAD, UK) using soaking membranes and sponges that had been 
pre-soaked in 1 x transfer buffer (20% methanol, 192 mM Glycine and 25 mM Tris 
base). Next, the sponges, membranes and gels were incubated at 25 V for 1 hour to 
allow the protein bands to be transferred from the SDS-polyacrylamide gel to the 
nitrocellulose membrane. Then, membranes were blocked in TBS/T buffer (25 mM 
Tris/HCl pH 7.5, 138 mM NaCl and 0.1% Tween-20) containing 5% (w/v) Marvel dry 
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skimmed milk powder on a rocker (30 rocks/min) for 1 hour at room temperature. All 
antibodies were diluted in TBS/T containing 5% (w/v) Marvel dry skimmed milk. 
Membranes were incubated in primary antibody for 1 hour at room temperature or 
overnight at 4oC with constant rocking (Table 2.4). Membranes were washed 3 times 
in TBS/T buffer for 5 minutes and after the washes, secondary antibodies (1: 5000) 
were added to membranes for 1 hour at room temperature. Then, 4 further washes in 
TBS/T were carried out. To detect the chemiluminescent signal, membranes were 
incubated with enhanced chemiluminescent solutions (WesternBrightTM ECL-spray 
(Advansta, USA), ECL SelectTM Western Blotting Detection Reagent (GE Healthcare, 
UK)) for 1 minute at room temperature. Following, membranes were placed on a 
protective plastic sleeve in a Hypercassette (Amersham Biosciences, UK) and were 
exposed to CL-XPosureTM Films (Thermo Fisher Scientific, USA). Exposure times 
varied depending on the primary antibody that had used. The films were automatically 
developed on a table top developer (Konica SRX-101A) and after detecting viral 
proteins, blots were stripped and washed by Restoring buffer A and B (Millipore, UK) 
for 10 and 15 minutes, respectively, and allowed to be re-probed.   
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Table 2. 4 List of antibodies. A detailed list of antibodies used in this study is shown below.  
 
 
Antibody Manufacturer Description Size of target Dilution used 
anti-
agnoprotein 
(pAb81038) 
Kindly provided 
by Professor 
Ugo Moens, The 
Arctic University 
of Norway 
Rabbit 11 kDa 1:10000 in WB 
anti-CFTR (sc-
376683) 
Santa Cruz, 
USA 
Mouse 165 kDa 1:100 in WB 
anti-GAPDH 
(sc-47724) 
Santa Cruz, 
USA 
Mouse 37 kDa 1:5000 in WB 
anti-VP1 
(P5G6) 
Kindly provided 
by Dr Denise 
Galloway, 
University of 
Washington, 
USA 
Mouse 42 kDa 1:1000 in WB 
anti-VP1 
(pAb597) 
Kindly provided 
by Dr Chris 
Buck, NIH, USA 
Mouse 42 kDa 1:250 in WB 
anti-VP2/VP3 
(ab53983) 
Abcam, UK Rabbit 38, 26 kDa 1:1000 in WB 
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2.7.5 Densitometry analysis of Western blots 
Western blot films were scanned on Photo Scanner as an 8-bit image and protein 
levels were quantified using ImageJ (National Institutes of Health, USA). Protein 
bands were selected with a square and the same square was used to select every 
protein band on the same film. This was repeated for each protein band of interest 
and protein band of loading control, following band intensity was determined with the 
measure function. The resulting data were entered into an Excel file to conduct a 
statistical analysis.  
 
2.8 Quantitative PCR 
Total DNA was extracted from RPTE cells using the E.Z.N.A Tissue DNA Kit (Omega 
Bio-Tek, USA) following the manufacturer’s protocol and approximately 5 ng/µl of the 
total extracted DNA was used per reaction. Quantitative PCR was performed using 
the QuantiFast SYBR Green PCR kit (Qiagen, Germany) and specific primers against 
the, BK Dunlop genome (FW:TGTGATTGGGATTCAGTGCT; 
RV:AAGGAAAGGCTGGATTCTGA). The PCR reaction was carried out on a Corbett 
Rotor-Gene 6000 (Qiagen, Germany) following three different steps. The initial 
activation step for 10 minutes at 95oC and a three-step cycle of denaturation of 10 
seconds at 95oC; the second step of annealing for 15 seconds at 60oC and the step 
of extension for 20 seconds at 72oC. All the three steps were repeated 40 times and 
concluded by melting curve analysis (Panou et al., 2018). 
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  BKPyV life cycle 
3.1 Introduction 
3.1.1 The BKPyV life cycle in its natural host 
Currently it is poorly understood how BKPyV establishes an infection in its natural 
host, completes a replication cycle and persists for a lifelong subclinical infection or 
becomes active again under immunosuppressive conditions. Therefore, the 
establishment of an in vitro cell system, which could be similar to in vivo conditions is 
required to study the virus life cycle in depth. Previous studies on BKPyV have been 
carried out using human embryonic kidney cells, human embryonic fibroblast cells or 
monkey-derived Vero cells, although these cell lines are not the most physiologically 
relevant host cell type for BKPyV in vivo (Maraldi et al., 1975; Seehafer et al., 1975). 
In other studies, human primary renal epithelial (RPTE) cells have been used in order 
to study the virus life cycle due to the fact that BKPyV is able to infect tubular 
epithelium in humans (Randhawa et al., 1999). RPTE cells regulate different cellular 
functions, including the maintenance of essential non-waste blood products, the 
regulation of blood volume and blood pressure, the production of vitamin precursors 
and the involvement in the release of cytokines upon infections or in the presence of 
molecules, which cause cell toxicity (Daha and van Kooten, 2000). Humes et al., 
(2002) reported that a model system has been developed in which human RPTE cells 
are capable of differentiation, in vitro, as they can be passaged up to six times. By 
using this primary cell system, we have the advantages to study many aspects of the 
virus life cycle that are still uncharacterized and to determine interactions between 
the virus and host cell factors in a known cell type susceptible to BKPyV.   
BKPyV must enter host cell to establish a successful infection, where it manipulates 
the host cellular machinery for transcription, replication and protein synthesis (Bennett 
et al., 2012). Studies have shown that the expression of early viral genes starts to be 
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detectable about 24 hours post-infection, with the expression levels to be increasing 
out to 72 hours post-infection (Low et al., 2004). Also, viral DNA replication and 
expression of late viral genes begin approximately 36 hours post-infection, with 
expression levels to be gradually increasing throughout later stages of the time-
course of BKPyV infection in RPTE cells. Thus, the release of the newly synthesized 
viral progeny initiates at later stages, approximately 48 hours post-infection (Low et 
al., 2004).  
 
3.1.2 Chapter aims 
The main aims of this Chapter are to highlight each stage of the generation of purified 
BKPyV and the establishment of a high-throughput method to measure the BKPyV 
titres. The time-course of the BKPyV life cycle in human primary RPTE cells is also 
studied in order to form a basis for further research on the virus life cycle and other 
host factors that could be potentially involved in a successful BKPyV infection.  
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3.2 Results 
3.2.1 Generation of purified BKPyV 
3.2.1.1 Enzymatic digestions and re-ligations of the BKPyV genome 
Preparation of BKPyV genome was required to generate a purified and infectious 
stock of BKPyV that could be used in further experiments. For that reason, 10 µg of 
pGem7 BKPyV Dunlop plasmid (951 ng/μl) was digested by the restriction enzyme 
BamHI-HF in order to separate the BKPyV genomic DNA from the plasmid DNA. The 
same enzyme reaction was repeated 4 independent times. Digested products were 
analysed on an 0.8% agarose gel and bands were visualized confirming that the 
BKPyV genome was separated from the backbone plasmid DNA (Figure 3.1A). 
The digested linearized products were re-ligated before they could be used in further 
experiments. This was carried out by setting up ligation enzymatic reactions using the 
T4 DNA ligase enzyme. The same enzymatic reaction was performed 4 independent 
times. After the overnight incubation time of the digested products with the T4 DNA 
ligase enzyme, the re-ligated products were purified using a purification kit (See 
Section 2.3.2) following manufacturer’s instructions. Purified samples were quantified 
using a spectrophotometer and further analysed on an 0.8% agarose gel. Bands of 
the products were visualized indicating that the BKPyV genome was separately re-
ligated from the backbone plasmid DNA, whilst other ligated products were generated 
(Figure 3.1B).  
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Figure 3. 1 Digestions and ligations of the BKPyV genome. A. Four independent digestions of pGem7 BKPyV Dunlop plasmid (10 μg each) were loaded onto an 
0.8% agarose gel and run for 40 minutes at 80 V. Lane 1: 6 μl of DNA ladder 1 kb; Lane 2-5: 6 μl of digested pGem7 BKPyV Dunlop. B. Re-ligated products were 
loaded onto an 0.8% agarose gel and run for 40 minutes at 80 V. Lane 1: 6 μl of DNA ladder 1 kb; Lane 2-5: 6 μl of purified and ligated products (n= 3). 
A B 
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3.2.1.2 Transfections of the BKPyV genome into Vero cells 
The methodology to generate an infectious BKPyV stock is summarized in Figure 3.2. 
Initially, Vero cells were transfected with 4 μg of BKPyV genome using the NanoJuice 
transfection kit in a ratio 1-part of DNA: 2-parts of Core reagent: 3-parts of Booster 
(See Section 2.4.1) (Figure 3.3A). Cells were harvested 10 days post-transfection, 
and cell suspensions were stored. Samples of both cell pellets and media were 
analysed to identify the presence of intracellular and secreted BKPyV virions. The 
major capsid protein, VP1, was used as an indication marker of viral protein 
expression.  
Total protein of both cell lysates and media samples were separated by SDS-PAGE. 
The corresponding Western blots were probed with a monoclonal VP1 antibody and 
with a commercial GAPDH antibody as a protein loading control. The presence of 
VP1 in every sample, both cell pellets and media, respectively, was confirmed 
showing a clear band at the expected molecular weight of approximately 42 kDa 
(Figure 3.3B). Clear bands of GAPDH at the expected molecular weight of 
approximately 37 kDa (Figure 3.3B) were also detected confirming the equal amount 
of loaded total protein. 
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Figure 3. 2 Schematic representation of the two distinct stages of the BKPyV generation. In the first 
stage, Vero cells were transfected with 4 μg of the BKPyV genome and incubated for 10 days. Cell 
suspension was harvested and used to further infect naïve Vero cells. This step initiates the second 
stage of the experimental procedure. Cells infected with BKPyV crude cell suspension were incubated 
for 14 days. Cell suspension was harvested and further analysed for BKPyV VP1 protein expression. 
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Figure 3. 3 Transfections of Vero cells with the BKPyV genome. A. Schematic representation of the first 
stage of the generation of BKPyV stock. Vero cells were transfected with 4 μg of the BKPyV genome 
and incubated for 10 days. B. Total protein of cell lysates and media samples from the collected cell 
suspension were separated by SDS-PAGE and probed for VP1 (P5G6) as a marker of BKPyV 
transfection, and GAPDH as a loading control. Representative blots are shown from 2 independent flasks 
containing transfected Vero cells with BKPyV genome (n= 3). 
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3.2.1.3 Infections of Vero cells with the crude BKPyV cell suspension 
Collected cell suspension from the first stage of the process and confirmed by 
Western blot analysis that VP1 was present both intracellularly and extracellularly 
(Figure 3.3B) was used in this second stage. Prior to Vero infections, the frozen 
harvested cell suspension thawed out using a sequential freeze-thaw protocol. Briefly, 
the suspension exposed to liquid N2 and a 40oC water bath for 3 times, which bursts 
the infected cells to release any intracellular BKPyV virions. Vero cells were infected 
with the crude BKPyV cell suspension and incubated for 14 days. Cell suspensions 
were stored and samples of both cell pellets and media were analysed to identify the 
presence of intracellular and secreted virions.  
Total protein of both cell lysates and media samples were separated by SDS-PAGE 
and the corresponding Western blots were probed with a monoclonal VP1 antibody 
and a GAPDH antibody as a loading control. The presence of VP1 in every sample, 
both cell pellets and media, respectively, was confirmed showing a clear band at the 
expected molecular weight (Figure 3.4B) suggesting that BKPyV virions positive to 
VP1 were produced. 
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Figure 3. 4 Infections of Vero cells with the BKPyV crude cell suspension. A. Schematic representation 
of the second stage of the generation of BKPyV stock. Vero cells were infected with BKPyV crude cell 
suspension and incubated for 14 days. B. Total protein of cell lysates and media samples from the 
collected cell suspension were separated by SDS-PAGE and probed for VP1 (P5G6) as a marker of 
BKPyV infection, and GAPDH as a loading control. Representative blots are shown from 6 independent 
flasks (n= 3). 
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3.2.1.4 Purification of BKPyV virions to generate a stock of infectious BKPyV 
In order to use the collected crude cell suspension after the long process of the virus 
production, a virus purification was required. For that reason, we performed a virus 
purification, which was based on ultracentrifugation. Two different ultracentrifugation 
spins were carried out to separate the viral particles and other macromolecules into 
different component parts using sucrose and caesium chloride (CsCl) gradients 
(Jiang et al., 2009). After the overnight ultracentrifugation of the sample, 2 distinct 
bands were appeared in the heavy CsCl gradient, which were collected carefully using 
an 18-gauge syringe (Figure 3.5A).  
Before the collected BKPyV was used in further experiments, the extracted sample 
was examined whether it was positive for BKPyV viral proteins. To achieve this, total 
protein from pure collected samples was separated by SDS-PAGE and the 
corresponding Western blot was probed with a monoclonal VP1 antibody, as a BKPyV 
marker (Figure 3.5B). The presence of VP1 in the extracted sample was confirmed, 
suggesting that BKPyV virions positive for VP1 were collected after the virus 
purification. Samples from the collected virus were assessed by cryo-EM (Conducted 
by Daniel Hurdiss), which demonstrated the identical size and morphology to native 
BKPyV virions (Figure 3.5C). 
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Figure 3. 5 Purification of BKPyV stock. A. Image after the virus purification. Collected crude BKPyV cell 
suspension containing VP1 positive viral particles was purified under 2 ultracentrifugation steps using 
sucrose and CsCl gradients. Following the overnight ultracentrifugation, 2 distinct bands of BKPyV were 
collected (indicated red arrows). B. 5 μl of the purified and collected virus and 5 μl of a confirmed 
infectious sample (positive control) were separated by SDS-PAGE and probed for VP1 (P5G6) as a 
BKPyV marker. C. Cryo-electron micrograph of purified BKPyV sample suspended in vitreous ice. Scale 
bars, 50 nm. 
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3.2.2 Establishment of a high-throughput method to measure BKPyV 
infectivity  
Our next experimental objective was to examine whether the purified BKPyV stock 
was infectious and to determine the viral titres in order to perform our following 
experimental procedures under identical conditions. 
Methods to quantify viral amounts accurately might be carried out based on different 
ways as described below. Determination of levels of virus infectivity and measurement 
of the presence or function of viral proteins can be performed. Also, detection of viral 
or marker nucleic acid within the viral genome and counting physical viral particles, 
whether labeled or unmarked can be done (Heider and Metzner, 2014). However, 
most of current methods are labour-intensive and susceptible to human error. 
Accurate determination of the BKPyV titres was conducted using the IncuCyte ZOOM 
machine (Stewart et al., 2015). Purified BKPyV stock in 1:10 dilution was added to 
the first well and then 2-fold serially diluted BKPyV was used to infect cells in the wells 
across the plate. RPTE cells were infected with BKPyV for 2 hours at 37oC and 
subsequently incubated for 48 hours. Cells were then fixed, permeablized and BKPyV 
infection assayed through staining for VP1 as a marker of virus production. Using 
IncuCyte ZOOM analysis, the number of positive infected cells was measured. 
Results revealed an accumulation of VP1 in the nucleus of infected RPTE cells 
(Figure 3.6A). Three different batches of purified BKPyV were used in this experiment, 
although only the data of one batch is presented below as a representative example. 
The number of infected cells per well of the first three wells of the first row of the 96-
well plate was presented (Figure 3.6B). A decrease in the number of infected cells 
per well was observed across the plate due to the serial dilutions performed. Based 
on the number of infected cells, the infectious units per ml (IU/ml) were calculated for 
each sample of purified BKPyV. Also, the number of IU/ml of the first three wells of a 
row was presented (Figure 3.6C). Approximately, 5 x 105 IU/ml was the value of 
infectious units using the most concentrated sample.  
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Figure 3. 6 Titration of the purified BKPyV. RPTE cells were infected with a batch of purified BKPyV for 
2 hours at 37oC. Purified BKPyV in 1:10 dilution was added to the first well. Then followed a 2-fold serially 
dilution of BKPyV across the plate and infected cells were incubated for 48 hours. RPTE cells were fixed 
and stained with a primary anti-VP1 (1:250) antibody (pAb597) and a secondary anti-mouse alexa fluor-
conjugated 488. BKPyV VP1 was used as a marker of BKPyV infection. A. Subcellular localization of 
VP1 protein was detected in the nucleus of BKPyV infected cells. B. Positive infected cells per well were 
calculated for the first three serial dilutions of BKPyV across the plate. Values represent the mean ±SD 
of positive infected cells (n= 3) C. Positive infected cells were calculated by the IncuCyte ZOOM and 
extrapolated to produce BKPyV infectious units per ml (IU/ml). Values represent the mean ±SD of IU/ml 
(n= 3). 
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3.2.3 Profile of the BKPyV course of infection 
The BKPyV life cycle is poorly characterized and there are several aspects that needs 
to be elucidated. To identify the protein expression profile of the different viral proteins 
during the BKPyV life cycle, infection assays were performed. RPTE cells were 
infected with BKPyV at an MOI of 0.5 for 2 hours at 37oC. Infected cells were 
incubated over a course of 72 hours and harvested every 12 hours from the starting 
point of 12 hours post-infection to the ending time-point of 72 hours post-infection.  
Isolated total protein from lysates and media samples over the course of 72 hours 
post-infection were separated by SDS-PAGE and assayed for the late viral proteins 
by Western blotting (Figure 3.7A and C). The corresponding Western blots were 
probed with a monoclonal VP1 antibody, a commercial SV40 VP2/VP3 antibody, an 
agnoprotein antibody and a GAPDH antibody as a protein loading control. 
The presence of intracellular VP1, VP2/VP3 and agnoprotein was confirmed 48 hours 
post-infection by showing clear bands at the appropriate molecular weight of 
approximately, 42 kDa, 38 kDa, 26 kDa and 11 kDa, respectively. Much higher levels 
of the late proteins were detected between 60 and 72 hours post-infection, 
respectively (Figure 3.7A). Secreted viral capsid proteins were detected 60 hours 
post-infection with the highest level of expression detected at the end of the 
experimental time-course (Figure 3.7C).  
The same secreted samples were used to further infect RPTE cells in order to 
examine whether the released virus was infectious. Infected cells were incubated for 
48 hours at 37oC. Following to this, cells were fixed and stained for VP1 protein using 
the respective antibody and IncuCyte ZOOM analysis was conducted. Data revealed 
that the released virus was infectious. Interestingly, RPTE cells infected with the 48 
hours-sample were also positive for VP1 expression, even though viral capsid 
proteins were not detectable in the media samples by Western blotting at the 48 
hours-time-point (Figure 3.7D). Also, a greater number of VP1 positive cells were 
detected towards the end of the time-course (Figure 3.7D). 
 Another crucial stage of the BKPyV life cycle is the viral genome replication. To study 
the BKPyV replication, the time-course of infection was repeated using the same 
critical time-points as described above. Total DNA was extracted from each harvested 
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sample and analysed by quantitative PCR using specific primers against the viral 
genome. Due to the very low but detectable levels of viral DNA seen during the first 
24 hours post-infection, it was speculated that this was an artifact from the input virus. 
The first greater increase in viral genome copy numbers occurred 36 hours post-
infection, whilst they were constantly increased throughout the time-course, peaking 
72 hours post-infection (Figure 3.7B).
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Figure 3. 7 Viral protein expression and DNA replication in the BKPyV life cycle. A. RPTE cells were infected with BKPyV at an MOI of 0.5. Infected cells were 
incubated over a time-course (72 hpi) and harvested at the indicated time-points (12, 24, 36,48, 60 and 72 hpi, respectively). Total protein of cell lysates from infected 
RPTE cells was separated by SDS-PAGE. VP1 (P5G6), VP2/VP3, agnoprotein and GAPDH were detected on the corresponding Western blots with the respective 
antibodies. Representative blots are shown from 3 independent repeats. B. RPTE cells were infected with BKPyV at an MOI of 0.5. Infected cells were incubated 
over a time-course and harvested at the indicated time-points as described above. Quantitative PCR analysis of DNA viral genome was performed. Values represent 
the mean ±SD of viral genome copy numbers (n= 3). C. Total protein of media samples was separated by SDS-PAGE. VP1, VP2/VP3 were detected on the 
corresponding Western blots with the respective antibodies. Representative blots are shown from 3 independent repeats.  D. Collected media samples from each of 
the indicated time-points of the time-course were used to further infect RPTE cells for 48 hours. Cells were fixed and stained with a primary anti-VP1 (1:250) (pAb597) 
antibody and a secondary anti-mouse alexa fluor-conjugated 488. BKPyV VP1 protein was used as an infection marker. Positive infected cells were calculated by 
IncuCyte ZOOM and data represent the mean ±SD of positive infected cells (n= 3).
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3.3 Discussion 
3.3.1 Generation of purified BKPyV stock 
Generation of a purified and infectious stock of BKPyV was required in order to be 
used in further infection assays (Chapter 4 and Chapter 5). Initially, the re-circularized 
BKPyV genome was prepared, which was transfected into Vero cells. At every step 
and in particularly following digestions and re-ligations of the BKPyV genome, 
digested and re-ligated products, respectively, were analysed on 0.8% agarose gels 
and bands were visualized. It was confirmed that BKPyV genome of approximately 
5.0 kbp was separated from the backbone plasmid DNA (Figure 3.1A). Also, as it is 
shown in Figure 3.1B by visualizing the re-ligated products, the BKPyV genome was 
separately re-ligated from the backbone plasmid DNA which was at an approximate 
size of 3.0 kbp. 
Vero cells were transfected with the re-ligated BKPyV genome and incubated for 10 
days. Following to this incubation time, cell suspensions were harvested and further 
analysed. The presence of both intracellular and extracellular VP1 protein with higher 
levels of VP1 protein detected in cell lysates were confirmed by Western blot analysis 
(Figure 3.3B). This suggested that BKPyV virions positive for the major capsid protein 
VP1 were present in Vero cells and there was a release of BKPyV virions in media 
samples to a certain extend. Harvested cell suspensions from transfected Vero cells 
were freezed and thawed using liquid nitrogen in order to burst the transfected cells 
and release any intracellular BKPyV virions into the media. Next, crude cell 
suspensions were used to further infect naïve Vero cells. Infected Vero cells were 
incubated for 14 days and harvested samples of cell lysates and media were further 
analysed. By Western blot analysis (Figure 3.4B) it was confirmed that VP1 protein 
was present in both cell lysates and media samples, suggesting the presence of both 
intracellular and secreted BKPyV virions. Crude cell suspensions collected from the 
last stage of this experimental procedure were purified under two ultracentrifugations 
using sucrose and CsCl gradients (Moriyama and Sorokin, 2009). Collected and 
purified virus was analysed by Western blotting and cryo-EM, suggesting that BKPyV 
virions positive for VP1 were collected after the virus purification (Figure 3.5B). 
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3.3.2 Titration of purified BKPyV  
In this study, we established a novel high-throughput method to measure the BKPyV 
infectivity. The determination of viral titres is necessary to carry out each experiment 
in identical conditions. We adopted and optimized a method, which was previously 
published for the measurement of the Hepatitis C virus titres utilizing the IncuCyte 
ZOOM equipment (Stewart et al., 2015). By this method we quantified accurately the 
BKPyV titres performing infections of 2-fold serially diluted BKPyV on human RPTE 
cells (Figure 3.6B and C). This method is based on fluorescence microscopy and 
gives us the advantages to quantify accurately the number of positive infected cells 
and to detect the subcellular localization of the major capsid protein, VP1, as it was 
used as a BKPyV infection marker.  
Previous studies have described methods that involve lengthy assays by labour-
intensive counting of infected cells manually. Moriyama and Sorokin (2009) described 
the standard plaque assay for determination of the BKPyV titres; this has been 
improved and consists the basis of Fluorescent focus assay (FFA). The difference 
between FFA and plaque assay is that the number of infected cells could be detected 
by using antibodies against the BKPyV TAg. Low et al., (2004) and Abend et al., 
(2007) conducted FFA to measure the BKPyV infectivity by performing 10-fold 
dilutions of BKPyV and incubating the cells for 4 days. The BKPyV titres were 
determined as fluorescent forming units (FFU) by counting manually five random 
fields of view. However, only a 48 hour-incubation is required, and a fully automated 
data analysis is performed using the IncuCyte ZOOM equipment. By this method we 
could have more accurate and precise results, the reproducibility is higher as well and 
the processivity is also increased. It is known that TCID50 and focus-forming unit 
methods require and end point dilution, although this is not essential for the method 
that we described in our study. Thus, an extensive number of viral dilutions for each 
tested sample is not required and that leads to a reduced reagent cost per assay 
(Stewart et al., 2015).  
Alternative methods for BKPyV titration, such as core protein Elisa assay, have been 
utilized previously but all of them show significant disadvantages. These assays are 
high-throughput techniques, although there is no distinguish between defective viral 
particles and infectious virions or antigen released from dead cells. The same 
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downside is observed using the hemagglutination assay. Studies have shown that 
JCPyV VP1 protein is responsible for red blood cell agglutination and HA inhibition 
and consequently hemagglutination assays have been utilized to determine the 
JCPyV infectious titres. However, the hemagglutination assay is poorly sensitive and 
measurement of JCPyV viral load is often impossible in vitro. It is also known that this 
method cannot be efficient under certain experimental conditions, such as using 
microtiter and transwell plates (Chapagain et al., 2006). Quantitative and Real-Time 
PCRs have also been described as methods to identify the JCPyV infectious titres 
with more accurate results compared to hemagglutination and HA inhibition assays 
(Chapagain et al., 2006).  
The IncuCyte ZOOM analysis can also be applied in multiple areas of BKPyV studies 
as most of them require sensitive and accurate measurements of viral infectivity. By 
using this method, we could identify and validate novel anti-viral compounds having 
as an infection marker, VP1 protein expression (Chapter 4 and 5). In conclusion, we 
established and optimized a novel high-throughput method to determine the BKPyV 
titres on human primary kidney cells by using the IncuCyte ZOOM equipment and the 
appropriate software. This assay is a powerful tool for all the basic research involving 
not only BKPyV, but also other closely related polyomaviruses and the identification 
of innovative anti-viral compounds targeting host cell factors that are essential in 
different stages of the viral life cycle.  
 
3.3.3 Time-course of the BKPyV life cycle 
BKPyV is a human pathogen that establishes a persistent infection. The main site into 
the hosts that BKPyV reactivates and complete its life cycle is within kidneys and the 
urinary tract (Bennett et al., 2012). This leads to an establishment of an in vitro cell 
system that is similar to in vivo conditions. Most of our studies have been carried out 
using human primary kidney epithelial cells (RPTE) cells, which is the most 
physiologically relevant cell system to study the virus life cycle. 
Virus attachment to the host cell surface results in internalization of BKPyV into the 
host cell, which in turn leads to a successful infection. BKPyV traffics through the 
cytoplasm towards the nucleus, where the uncoated double-stranded DNA genome 
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manipulates the cellular machinery for early genes transcription, genome replication 
and late genes transcription. We performed infection assays on human RPTE cells to 
investigate the profile of BKPyV viral protein expression and genome replication over 
a specific period.  
Previous studies have examined the time-course of the BKPyV life cycle as well (Low 
et al., 2004). Infection assays, over the course of 11 days, identified that TAg 
expression was first detected approximately 24 hours post-infection and its 
expression levels peaked at 7 days post-infection and remained at the same levels 
throughout the rest of the incubation time (Low et al., 2004). In our studies, we failed 
to detect TAg by Western blotting (Data not shown), therefore we focused on the 
expression of the late viral proteins.  
Following to early genes transcription, the viral genome replication occurs. To 
examine the time-course of viral DNA replication, we performed infection assays of 
human RPTE cells over a time-course of 72 hours. Total DNA was extracted from 
infected RPTE cells and quantitative PCR analysis was performed. Very low levels of 
BKPyV DNA were detected during the first 12 and 24 hours post-infection, 
respectively (Figure 3.7B). This suggested that it was observed as an artifact from the 
DNA of input virus. The first higher increase in viral genome copy numbers was 
observed 36 hours post-infection, which was expected due to the initiation of TAg 
expression approximately 24 hours post-infection, as it was previously demonstrated 
from other studies (Low et al., 2004). The viral DNA levels were constantly increased 
and peaked towards the end of the time-course. Previous studies demonstrated that 
viral DNA levels were detected approximately 36 hours post-infection showing an 
increasing trend throughout the course of infection and reaching their highest levels 
9 days post-infection (Low et al., 2004), supporting our findings.  
After identifying the stages of the early viral genes transcription, and the viral DNA 
replication, we determined the stage of the BKPyV life cycle that the late viral proteins 
were expressed. Total intracellular and secreted proteins were isolated from infected 
RPTE cells over a time-course of infection. The late viral proteins were detectable 
intracellularly approximately 48 hours post-infection (Figure 3.7A). Previous studies 
demonstrated the presence of VP1 between 36 and 48 hours post-infection by 
Western blot analysis. It was also suggested that VP1 expression levels were 
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increased throughout the course of infection peaking approximately 11 days post-
infection (Low et al., 2004). These findings are partially agreed with our data, as we 
detected the VP1 expression approximately 48 hours after infection. 
Progeny viral particles formed when viral capsomeres assemble around newly 
synthesized viral genomes, although the mechanism of viral egress is not fully defined 
(Bennett et al., 2012). To identify the stage that newly synthesized viral progeny was 
secreted, infection assays were performed under identical conditions as previously 
described. It was identified that secreted late viral proteins were detectable at later 
stages of the viral life cycle, approximately 60 hours post-infection (Figure 3.7C). In 
addition to that, we examined whether the released virus over this time-course was 
infectious. Notably, the released viral progeny was infectious, and it was also found 
that there was release of BKPyV virions approximately 48 hours post-infection, even 
though that was not detected by Western blotting (Figure 3.7C and D). This might be 
due to higher sensitivity of the IncuCyte ZOOM analysis compared to Western 
blotting. A greater number of infected cells was observed towards the end of the time-
course peaking approximately 72 hours post-infection (Figure 3.7D). Due to very low 
numbers of infected cells seen during the initial 36 hours post-infection, we suggested 
that this was an artifact from the input virus.  
By examining and determining all the critical steps of the BKPyV life cycle, we could 
have assayed inhibitory compounds that target host cell factors at specific time-points 
and study their effect on the virus life cycle. These studies are clearly defined in the 
following Chapters (Chapter 4 and 5). 
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 Host ion channels and the BKPyV life cycle 
4.1 Introduction 
4.1.1 Targeting host cell factors as potential anti-viral therapy 
Viruses as obligate intracellular parasites require host cellular machineries to 
complete their life cycles. In order to transport their genetic material through the host 
cells, attachment of the virions to host cell receptors and/or additional co-receptor(s) 
is required (Bhattacharjee, 2015). Following successful binding to host cell receptor, 
the internalization is mediated by endocytic transport pathways, which are distinct to 
each virus (Bhattacharjee, 2015). There are several mechanisms of virus entry; by 
exemplification many enveloped viruses, including members of Paramyxoviridae, 
enter host cells via activation of viral fusion proteins, whereas influenza virus utilizes 
a receptor-mediated endocytic pathway for a successful entry (Kielian, 2014). On the 
other hand, the entry mechanism of non-enveloped viruses may significantly vary; 
from disruption of endosomes at low pH levels, which observed during adenovirus 
infection, or pore formation at plasma membrane during poliovirus infection and via 
caveolae, which is identified during SV40 infection (Marsh and Helenius, 2006; 
Mudhakir and Harashima, 2009). Recent accumulating evidence reveals a clathrin-
independent endocytic pathway, micropinocytosis, which is utilized by several viruses 
from different families including Ebola virus, influenza virus A, adenovirus 35, 
Kaposi’s sarcoma-associated herpesvirus, Nipah virus and Old World Arenaviruses 
(Kunz, 2009; Mercer and Helenius, 2012). Then, viruses enter host cell nucleus to 
replicate their genome by exploiting host cellular machineries.  
Specific viral proteins and enzymes can be targeted as a conventional therapeutic 
approach against viral infections, although by this approach there is always the risk 
of targeting viral factors that are evolved to resistant varieties due to the ability of 
viruses for rapid genetic changes and evolution (Bhattacharjee, 2015). Therefore, 
there is an urgent need to identify a novel therapeutic strategy that avoids selection 
of resistant viral strains and shows greater efficiency and specificity. This implies to 
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target critical virus-host interactions that are required for a successful viral infection. 
Currently, there are few promising drugs that target host proteins and are ready to be 
commercially available; including Maraviroc which is a CCR5 co-receptor antagonist 
as a therapy for HIV and DAS181, a recombinant sialidase fusion protein that acts 
against influenza virus and TSG101 (de Chassey et al., 2012). Thus, investigating 
and understanding of virus and host interactions is a prerequisite to identify novel 
druggable cellular targets. 
 
4.1.2 Chapter Aims 
Ion channels have emerged as essential host factors in the life cycles of a number of 
human viruses (Hover et al., 2017). The main aim of this Chapter is to determine the 
role of host ion channels in the BKPyV life cycle and to validate their potential as a 
target for novel anti-viral therapeutics to treat PVAN, the leading cause of kidney 
transplant rejection worldwide. Preliminary data from our group showed that blockade 
of host cell K+ channels impedes the BKPyV life cycle by an uncharacterized 
mechanism. K+ channels were selected for initial investigations as they represent the 
largest ion channel family distributed in most cell types and an array of blockers to 
specific K+ channel family members are available and well characterized. 
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4.2 Results 
4.2.1  Examination of host K+ channels as potential targets against BKPyV 
4.2.1.1 Host K+ channels might be critical for BKPyV infection 
Previous studies from our group suggested that the host cell K+ channel family is 
involved in the BKPyV life cycle by an unknown mechanism. The initial experimental 
objective was to validate these findings. Primary renal proximal tubular epithelial cells 
(RPTE cells) were infected with BKPyV at an MOI of 0.5 for 2 hours at 37oC and then 
were treated with tetraethylammonium (TEA), which is a broad-spectrum K+ channel 
blocker, at a range of concentrations for 48 hours post-infection. Cells were then fixed 
and BKPyV infection assayed through staining for VP1 as a marker of virus 
production. Using IncuCyte ZOOM analysis, an accumulation of VP1 was observed 
in the nucleus of infected cells 48 hours post-infection (Figure 4.1A). A decrease of 
BKPyV VP1 expression in a dose-dependent manner was revealed upon treatment 
with TEA. The highest dose of TEA (20 mM) caused a greater than 60% reduction of 
VP1 expression (Figure 4.1B).   
More chemical compounds that impact on K+ channel family were next used to study 
their effect on BKPyV production. RPTE cells were infected with BKPyV at an MOI of 
0.5 for 2 hours at 37oC. Following infections, cells were treated with 20 mM of TEA 
and 30 mM of potassium chloride (KCl), which collapses K+ gradient across cellular 
membrane and inhibits K+ channels indirectly. Cells were also treated with 30 mM of 
sodium chloride (NaCl) for 48 hours as a control for osmolarity (Figure 4.2A). Cell 
pellets were lysed, and total protein was separated by SDS-PAGE. The 
corresponding Western blots were probed with a polyclonal VP1 antibody and a 
GAPDH antibody as a loading control. The presence of VP1 was confirmed at the 
expected molecular weight (42 kDa). Both TEA and KCl caused a decrease of VP1 
protein expression, although there was no effect upon treatment with NaCl (Figure 
4.2B). 
Pharmacological analysis with identical treatments were repeated with the addition of 
15 μg/ml of Cidofovir, which is an anti-viral agent, as a positive control (Figure 4.2A). 
Treated cells were incubated for 48 hours, then were fixed, and BKPyV infection 
assayed through staining for VP1 as a marker of virus production. Using IncuCyte 
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ZOOM analysis, the level of VP1 expression was measured. An accumulation of VP1 
was observed in the nucleus of infected cells 48 hours post-infection (Figure 4.2C). 
Results revealed that TEA caused a decrease of BKPyV VP1 expression of 
approximately 70% and both KCl and Cidofovir had a similar effect on VP1 protein 
levels causing 40% reduction. NaCl did not affect VP1 expression levels (Figure 
4.1D). Taken together, these data suggest that K+ channels might impact on the 
BKPyV life cycle.  
Modulators that were used in this study have been examined by cell toxicity assay 
and there was no detrimental effect on cell viability suggesting that their effect is 
caused by the actual modulator and not because of cell mortality (Figure 4.2E).   
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Figure 4. 1 TEA inhibits BKPyV infection in RPTE cells. A. RPTE cells were infected with BKPyV at an 
MOI of 0.5 and treated with 5 mM, 10 mM and 20 mM of TEA, respectively for 48 hours. RPTE cells 
were fixed and stained with a primary anti-VP1 (1:250) (pAb597) antibody and a secondary anti-mouse 
alexa fluor-conjugated 488. BKPyV VP1 was used as marker of BKPyV infection. Subcellular localization 
of VP1 protein was detected in the nucleus of BKPyV infected cells. B. Positive infected cells were 
calculated by IncuCyte ZOOM and normalized to the no-drug control sample. Values represent the mean 
±SD of positive infected cells (n= 3) (*, significant difference at the p ≤ 0.05 level).
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Figure 4. 2 K+ channels inhibition reduces BKPyV infection in RPTE cells. A. Table presenting chemical compounds and concentration applied to cells. B. RPTE 
cells were infected with BKPyV at an MOI of 0.5 and treated with chemical modulators presented on the table for 48 hours. Total protein of cell lysates from infected 
cells was separated by SDS-PAGE and probed for VP1 (pAb597) as a BKPyV infection marker, and GAPDH as a loading control. Representative blots are shown 
from two independent infections. C. RPTE cells were infected with BKPyV at an MOI of 0.5 and treated with chemical compounds presented on the table for 48 
hours. RPTE cells were fixed and stained with a primary anti-VP1 antibody (pAb597) and a secondary anti-mouse alexa fluor-conjugated 488. BKPyV VP1 was used 
as marker of BKPyV infection. Subcellular localization of VP1 protein was detected in the nucleus of BKPyV infected cells. D. Positive infected cells were calculated 
by IncuCyte ZOOM and normalized to the no-drug control. Values represent the mean ±SD of positive infected cells (n= 3) (TEA and KCl treatments were performed 
at the same time- NaCl and Cidofovir were performed at different times, respectively). E. RPTE cells were treated under identical treatment conditions and cell 
viability assessed via MTT assays. Values represent the mean ±SD normalized to the untreated controls (n= 3) (*, significant difference at the p ≤ 0.05 level; **, 
significant difference at the p ≤ 0.01 level).
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4.2.1.2 ATP-sensitive K+ channels are required for a productive BKPyV infection 
K+ channel family can regulate several cellular processes and is the largest ion 
channel family consisting of a number of different K+ channel subfamilies (Table 4.1). 
To identify which subfamily of this wide group might be required for a productive life 
cycle, a more detailed pharmacological analysis was performed. To achieve this, 
RPTE cells were infected with BKPyV at an MOI of 0.5 for 2 hours at 37oC. Cells were 
treated with a panel of K+ channel modulators that target different K+ channel 
subfamilies. Cells were treated with 20 mM of TEA and 50 μM of Quinidine, which are 
broad-spectrum inhibitors of K+ channels. Infected RPTE cells were also treated with 
1 mM of barium chloride (BaCl2), which blocks the function of inward rectifier K+ 
channels. 4-Aminopyridine (4AP) was also used at 0.5 mM; this organic compound 
inhibits voltage-gated K+ channels; 20 μM of Glibenclamide, which impedes the 
function of ATP-sensitive K+ channels, and 0.5 μM of Apamin, which blocks Ca+2-
activated K+ channels were utilized (Figure 4.3A). Cells were lysed 48 hours post-
infection, and VP1 expression assessed by Western blot analysis. Treatment with 
TEA and Glibenclamide caused a decrease of VP1 protein expression levels, with 
Glibenclamide showing a more potent effect. In contrast, there was no effect upon 
treatment with the other ion channel modulators (Figure 4.3B and C). These results 
suggested that ATP-sensitive K+ channels, as a major Glibenclamide target, might 
play a role in the BKPyV life cycle.  
Ion channel blockers that were used have been examined by cell toxicity assay to 
identify whether the resulting effect was due to loss of cell viability. Findings from 
toxicity assays reveal that Quinidine and Glibenclamide at the applied concentration 
reduced cell viability by approximately 25%, respectively.  Although, Quinidine did not 
cause any decrease of VP1 protein expression levels and Glibenclamide had a 
greater impact on VP1 expression, which was not occurred due to loss of cell viability 
entirely (Figure 4.3D). 
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Table 4. 1 Potassium channel family. K+   channel classes , subclasses, function and pharmacology are 
shown below (Rang, 2003).
Class Subclasses Function Blockers Activators 
Ca2+-
activated 
6T & 1T 
• BK 
channel 
• SK 
channel 
• IK 
channel 
Inhibition in response 
to rising intracellular 
Ca2+ 
• Charybdotoxin, 
Iberiotoxin 
• Apamin 
• 1-EBIO 
• NS309 
• CyPPA 
Inwardly 
rectifying 
2T &1P 
• ROMK • Recycling 
and secretion 
of K+ in 
nephrons 
• Non-selective Ba2+, 
Cs+ 
• none 
• GPCR 
regulated 
• Mediate the 
inhibitory 
effect of 
many 
GPCRs 
• GPCR antagonists 
• Ifenprodil 
• GPCR 
agonists 
• ATP-
sensitive 
• Close when 
ATP is high 
to promote 
insulin 
secretion 
• Glibenclaimde 
• Tolbutamide 
• Diazoxide 
• Pinacidil 
• Minoxidil 
• Nicorandil 
Tandem 
pore 
domain 
4T & 2P 
• TWIK 
• TREK 
• TASK 
• TALK 
• THIK 
• TRESK 
• Contribute to 
resting 
potential 
• Bupivacaine 
• Quinidine 
• Halothane 
Voltage-
gated 6T 
&1P 
• Herg 
• KvLQT1 
• Action 
potential 
repolarization 
• Limits 
frequency of 
action 
potentials  
• Tetraethylammonium 
• 4-Aminopyridine 
• Dendrotoxins 
• Retigabine 
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Figure 4. 3 ATP-sensitive K+ channels are required for BKPyV production in RPTE cells. A. Table 
presenting chemical compounds and concentration applied to cells. B. RPTE cells were infected with 
BKPyV at an MOI of 0.5 and treated with chemical modulators for 48 hours. Total protein of cell lysates 
from infected cells was separated by SDS-PAGE and probed for VP1 (pAb597) as a marker of BKPyV 
infection, and GAPDH as a loading control. Representative blots are shown from three independent 
infections. C. Densitometry analysis of Western blots was performed. Values represent the mean ±SD 
normalized to the no-drug control (n= 3). D. RPTE cells were treated as above and cell viability assessed 
via MTT assays. Values represent the mean ±SD normalized to the untreated control (n= 3) (*, significant 
difference at the p ≤ 0.05 level; **, significant difference at the p ≤ 0.01 level; ***, significant difference at 
the p ≤ 0.001).  
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4.2.2 Targeting ATP-sensitive K+ channels to study their impact on the BKPyV 
life cycle 
ATP-sensitive K+ channel complexes are regulated by intracellular nucleosides, such 
as ATP and ADP. They are composed of an inward rectifier Kir6.x-type (1, 2) subunit 
and the sulfonylurea receptor-type (SUR1, SUR2A, SURS2B) subunits (Stephan et 
al., 2006). Sulfonylurea pharmacological compounds, including Glibenclamide, can 
inhibit the ATP-sensitive K+ channels by binding to sulfonylurea regulatory subunits 
(Serrano-Martín et al., 2006). Tolbutamide is also a sulfonylurea inhibitor, blocks the 
function of ATP-sensitive K+ channels and shows a higher specificity to ion channel 
complexes composed of SUR1-type subunits (Walker and Parrish, 1988).  
Previous findings revealed that ATP-sensitive K+ channels might play an important 
role in the BKPyV life cycle, because inhibition of these ion channel complexes 
impedes viral protein expression. Pharmacological analysis using other chemical 
modulators that target specifically the same family member was performed. RPTE 
cells were infected with BKPyV at an MOI of 0.5 for 2 hours at 37oC. Cells were treated 
with two different sulfonylurea inhibitors, including 20 μM of Glibenclamide and 150 
μM of Tolbutamide for 48 hours (Figure 4.4A). Cells were fixed, and BKPyV infection 
assayed through staining for VP1 as a marker of virus infection using IncuCyte ZOOM 
analysis. Results showed an accumulation of VP1 within the nucleus of infected RPTE 
cells (Figure 4.4B). There was an ~83% decrease in VP1 positive cells compared to 
the untreated control sample upon treatment with Glibenclamide. However, a more 
modest effect of Tolbutamide was observed, causing a 20% reduction of VP1 
expression levels, even though both chemical modulators target the same family 
member (Figure 4.4C). These findings suggest that the potential ATP-sensitive K+ 
channel complex, which is expressed in RPTE cells and affects BKPyV is likely less 
sensitive to Tolbutamide. Both inhibitors have been examined by cell toxicity assay to 
identify whether the resulting effect was due to loss of cell viability. Findings from 
toxicity assays revealed that Tolbutamide did not cause any effect on cell viability. 
Glibenclamide at the applied concentration reduced cell viability by approximately 
25% (Figure 4.4D). 
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Plasma membrane channels play a critical role in regulating the resting membrane 
potential, which can become hyperpolarized (more negatively charged) or 
depolarized (more positively charged) depending on specific stimuli that regulates the 
channel activity. DiBAC4(3) is a fluorescent dye that has been used to monitor 
changes in the resting membrane potential over short time periods (Bräuner et al., 
1984). In cells treated with DiBAC4(3), increased fluorescence is indicative of 
membrane depolarization, whilst a decrease in fluorescence over time indicates 
membrane hyperpolarization (Baxter et al., 2002). To support the pharmacological 
data, the effects of both modulators on the resting membrane potential of RPTE cells 
were investigated, DiBAC4(3) was added to RPTE cells treated with 20 μM of 
Glibenclamide or 150 μM of Tolbutamide for 48 hours and DiBAC4(3) fluorescence 
assessed by flow cytometry. Glibenclamide led to a depolarization of plasma 
membrane evidenced by the 0.2-fold increase in fluorescence observed following 
drug treatments, compared to no-drug controls (Figure 4.4E). However, there was no 
effect of Tolbutamide treatment on plasma membrane polarization as no shift of the 
fluorescence dye was observed (Figure 4.4E) in comparison with the untreated 
control sample, suggesting that at the applied concentrations only Glibenclamide was 
able to alter resting membrane potential.  
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Figure 4. 4 ATP-sensitive K+ channels expressed in RPTE cells are more sensitive to Glibenclamide 
compared to Tolbutamide. A. Table presenting chemical compounds and concentration applied to cells. 
B. RPTE cells were infected with BKPyV at an MOI of 0.5 and treated with chemical modulators for 48 
hours. Cells were fixed and stained with a primary anti-VP1 (pAb597) antibody and a secondary alexa 
fluor-conjugated 488. BKPyV VP1 was used as marker of BKPyV infection. Subcellular localization of 
VP1 protein was detected in the nucleus of BKPyV infected cells. C. Positive infected cells were 
normalized to the untreated control sample. Values represent the mean ±SD of positive infected cells 
(n= 3). D. RPTE cells were treated as above, and cell viability assessed via MTT assays. Values 
represent the mean ±SD normalized to the untreated control (n= 3). E. RPTE cells were treated with 20 
μM of Glibenclamide or 150 μM of Tolbutamide and incubated for 48 hours. 20 μM of DiBAC4(3) was 
added to treated cells and flow cytometry analysis of total cell fluorescence was measured. Values 
represent the mean ±SD normalized to the untreated control (n= 3) (*, significant difference at the p ≤ 
0.05 level; **, significant difference at the p ≤ 0.01 level; ***, significant difference at the p ≤ 0.001).  
C(i) A 
0
20
40
60
80
100
120
%
V
P
1
 p
o
s
it
iv
e
 c
e
lls
Treatment
*** 
B 
VP1 VP1 
VP1 
Mock Untreated 
Glibenclamide 
(20 μΜ) 
VP1 
Tolbutamide 
(150 μΜ) 
D 
0
20
40
60
80
100
120
140
%
C
e
ll 
v
ia
b
ili
ty
Treatment
*
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
F
o
ld
s
 o
f 
n
o
rm
a
liz
e
d
 D
iB
A
C
4
(3
) 
fl
u
o
re
s
c
e
n
c
e
Treatment
E 
0
20
40
60
80
100
120
%
V
P
1
 p
o
s
it
iv
e
 c
e
lls
Treatment
** 
C(ii) 
144 
 
 
To test more chemical compounds which modulate ATP-sensitive K+ channels either 
by inhibiting or activating them, further pharmacological-based analysis was 
conducted. ATP-sensitive K+ channels are located on the plasma membrane, 
although previous studies have identified that these ion channel complexes can also 
be found on subcellular membranes including mitochondrial, sarcolemmal and 
nuclear membranes (Stephan et al., 2006). Studies have shown that Glibenclamide 
and Tolbutamide exhibit different potencies for the different SUR subunits. It is also 
known that the chemical compound U-37883A inhibits selectively ATP-sensitive K+ 
channels containing Kir6.1-type subunits and has no inhibitory impact on ATP-
sensitive K+ channels composed of Kir6.2-type subunits, regardless of the co-
expressed SUR-type subunits (Teramoto, 2006). 
RPTE cells were infected with BKPyV at an MOI of 0.5 for 2 hours at 37oC and treated 
with compounds that target ATP-sensitive K+ channels located on mitochondrial 
membranes (5-Hydroxydecanoate (5HD)) and ATP-sensitive K+ channels containing 
Kir6.1-type subunits (U-37883A). 500 μM of 5HD or 50 μM of U-37883A were added 
to infected RPTE cells for 48 hours (Figure 4.5A). Cells were then fixed, and BKPyV 
infection examined through staining for BKPyV VP1 as a marker of infection. Results 
showed an accumulation of VP1 within the nucleus of infected RPTE cells (Figure 
4.5B). However, there was no effect on VP1 expression upon treatment with the 
modulators (Figure 4.5C). These findings suggest that the potential ATP-sensitive K+ 
channel complex, which is expressed in RPTE cells and affects BKPyV is not located 
on mitochondrial membranes or composed of Kir6.1-type subunits. Both inhibitors 
have been assessed by cell toxicity assays and findings revealed that neither 5HD or 
U-37883A cause reduction of cell viability (Figure 4.5D). The ability of both modulators 
to influence the resting membrane potential of RPTE cells was investigated. To 
determine this, RPTE cells were treated with 500 μM of 5HD or 50 μM of U-37883A 
for 48 hours and DiBAC4(3) was added to treated cells. Flow cytometry analysis 
showed that 5HD caused a very modest effect on membrane polarization of RPTE 
cells as evidenced by the 0.1-fold increase in fluorescence compared to no-drug 
controls. Notably, U-37883A had a higher impact on resting membrane potential of 
RPTE cells as revealed by the 0.7-fold increase in DiBAC4(3) fluorescence in treated 
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cells compared to the untreated controls (Figure 4.5E), suggesting that U-37883A 
treatment at the applied concentration is able to cause depolarization of RPTE cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
146 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 5 Mitochondrial or Kir6.1-type-ATP-sensitive K+ channel blockers do not reduce BKPyV 
infection in RPTE cells. A. Table presenting chemical compounds and concentration applied to cells. B. 
RPTE cells were infected with BKPyV at an MOI of 0.5 and treated with 5HD and U-37883A for 48 hours. 
Cells were fixed and stained with a primary anti-VP1 (pAb597) antibody and a secondary anti-mouse 
alexa fluor-conjugated 488. VP1 protein was detected by IncuCyte ZOOM screening as a marker of 
infection. VP1 protein was detected in the nucleus of BKPyV infected cells. C. Positive infected cells 
were calculated by IncuCyte ZOOM and normalized to the untreated control. Values represent the mean 
±SD of positive infected cells (n= 3). D. RPTE cells were treated as above for 48 hours and cell viability 
assessed via MTT assays. Values represent the mean ±SD of three independent experiments and 
normalized to the untreated control. E. RPTE cells were treated as above for 48 hours. 20 μM of 
DiBAC4(3) was added to treated cells and flow cytometry analysis of total cell fluorescence was 
measured. Values represent the mean ±SD normalized to the no-drug control (n= 3) (*, significant 
difference at the p ≤ 0.05 level; **, significant difference at the p ≤ 0.01 level).  
 
A B 
VP1 
Mock 
VP1 
Untreated 
VP1 
U-37883A 
(50 μΜ) 
VP1 
5HD (500 μΜ) 
C(i) 
0
20
40
60
80
100
120
%
V
P
1
 p
o
s
it
iv
e
 c
e
lls
Treatment
D 
0
20
40
60
80
100
120
140
%
C
e
ll 
v
ia
b
ili
ty
Treatment
* 
E 
0
0.5
1
1.5
2
2.5
F
o
ld
s
 o
f 
n
o
rm
a
liz
e
d
 D
iB
A
C
3
(4
) 
fl
u
o
re
s
c
e
n
c
e
Treatment
**
0
20
40
60
80
100
120
140
160
180
%
V
P
1
 p
o
s
it
iv
e
 c
e
lls
Treatment
C(ii) 
147 
 
There are well characterized ATP-sensitive K+ channel openers, such as Diazoxide 
and Pinacidil (Chowdhury et al., 2013; Gollasch et al., 1995) and their function were 
assessed to investigate their effect on BKPyV production. RPTE cells were infected 
with BKPyV (MOI 0.5) for 2 hours at 37oC and treatment with 50 μM of Diazoxide or 
20 μM of Pinacidil was performed for 48 hours (Figure 4.6A). Cells were lysed 48 
hours post-infection, and VP1 expression assessed by Western blot analysis. Results 
from Western blotting confirmed the expression of VP1. Interestingly, there was a 
reduction of VP1 protein expression in the presence of Diazoxide, whereas no effect 
was observed upon treatment with Pinacidil (Figure 4.6B). Findings from toxicity 
assays revealed that neither Diazoxide or Pinacidil caused metabolic changes (Figure 
4.6C). 
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Figure 4. 6 ATP-sensitive K+ channel openers and BKPyV production. A. Table presenting chemical 
compounds and concentration applied to cells. B. RPTE cells were infected with BKPyV at an MOI of 
0.5 and treated with ion channel activators for 48 hours. Total protein of cell lysates from infected cells 
was separated by SDS-PAGE and probed for VP1 (pAb597) as a BKPyV infection marker, and GAPDH 
as a loading control. Representative blots are shown from two independent infections. C. RPTE cells 
were treated as above for 48 hours and cell viability assessed via MTT assays. Values represent the 
mean ±SD normalized to the untreated control (n= 3). 
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Taken together all the previous data, Glibenclamide causes a reduction of VP1 
expression suggesting that ATP-sensitive K+ channels which are targeted by 
Glibeclamide might be involved in the BKPyV life cycle by an unknown mechanism. 
However, pharmacological analysis using other chemical modulators which also 
target this family member indicate that there is no effect on viral protein expression 
upon treatments. Therefore, ATP-sensitive K+ channels might not be required for a 
successful BKPyV life cycle in RPTE cells. Although, Glibenclamide might target 
another host factor which is essential for BKPyV production and a more in-depth 
analysis was performed to identify the target of this compound.  
 
4.2.3 Glibenclamide reduces BKPyV infection in RPTE cells 
4.2.3.1 Glibenclamide blocks BKPyV in a dose-dependent fashion 
To identify the highest dose of Glibenclamide that could be applied to cells without 
causing cell toxicity and the lowest dose that could be applied to minimize its effect 
on BKPyV, titration of Glibenclamide was carried out. RPTE cells were infected with 
BKPyV at an MOI of 0.5 for 2 hours at 37oC and then treated with Glibeclamide for 48 
hours; 10 μM, 20 μM, 35 μM and 50 μM, respectively. Cells were lysed and BKPyV 
infection assessed through the expression of VP1 by Western blotting. 
Results from Western blotting indicated that the presence of VP1 was confirmed in 
the untreated control sample showing a clear band at the expected molecular weight 
of approximately 42 kDa. Faint bands of VP1 were identified in the other samples 
suggesting that even lower doses of Glibenclamide (10 μM) can cause detrimental 
effects on VP1 protein expression (Figure 4.7A). Cell viability assays were also 
performed to examine whether this loss of VP1 expression was due to toxicity caused 
by the increasing doses of Glibenclamide. Data suggested that doses higher than 20 
μM of Glibenclamide lead to decrease of cell viability. (Figure 4.7B).  
In order to determine the minimum concentration at which Glibenclamide can inhibit 
VP1 expression, a more detailed titration was conducted. RPTE cells were infected 
with BKPyV at an MOI of 0.5 for 2 hours at 37oC and then treated with different doses 
of Glibenclamide for 48 hours; 0.5 μM, 1 μM, 2 μM, 4 μM, 6 μM, 8 μM, 10 μM, 15 μM 
150 
 
and 20 μM, respectively. Cells were fixed, and BKPyV infection assayed through 
staining for VP1 as a marker of virus production using IncuCyte ZOOM analysis. 
BKPyV VP1 staining was again observed in the nucleus of infected cells, 48 hours 
post-infection (Figure 4.7C). There was approximately 25% reduction of VP1 
expression upon treatment with the lowest concentration of Glibenclamide. A 
significant and proportional decreasing trend of VP1 expression levels was observed 
upon the gradually higher doses of Glibenclamide (Figure 4.7D). Taken together, 
these data suggest that Glibenclamide inhibits BKPyV production in a dose-
dependent manner.   
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Figure 4. 7 Glibenclamide reduces BKPyV production in a dose-dependent manner. A. RPTE cells were infected with BKPyV at an MOI of 0.5 and treated with 10 
μM, 20 μM, 35 μM and 50 μM of Glibenclamide, respectively for 48 hours. Total protein of cell lysates from infected cells was separated by SDS-PAGE and probed 
for VP1 (P5G6) as a marker of BKPyV infection, and GAPDH as a loading control. Representative blots are shown from two independent infections. B. RPTE cells 
were treated as above for 48 hours and cell viability assessed via MTT assays. Values represent the mean ±SD normalized to the no-drug control (n= 3). C. RPTE 
cells were infected with BKPyV at an MOI of 0.5 and treated with 0.5 μM, 1 μM, 2 μM, 4 μM, 6 μM, 8 μM, 10 μM, 15 μM and 20 μM of Glibenclamide, respectively 
for 48 hours. Cells were fixed and stained with a primary anti-VP1 (1:250) (pAb597) antibody and a secondary anti-mouse alexa fluor-conjugated 488. BKPyV VP1 
was used as marker of BKPyV infection. Subcellular localization of VP1 protein was detected in the nucleus of BKPyV infected cells. D. Positive infected cells were 
normalized to the untreated control sample. Values represent the mean ±SD of positive infected cells (n= 3) (*, significant difference at the p ≤ 0.05 level; **, significant 
difference at the p ≤ 0.01 level; ***, significant difference at the p ≤ 0.001 level; ****, significant difference at the p ≤ 0.0001 level).
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4.2.3.2 Glibenclamide inhibits BKPyV production in an MOI-independent manner 
To identify whether the effect of Glibenclamide was dependent on the amount of 
infectious virus that was added to cells, infection assays using different MOIs of 
BKPyV were conducted. To achieve this, RPTE cells were infected with BKPyV at an 
MOI of 0.5 and 5, respectively, for 2 hours at 37oC and treated with 20 μM of 
Glibenclamide for 48 hours. Then, infected cells were fixed, and BKPyV infection 
assayed through staining for VP1 as a marker of virus production using IncuCyte 
ZOOM analysis. BKPyV VP1 staining was observed in the nucleus of infected cells, 
48 hours post-infection (Data not shown). Results demonstrated that there was a 
significant reduction (~ 80%) of VP1 expression regardless of the different amount of 
virus that was added to cells (Figure 4.8 A and B).   
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Figure 4. 8 The Glibenclamide effect is BKPyV MOI-independent. A. RPTE cells were infected with 
BKPyV at an MOI of 0.5 and treated with 20 μM of Glibenclamide for 48 hours. Cells were fixed and 
stained with a primary anti-VP1 (1:250) (pAb597) antibody and a secondary anti-mouse alexa fluor-
conjugated 488. BKPyV VP1 protein was used as a marker of BKPyV infection. Positive infected cells 
were normalized the untreated control. Data represent the mean ±SD of positive infected cells (n= 3). B. 
RPTE cells were infected with BKPyV at an MOI of 5 and treated with 20 μM of Glibenclamide for 48 
hours. Cells were fixed and stained with a primary anti-VP1 (1:250) (pAb597) antibody and a secondary 
anti-mouse alexa fluor-conjugated 488. Positive infected cells were normalized to the no-drug control. 
Values represent the mean ±SD of positive infected cells (n= 3) (***, significant difference at the p ≤ 
0.001 level). 
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4.2.3.3 Glibenclamide reduces BKPyV viral proteins expression and genome 
replication 
In previous experiments BKPyV VP1 was used as an infection marker, therefore we 
next investigated the effect of Gliblenclamide on other aspects of the life cycle 
including viral protein expression and genome replication. For that reason, RPTE cells 
were infected with BKPyV (MOI 0.5) for 2 hours at 37oC and treated with 20 μM of 
Glibenclamide for 48 hours. Isolated total protein from lysates was separated by SDS-
PAGE and assayed for viral protein expression by Western Blotting. The 
corresponding Western blots were probed with a hybridoma polyclonal VP1 antibody, 
a commercial polyclonal VP2/VP3 antibody, which detects both late proteins, and 
GAPDH as a loading control. Results showed that Glibenclamide decreases not only 
VP1 expression but also other late proteins including VP3; VP2 was not successfully 
detected on the corresponding Western blots (Figure 4.9A). 
To examine whether Glibenclamide has an impact on viral genome replication, 
quantitative PCR analysis was carried out. RPTE cells were infected with BKPyV 
(MOI 0.5) for 2 hours at 37oC and treated with 20 μM of Glibenclamide or 15 μg/ml of 
Cidofovir, as a positive control, for 48 hours. Total DNA was extracted from each 
sample and analyzed by quantitative PCR using specific primers against the viral 
genome. Data extracted following the qPCR analysis indicated that both 
Glibenclamide and Cidofovir caused a significant decrease on viral DNA levels. There 
was approximately 80% decrease of viral genome copy numbers upon treatment with 
Glibenclamide and about 75% reduction in the presence of Cidofovir (Figure 4.9B). 
Taken together these data suggest that Glibenclamide decreases BKPyV infection 
not only at a protein level, but also at a DNA level. 
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Figure 4. 9 Glibenclamide decreases BKPyV viral protein expression and genome replication. A. RPTE 
cells were infected with BKPyV at an MOI of 0.5 and treated with 20 μM of Glibenclamide for 48 hours. 
Total protein of cell lysates from infected cells was separated by SDS-PAGE. VP1 (pAb597), VP3 and 
the loading control GAPDH were detected on the Western blot with the appropriate antibodies. 
Representative blots are shown from two independent infections. B. RPTE cells were infected with 
BKPyV at an MOI of 0.5 and treated with 20 μM of Glibenclamide or 15 μg/ml of Cidofovir for 48 hours. 
Quantitative PCR analysis of DNA viral genome was performed. Values represent the mean ±SD of viral 
genome copy numbers normalized to the untreated control sample (n= 3) (**, significant difference at the 
p ≤ 0.01 level). 
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4.2.3.4 Glibenclamide decreases the titres of the released viral progeny 
To identify whether Glibenclamide treatment affects the release of viral progeny from 
infected cells, infection assays were carried out. RPTE cells were infected with BKPyV 
at an MOI of 0.5 for 2 hours at 37oC and then treated with 20 μM of Glibenclamide or 
15 μg/ml of Cidofovir, as a control, for 48 hours. Supernatants were collected 48 hours 
post-infection and utilized to further infect RPTE cells for 48 hours (Figure 4.10A). 
Cells were then fixed, and BKPyV infection assayed through staining for VP1 as a 
marker of virus production. Using IncuCyte ZOOM analysis, it was demonstrated that 
the released viral progeny was infectious as an accumulation of BKPyV VP1 was 
observed in the nucleus of infected cells, 48 hours post-infection (Figure 4.10B). 
Interestingly, both Glibenclamide and Cidofovir caused a decrease in the titres of the 
synthesized viral progeny. There was approximately an 80% reduction of VP1 
expression in infected cells with the supernatant sample from the Glibenclamide 
treatment and 90% from the Cidofovir treatment, respectively (Figure 4.10C). 
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Figure 4. 10 Glibenclamide treatment decreases the titres of released viral progeny. A. Schematic 
representation of the infection assay. B. RPTE cells were infected with BKPyV at an MOI of 0.5 and 
treated with 20 μM of Glibenclamide or 15 μg/ml of Cidofovir for 48 hours. Supernatants were collected 
and used to further infect RPTE cells for 48 hours.  Cells were fixed and stained with a primary anti-VP1 
(pAb597) (1:250) antibody and a secondary anti-mouse alexa fluor-conjugated 488. BKPyV VP1 protein 
was used as a marker of BKPyV infection. Subcellular localization of VP1 protein was detected in the 
nucleus of BKPyV infected cells. C. Positive infected cells were calculated by IncuCyte ZOOM and 
normalized to the untreated control. Data represent the mean ±SD of positive infected cells (n= 3) (***, 
significant difference at the p ≤ 0.001 level). 
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It is known that Glibenclamide acts as a non-selective inhibitor of ATP-sensitive K+ 
channels by binding to SUR subunits. Taken together our pharmacological data, 
Glibenclamide treatment impacts on the BKPyV life cycle, but not through directly 
targeting ATP-sensitive K+ channels. Glibenclamide can inhibit other ABCC 
transporters, which the SUR subunits belong to. Therefore, the next experimental 
objective was to test more compounds that target other members of the ABCC 
subfamily. 
 
4.2.4 CFTR172 impacts on the BKPyV life cycle 
The SURs belong to the subfamily ABCC of the ABC-transporters and are involved 
in several processes, such as neuronal and muscle function and insulin secretion 
(Dean et al., 2001). Amongst the thirteen ABCC members, the Cystic fibrosis 
transmembrane conductance regulator (CFTR) is characterized as a chloride (Cl-) 
channel permitting the influx and efflux of Cl- across epithelial cell membranes 
(Riordan et al., 1989). Mutation or loss of CFTR function is strongly related to a 
genetic disorder, the Cystic fibrosis (Dean et al., 2001). It is also established that 
CFTR is abundantly expressed in human renal epithelial cells (Souza-Menezes and 
Morales, 2009), thus given that CFTR is sensitive to Glibenclamide we focused on 
studying and investigating a potential implication of CFTR in the BKPyV life cycle.  
 
4.2.4.1 CFTR172 inhibits BKPyV infection in a dose-dependent manner 
To examine whether CFTR plays an essential role in the BKPyV life cycle, 
pharmacological assays were performed. For that reason, RPTE cells were infected 
with BKPyV (MOI 0.5) for 2 hours at 37oC and then treated with a range of 
concentrations of CFTR172, which inhibits specifically CFTR, for 48 hours. 
Treatments of 10 μM, 20 μM, 30 μM, and 40 μM of CFTR172, respectively, were 
performed. Cells were lysed 48 hours post-infection, and VP1 expression assessed 
by Western blot analysis. When VP1 expression was assessed ±CFTR172, there was 
a reduction of VP1 expression, suggesting that CFTR might impede a successful 
BKPyV infection (Figure 4.11A).  
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Cell toxicity assays were also performed in order to identify whether this potent effect 
of CFTR172 was due to loss of cell viability. Results revealed that doses higher than 
30 μM of CFTR172 caused a decrease up to 30% of cell viability. Whereas, lower 
concentration, such as 10 μM and 20 μM of CFTR172, were not toxic to RPTE cells 
(Figure 4.11B).  
A more detailed CFTR172 titration was carried out to identify the minimum 
concentration at which CFTR172 can inhibit VP1 expression. RPTE cells were 
infected with BKPyV (MOI 0.5) for 2 hours at 37oC and treated with 1 μM, 2 μM, 4 μM, 
6 μM, 8 μM and 10 μM of CFTR172, respectively for 48 hours. Cells were fixed, and 
BKPyV infection assayed through staining for VP1 as a marker of virus infection. 
Using IncuCyte ZOOM analysis, an accumulation of VP1 was again observed in the 
nucleus of infected cells, 48 hours post-infection (Figure 4.11C). Moreover, we 
demonstrated that at the lowest concentration of CFTR172, 1μM, there was 
approximately 30% reduction of VP1 expression compared to the untreated control 
sample. A statistical significant decrease of VP1 was observed upon the gradually 
higher doses of CFTR172 showing approximately more than 80% decrease of VP1 
expression at the highest concentration of 10 μM (Figure 4.11D). Taken together 
these data suggest that CFTR172 inhibits BKPyV infection in a dose-dependent 
manner indicating a potential implication of CFTR in the BKPyV life cycle. 
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Figure 4. 11 CFTR172 reduces BKPyV infection in a dose-dependent manner. A. RPTE cells were infected with BKPyV at an MOI of 0.5 and treated with 10 μM, 20 
μM, 30 μM and 40 μM of CFTR172, respectively for 48 hours. Total protein of cell lysates from infected cells was separated by SDS-PAGE and corresponding blots 
were probed for VP1 (pAb597) as a BKPyV infection marker, and GAPDH as a loading control. Representative blots are shown from two independent infections. B. 
RPTE cells were treated as above for 48 hours, and cell viability assessed via MTT assays. Values represent the mean ±SD normalized to the untreated control (n= 
3). C. RPTE cells were infected with BKPyV at an MOI of 0.5 and treated with 1 μM, 2 μM, 4 μM, 6 μM, 8 μM and 10 μM of CFTR172, respectively for 48 hours. 
Cells were fixed and stained with a primary anti-VP1 (1:250) (pAb597) antibody and a secondary anti-mouse alexa fluor-conjugated 488. VP1 protein was used as 
a marker of BKPyV infection. D. Positive infected cells were calculated by IncuCyte ZOOM and normalized to the untreated control. Data represent the mean ±SD 
of positive infected cells (n= 3) (*, significant difference at the p ≤ 0.05 level; **, significant difference at the p ≤ 0.01 level).
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4.2.4.2 CFTR172 inhibits BKPyV production in an MOI-independent manner 
Our next experimental objective was to investigate whether the effect of CFTR172 
varied depending on the amount of virus that cells were exposed to. To achieve this, 
RPTE cells were infected with BKPyV at an MOI of 0.5 and 5, respectively, for 2 hours 
at 37oC. Following to this, infected cells were treated with 10 μM of CFTR172 for 48 
hours and fixed. BKPyV infection assayed through staining for VP1 as a marker of 
BKPyV production. Using IncuCyte ZOOM analysis, an accumulation of VP1 was 
observed in the nucleus of infected cells, 48 hours post-infection (Data not shown). 
Results indicated that CFTR172 had a drastic effect on VP1 levels in an MOI-
independent manner, causing ~ 80% reduction of VP1 positive infected cells 
compared to the untreated control sample (Figure 4.12A and B). 
 
 
 
 
 
 
 
 
Figure 4. 12 CFTR172 affects BKPyV at an MOI-independent manner. RPTE cells were infected with 
BKPyV at an MOI of 0.5 (A) or 5 (B), respectively, and treated with 10 μM of CFTR172 for 48 hours. 
Cells were fixed and stained with a primary anti-VP1 (1:250) (pAb597) antibody and a secondary anti-
mouse alexa fluor-conjugated 488. VP1 protein was used as a marker of BKPyV production and positive 
infected cells were calculated by IncuCyte ZOOM and normalized to the no-drug control. Data represents 
the mean ±SD of positive infected cells (n= 3) (**, significant difference at the p ≤ 0.01 level). 
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4.2.4.3 CFTR172 reduces BKPyV genome replication 
Our previous findings suggested that CFTR172 causes a reduction in BKPyV protein 
expression. Following to this, quantitative PCR analysis was conducted in order to 
identify whether CFTR172 has an impact on BKPyV genome levels as well. To 
achieve this, RPTE cells were infected with BKPyV (MOI 0.5) for 2 hours at 37oC and 
treated with 10 μM of CFTR172 or 15 μg/ml of Cidofovir, as a positive control sample. 
Infected and treated cells were incubated for 48 hours prior to total DNA extraction. 
Data collected after the quantitative PCR analysis showed that CFTR172 caused a 
significant decrease on BKPyV genome replication. About 80% decrease of viral 
genome copy numbers compared to the untreated control sample was observed upon 
treatment with 10 μM of CFTR172. Cidofovir, the positive control, caused 
approximately 70% reduction of viral DNA levels (Figure 4.13). Given this, inhibition 
of CFTR function results in reduction of BKPyV genome replication. 
 
 
 
 
 
 
 
Figure 4. 13 CFTR172 treatment decreases BKPyV genome replication. RPTE cells were infected with 
BKPyV at an MOI of 0.5 and treated with 10 μM of CFTR172 or 15 μg/ml of Cidofovir. Infected and 
treated cells were incubated and harvested 48 hours post-infection prior to quantitative PCR analysis. 
Data represent the mean ±SD of genome copy numbers normalized to the no-drug control from three 
independent experiments (*, significant difference at the p ≤ 0.05 level; **, significant difference at the p 
≤ 0.01 level). 
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4.2.4.4 CFTR172 decreases the titres of the BKPyV released progeny 
To determine the impact of CFTR on the released BKPyV viral progeny, infection 
assays were performed. For that reason, RPTE cells were infected with BKPyV (MOI 
0.5) for 2 hours at 37oC and then treated with 10 μM of CFTR172 or 15 μg/ml of 
Cidofovir, as a positive control, for 48 hours. Collected supernatants from these 
treatments were utilized to further infect RPTE cells for an additional 48 hour-
incubation period (Figure 4.14A). Cells were then fixed, and BKPyV infection assayed 
through staining for VP1 as a marker of virus production. Data collected following 
IncuCyte ZOOM analysis indicated that the released viral progeny was infectious 
since an accumulation of VP1 protein was observed in infected RPTE cells 48 hours 
post-infection (Figure 4.14B). Interestingly, both agents, CFTR172 and Cidofovir 
caused a statistical significant reduction of the titres of the synthesized viral progeny. 
Only 20% of cells were positive for VP1 expression after infections with supernatant 
from CFTR172 treatment and approximately 10% of cells that were infected with 
supernatant from Cidofovir treatment, respectively (Figure 4.14C).  
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Figure 4. 14 CFTR172 reduces the titres of the released BKPyV progeny. A. Schematic representation 
of the protocol for infection assays. B. RPTE cells were infected with BKPyV at an MOI of 0.5 and treated 
with 10 μM of CFTR172 or 15 μg/ml of Cidofovir for 48 hours. Supernatants were collected 48 hours 
post-infection and used to further infect RPTE cells. Infected cells were incubated for another 48 hours.  
Cells were fixed and stained with a primary anti-VP1 (1:250) (pAb597) antibody and a secondary anti-
mouse alexa fluor-conjugated 488. BKPyV VP1 was used as a marker of BKPyV production. Subcellular 
localization of VP1 protein was detected in the nucleus of BKPyV infected cells. C. Positive infected cells 
were calculated by IncuCyte ZOOM and normalized to the no-drug control. Data represent the mean 
±SD of positive infected cells (n= 3) (**, significant difference at the p ≤ 0.01 level; ***, significant 
difference at the p ≤ 0.001 level). 
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4.2.5 ROMK does not affect BKPyV production 
The general and canonical ATP-sensitive K+ channel complex consists of an ABC 
family member and a Kir family member (Welling and Ho, 2009).  It is known that the 
renal outer medullary K+ channel (ROMK) is a member of the inward-rectifier K+ 
channel subfamily and forms a type of ATP-sensitive K+ channel with the CFTR 
subunit (Welling and Ho, 2009). Previous studies have shown that the chemical 
compound VU591 blocks the function of ROMK (Swale et al., 2015).  
Our next experimental objective was to examine whether an ATP-sensitive K+ channel 
complex composed by the CFTR and ROMK subunits plays a role in a successful 
BKPyV infection. To identify the importance of ROMK function for a BKPyV infection, 
pharmacological analysis was performed using the VU591 modulator. RPTE cells 
were infected with BKPyV (MOI 0.5) for 2 hours at 37oC and treated with a range of 
concentrations of VU591 for 48 hours; 5 μM, 10 μM, 15 μM and 20 μM of VU591, 
respectively. Cells were lysed 48 hours post-infection, and VP1 expression assessed 
by Western blot analysis. Data showed that there was no effect on VP1 expression 
upon treatment with 5 μM, 10 μM and 15 μM of VU591, respectively. A decrease of 
VP1 levels after treatment with the highest concentration of VU591 was observed, 
although levels of GAPDH were lower in this sample compared to the untreated 
control sample (Figure 4.15A). To investigate whether VU591 cause a real effect on 
BKPyV, cell viability assays were performed. RPTE cells were treated under identical 
treatment conditions prior to toxicity analysis. 
Data from toxicity assay revealed that 5 μM and 10 μM of VU591 did not cause any 
effect on cell viability. However, there was a decrease of cell viability of approximately 
40% upon treatment with 20 μM of VU591 (Figure 4.15B). This indicated that the 
decrease of VP1 expression levels after treatment with 20 μM of VU591 was due to 
reduction of cell viability. Moreover, VU591 compound at the applied concentration 
was not able to affect resting membrane potential assessed through DiBAC4(3) 
fluorescence in RPTE cells (Figure 4.15C). Thus, it is likely that ROMK does not 
impact on BKPyV production.  
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Figure 4. 15 VU591 does not affect a BKPyV successful infection. A. RPTE cells were infected with BKPyV at an MOI of 0.5 and treated with 5 μM, 10 μM, 15 μM 
and 20 μM of VU591, respectively for 48 hours. Total protein of cell lysates from infected cells was separated by SDS-PAGE and probed for VP1 (pAb597) as a 
BKPyV infection marker, and GAPDH as a loading control. Representative blots are shown from three independent infections. B. RPTE cells were treated as above 
for 48 hours and cell viability assessed via MTT assays. Values represent the mean ±SD normalized to the untreated control (n= 3). C. RPTE cells were treated with 
10 μM of VU591 and incubated for 48 hours. 20 μM of DiBAC4(3) was added to treated cells and flow cytometry analysis of total cell fluorescence was measured. 
Values represent the mean ±SD normalized to the untreated control (n= 3) (*, significant difference at the p ≤ 0.05 level).
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4.2.6 BKPyV exploits host ion channels 
4.2.6.1 CFTR is required at an early stage of the BKPyV life cycle 
Findings from our pharmacological data suggested that CFTR might be important for 
the establishment of a successful BKPyV life cycle into host cells. To identify at which 
stage of the virus life cycle, CFTR might play a role, time-of-addition experiments 
were conducted. To achieve this, RPTE cells were infected with BKPyV at an MOI of 
0.5 at 4oC for 2 hours. Cells were placed at 4oC in the presence of virus to achieve a 
synchronized infection. Following to that period, cells were transferred at 37oC and 
treated with 20 μM of Glibenclamide or 10 μM of CFTR172 at specific time-points; 0, 
12 and 24 hours post-infection, respectively (Figure 4.16A). Infected and treated cells 
were incubated for a total 48 hour-incubation period before harvesting. To examine 
whether CFTR channel was required for the initial binding of BKPyV to host cell 
receptors, treatment under certain conditions was performed. RPTE cells were 
treated with 20 μM of Glibenclamide or 10 μM of CFTR172 for 1 hour before and 
during the synchronized infection as well. Then, both compounds were removed and 
replaced with fresh complete growth media for a total incubation of 48 hours. Cells 
were lysed, and VP1 expression assessed by Western blot analysis.  
Results from Western blotting demonstrated that both Glibenclamide and CFTR172 
caused a reduction of VP1 expression during the first 12 hours of the BKPyV life cycle. 
However, there was no effect when either drug was added at the stage of the binding 
of BKPyV to host cell receptors, suggesting that CFTR channel is required at an early 
stage of the life cycle but following virus internalization Figure 4.16B). 
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Figure 4. 16 CFTR is required during the first 12 hpi. A. Schematic representation of the treatments 
performed at the indicated time-points of the life cycle. B. RPTE cells were infected with BKPyV at an 
MOI of 0.5 for 2 hours at 4oC and treated with 20 μM of Glibenclamide or 10 μM of CFTR172, 
respectively, before and during synchronized infection, 0, 12 and 24 hpi, respectively. Infected and 
treated RPTE cells were incubated for 48 hours in total. Total protein of cell lysates from infected cells 
was separated by SDS-PAGE and probed for VP1 (pAb597) as a marker of BKPyV infection, and 
GAPDH as a loading control. Blots are shown from independent infections (Glibenclamide- n= 3; 
CFTR172- n= 1). 
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4.2.6.2 CFTR is required at a very early stage of the BKPyV life cycle 
Findings from time-of-addition experiments suggested that CFTR plays a critical role 
for BKPyV infection during the first 12 hours of the life cycle. A more detailed time-
course with shorter time-points was performed to identify the specific time-point of the 
life cycle that CFTR function is essential. For that reason, RPTE cells were infected 
with BKPyV at an MOI of 0.5 for 2 hours at 4oC to achieve a synchronized infection. 
Cells were treated with 20 μM of Glibenclamide or 10 μM of CFTR172 at the indicated 
time-points; 0, 1, 2, 4, 6, 8 and 10 hours post-infection, respectively, and incubated 
for 48 hours totally before harvesting (Figure 4.17A). Cells were lysed and VP1 
expression assessed by Western blot analysis. Data showed that both chemical 
modulators caused a reduction of VP1 expression during the first 4 hours post-
infection. Given this, CFTR is involved in a process occurring at a very early stage 
and its blockade affects BKPyV infection (Figure 4.17B).  
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Figure 4. 17 CFTR is required within the first 4 hpi. A. Schematic representation of the treatments that 
performed at the indicated time-points of the life cycle. B. RPTE cells were infected with BKPyV at an 
MOI of 0.5 for 2 hours at 4oC and treated with 20 μM of Glibenclamide or 10 μM of CFTR172, at 0, 1, 2, 
4, 6, 8 and 10 hpi, respectively. Infected and treated RPTE cells were incubated for 48 hours in total. 
Total protein of cell lysates from infected cells was separated by SDS-PAGE and probed for VP1 
(pAb597) as a BKPyV infection marker, and GAPDH as a loading control. Blots are shown from 
independent infections (Glibenclamide- n= 3; CFTR172- n= 1). 
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4.2.6.3 A low-pH step is critical for BKPyV infection 
To investigate the intracellular trafficking pathway of BKPyV into RPTE cells, a 
pharmacological analysis by treating RPTE cells with chemical compounds that are 
known to block distinct cellular processes was performed. It is known that BKPyV 
requires a low-pH environment into the host cells for a successful infection (Jiang et 
al., 2009). The next experimental objective was to determine whether a low-pH 
microenvironment is essential in the BKPyV life cycle. RPTE cells were infected with 
BKPyV at two different MOIs; 0.5 and 5, respectively, for 2 hours at 37oC and then 
treated with 6.25 mM of NH4Cl for 48 hours. NH4Cl is a lysosomotropic compound 
that enters only intracellular compartments with low internal pH and increases the 
level of pH, disrupting their internal acidification. Cells were then fixed, and BKPyV 
infection assayed through staining for VP1 as a marker of virus production.  
Data following IncuCyte ZOOM analysis revealed that there was a statistically 
significant reduction of approximately 40% of VP1 positive infected cells upon 
treatment with NH4Cl compared to the untreated control, regardless of the amount of 
virus that cells were exposed to (Figure 4.18A and B). These findings suggest that 
low pH in intracellular compartments is essential for BKPyV infection irrespective of 
BKPyV MOIs.  
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Figure 4. 18 BKPyV requires low-pH for a successful infection in an MOI-independent manner. A. RPTE 
cells were infected with BKPyV at an MOI of 0.5 (A) or 5 (B) and treated with 6.25 mM of NH4Cl for 48 
hours. Cells were fixed and stained with a primary anti-VP1 (1:250) (pAb597) antibody and a secondary 
anti-mouse alexa fluor-conjugated 488. BKPyV VP1 was used as a marker of BKPyV infected cells. 
Positive infected cells were calculated by IncuCyte ZOOM and normalized to the no-drug control. Values 
represent the mean ±SD of positive infected cells (n= 3) (**, significant difference at the p ≤ 0.01 level). 
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4.2.6.4 Low-pH is critical at an early stage of the BKPyV life cycle 
To gain a better understanding of the pH-requirement for a successful BKPyV 
infection, time-of-addition experiments were carried out. To achieve this, RPTE cells 
were infected with BKPyV at an MOI 0.5 for 2 hours at 4oC to synchronize the infection 
and entry of the virus was initiated by transferring the cells to 37oC. Following to this, 
infected cells were treated with 6.25 mM of NH4Cl at the indicated time-points; 0, 1, 
2, 4, 6, 8 and 10 hours post-infection, respectively, and incubated for 48 hours in total 
prior to harvesting. (Figure 4.19A). Cells were lysed and VP1 expression assessed 
by Western blot analysis.  
Results after Western blotting showed that there was a reduction of VP1 expression 
upon treatment with NH4Cl at various time-points throughout the time course. Given 
the data suggest that the requirement of a low-pH environment is crucial for BKPyV 
during the early stages of the life cycle (Figure 4.19B).  
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Figure 4. 19 Low pH-environment is required at an early stage of the BKPyV life cycle. A. Schematic 
diagram of the treatments that performed at the indicated time-points of the life cycle. B. RPTE cells 
were infected with BKPyV at an MOI of 0.5 for 2 hours at 4oC and treated with 6.25 mM of NH4Cl at 0, 
1, 2, 4, 6, 8 and 10 hpi, respectively. Infected and treated RPTE cells were incubated for 48 hours in 
total. Total protein of cell lysates from infected cells was separated by SDS-PAGE and probed for VP1 
(pAb597) as a BKPyV infection marker, and GAPDH as a loading control. Representative blots are 
shown from independent infections (n= 2). 
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4.2.6.5 CFTR knocked down leads to inhibition of BKPyV production 
Based on our pharmacological data, it is proposed that CFTR is involved in the BKPyV 
life cycle by an unknown mechanism. Molecular-based techniques were performed to 
validate the implication of CFTR in the virus life cycle. To determine this, RPTE cells 
were transfected with a pooled siRNA (400 nM), that target specifically CFTR mRNA 
molecules, and with non-targeting Scramble siRNA molecules, as a negative control. 
Transfected RPTE cells were incubated for 48 hours at 37oC to ensure that silencing 
of CFTR successfully occurred. Following to that incubation period, transfected RPTE 
cells were infected with BKPyV (MOI of 0.5) for 2 hours at 37oC and incubated for a 
48 hour-incubation period prior to harvesting.  
Isolated total protein from lysates was separated by SDS-PAGE and assayed for VP1, 
as a marker of BKPyV infection, and CFTR expression by Western Blotting. The 
corresponding Western blots were probed with a hybridoma polyclonal VP1 antibody, 
a commercial CFTR antibody and a GAPDH antibody as a loading control. Data 
revealed that silencing of CFTR mRNA occurred to a certain extend (Figure 4.20A). 
CFTR expression was reduced by approximately 50% (Figure 4.20B). In parallel, we 
identified that by knocking down CFTR expression, VP1 expression was also 
decreased by more than 20% (Figure 4.20A and B). Taken together these data 
suggest that CFTR is implicated in the BKPyV life cycle and plays a significant role 
for a successful infection into host cells.  
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Figure 4. 20 Silencing of CFTR causes reduction of BKPyV infection. A. RPTE cells were transfected 
with pooled siRNA molecules against CFTR (400 nM) and Scramble siRNAs, as a negative control. 
Transfected RPTE cells were incubated for 48 hours and then infected with BKPyV at an MOI of 0.5 for 
2 hours at 37oC. Infected RPTE cells were incubated for 48 hours. Total protein of cell lysates from 
infected cells was separated by SDS-PAGE and probed for VP1 (pAb597) as a marker of BKPyV 
infection, CFTR, and GAPDH as a loading control. Representative blots are shown from three 
independent infections. B. Densitometry analysis of Western blots was performed. Values represent the 
mean ±SD normalized to the Scramble control (*, significant difference at the p ≤ 0.05 level). 
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4.3 Discussion 
4.3.1 Host cell CFTR is required for a successful BKPyV infection  
Ion channels are pore-forming proteins composed of multiple subunits and are 
located on cellular membranes. It is established that selective influx and efflux of ions 
across all cell membranes are controlled by ion channels (Yu et al., 2005). Ion 
channels are expressed in all cell types, both excitable and non-excitable cells and 
localized on both cell plasma membranes and membranes of intracellular organelles, 
regulating several functions, including cellular ion homeostasis (Hover et al., 2017). 
Due to their significant implication in numerous cellular processes, ion channel 
malfunction can lead to the onset and progression of diseases named 
channelopathies (Kim, 2014). 
Viruses manipulate the intracellular machineries of host cells in order to complete 
their life cycles; to replicate, release their viral progeny and survive into the host 
organism. Previous studies have identified that host cell ion channels are manipulated 
by viruses at different stages of their life cycles (Hover et al., 2017). Therefore, a new 
strategy to identify novel anti-viral targets is to examine through which mechanism(s) 
viruses exploit host ion channels and then to validate whether these interactions could 
be targeted. 
 Potassium (K+) channels, were initially identified as the molecular entities that allow 
the influx and efflux of K+ across nerve membranes (Miller, 2000). Currently, they have 
been detected in most cell types of all organisms and are known to control several 
physiological functions (Miller, 2000). The genomes of humans, Drosophila, and 
Caenorhabditis elegans contain 30-100 K+ channel genes each, and some of these 
are subject to elaborate alternative splicing (Miller, 2000). Disruption of K+ channel 
genes leads to pathologies, including deafness, diabetes, mis-regulation of blood 
pressure and cardiac arrhythmias (Miller, 2000). 
Preliminary data produced in our group suggested that host K+ channels might be 
required for a productive BKPyV infection. Thus, the main aim of this Chapter was to 
identify a potential role of host ion channels in the BKPyV life cycle (Table 4.2).  A 
rational panel of broad spectrum K+ channel modulators were used to examine the 
impact of K+ channel family on BKPyV infection. We identified that upon treatment 
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with 20 mM of Tetraethylammonium (TEA) there was a significant decrease of BKPyV 
VP1 expression in infected RPTE cells of approximately 70% (Figure 4.2). Previous 
studies have shown that extracellular addition of TEA can inhibit K+ channels by 
binding in the pore of the channel (Armstrong, 1966; Armstrong and Hille, 1972; 
Kirsch et al., 1991). K+ channels are composed by four distinct protein subunits that 
form a single channel and TEA is able to interact with all of them (Kavanaugh et al., 
1992). Thus, based on previous studies and our pharmacological analysis, we 
speculated that host K+ channels might be important for a BKPyV infection. It is also 
reported that Cidofovir can block BKPyV load in RPTE cells in a dose-dependent 
manner showing a 90% reduction after treatment with 40 μg/ml (Bernhoff et al., 2008). 
Based on our studies, Cidofovir caused a statistically significant decrease of BKPyV 
VP1 expression levels in infected RPTE cells supporting previous published findings 
(Figure 4.2).  
A pharmacological analysis was carried out using a panel of modulators that target 
different subfamilies of the K+ channel family to identify the candidate family member, 
which might be required for a successful BKPyV life cycle. Data showed that 
Glibenclamide caused a decrease of BKPyV VP1 expression (Figure 4.3). 
Glibenclamide is a clinically available drug that is used as a therapy for diabetes 
mellitus type 2 and is known as a second-generation sulfonylurea inhibitor (Marble, 
1971). Studies have shown that Glibenclamide acts by inhibiting ATP-sensitive K+ 
channels located on cell plasma membranes. These are complexes consisted by two 
types of subunits, the pore-forming subunits which are the inwardly rectifier Kir6.x-
type and the sulfonylurea receptors, SURs-type (Ashcroft and Gribble, 1998; Aguilar-
Bryan and Bryan, 1999). There are two types of SURs and are classified as members 
of the ATP-binding cassette protein superfamily (Sakura et al., 1995; Tusnády et al., 
1997). SUR1 is predominantly expressed in pancreatic β-cells and in brain, whereas 
SUR2-type is mainly found in muscles (Sakura et al., 1995). It is known that SUR2 is 
expressed in two isoforms which they have a 42 amino acid-difference in their last 
exon. SUR2A is mainly expressed in striated and SUR2B in smooth muscles (Isomoto 
et al., 1996; Inagaki et al., 1996). Glibenclamide binds to SUR1-type with higher 
affinity compared to SUR2-type and this is because to a serine in position 1206 in 
SUR1-type, which is replaced with a tyrosine in the same position in SUR2 (Ashfield 
et al., 1999).  
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Barium ions inhibit K+ channels (Piasta et al., 2011; Neyton and Miller, 1988) and 
particularly the inwardly rectifying K+ channels (Alagem et al., 2001). Quayle et al., 
(1988) stated that there was a voltage-dependent blockade of ATP-sensitive K+ 
channels expressed in frog skeletal muscle in the presence of barium ions. However, 
we interestingly did not detect any effect of BaCl2 on BKPyV VP1 expression at the 
applied concentration (Figure 4.3). Higher concentrations than 1mM of BaCl2 could 
not be applied to RPTE cells since BaCl2 was cytotoxic causing approximately 60% 
decrease of cell viability (Data not shown). 
Based on our pharmacological data, we hypothesized that ATP-sensitive K+ channels 
might be implicated in the BKPyV life cycle as upon treatment with Glibenclamide 
there was a reduction of VP1 expression levels. Following to this, other chemical 
modulators that target the same family member, either by inhibiting or activating it, 
were also utilized in order to study their effect on a BKPyV infection. Infected RPTE 
cells were treated with Glibenclamide and Tolbutamide, which is a sulfonylurea 
compound classified as a first-generation sulfonylurea inhibitor. Interestingly, results 
from IncuCyte ZOOM analysis revealed that Tolbutamide caused a significant 
decrease on BKPyV production compared to the no-drug control, but not as potent as 
Glibenclamide treatment (Figure 4.4). Previous studies have suggested that there is 
a tissue specificity of sulfonylureas (Gribble et al., 1998; Babenko et al., 1999). It is 
proposed that ATP-sensitive K+ channels expressed in cardiac muscles and beta-
cells are composed by the same pore-forming subunit, Kir6.2, although SUR1-type is 
expressed in beta-cells and SUR2A-type in cardiac muscles. Tolbutamide could 
inhibit the function of the Kir6.2/SUR1 ion channel complex with high affinity, but not 
the Kir6.2/SUR2A ion channel complex. However, Glibenclamide treatment causes 
the blockade of both combinations of ion channel complexes with high affinity. These 
findings could support our data and indicate a potential SUR-type composition of the 
ATP-sensitive K+ channel complex that might be expressed in RPTE cells and affect 
the BKPyV life cycle. Moreover, at the applied concentrations only Glibenclamide 
could alter resting membrane potential of RPTE cells.  
Several studies have shown that 5-Hydroxydecanoate (5HD) is a fatty acid and is 
characterized as a specific inhibitor of mitochondrial ATP-sensitive K+ channels 
(Hanley et al., 2005; Garlid and Halestrap, 2012; Vadzyuk and Kosterin, 2018). 
Vadzyuk and Kosterin, (2018) stated that 200 μM of 5HD blocked the function of 
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mitochondrial ATP-sensitive K+ channels. In our studies, 500 μM of 5HD did not cause 
any effect on BKPyV VP1 expression in infected RPTE cells, suggesting that 
mitochondrial ATP-sensitive K+ channels might not be involved in the BKPyV life 
cycle, even though this treatment was able to cause a modest change on resting 
membrane potential (Figure 4.5). Moreover, treatment with U-37883A compound did 
not have a potent effect on VP1 expression, suggesting that the ATP-sensitive K+ 
channel complex that possibly expressed in RPTE cells might not consist of the Kir6.1-
type subunit (Figure 4.5). Although, U-37883A treatments caused depolarization of 
plasma membranes suggesting that the compound at the applied concentrations was 
actually blocking the ion channels composed of the Kir6.1-type subunit. Quantitative 
RT-PCR analysis using specific primers against all the SUR-types and Kir6.x-types 
of subunits in infected RPTE cells, failed to detect any levels of the canonical subunits 
of a typical ATP-sensitive K+ channel (Data not shown).  
Given these data, we hypothesized that a non-canonical combination of an ATP-
sensitive K+ channel complex might be expressed in RPTE cells or that Glibenclamide 
could target another type of host ion channel. For that reason, a more in-depth 
investigation of Glibenclamide on infected RPTE cells was carried out. We identified 
that 20 μM of Glibenclamide can cause approximately 90% reduction of VP1 
expression in infected RPTE cells without causing any detrimental effect on cell 
viability (Figure 4.7) and is able to block BKPyV production at an MOI-independent 
manner (Figure 4.8). Furthermore, Glibenclamide treatment decreases not only 
BKPyV VP1 expression but also other viral proteins, including VP3, and can reduce 
viral genome replication by approximately 80% compared to the untreated sample 
(Figure 4.9). We also showed that Glibenclamide decreases the titres of the released 
viral progeny by 80% following IncuCyte ZOOM analysis (Figure 4.10). Taken 
together, we demonstrated that Glibenclamide impacts on a successful BKPyV 
production in RPTE cells.  
Several studies suggested that Glibenclamide acts not only as a non-selective ATP-
sensitive K+ channel blocker, but also as an inhibitor of the cystic fibrosis 
transmembrane conductance regulator (CFTR) (Sheppard and Welsh, 1992; 
Sheppard and Robinson, 1997; Melin et al., 2007; Hwang and Kirk, 2013). CFTR is 
classified as a Cl- channel, which is controlled by the cAMP-dependent 
phosphorylation and the intracellular ATP, like the ATP-sensitive K+ channels 
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(Sheppard and Welsh, 1992). Both CFTR and SURs belong to the same ABCC 
subfamily, therefore modulators could act on them in similar ways. Studies have 
examined the effect of K+ channel modulators on cells expressing recombinant CFTR 
(Sheppard and Welsh, 1992; Sheppard and Robinson, 1997; Melin et al., 2007). Both 
Glibenclamide and Tolbutamide could inhibit the function of CFTR, with 
Glibenclamide having a greater effect. Also, even though Diazoxide is a well 
characterized K+ channel opener, studies have shown that it causes the opposite 
effect on CFTR as its function was blocked upon treatment with Diazoxide (Sheppard 
and Welsh, 1992). These studies could also support our findings as shown in Figure 
4.6.  
Furthermore, quaternary ammonium compounds, including tetraethylammonium ion 
(TEA) and its derivatives, have been extensively used to identify the implication of K+ 
channels in physiological processes in several tissues (Armstrong, 1974; Stanfield, 
1983; Hille, 1978). However, not all of the K+ channels are inhibited by TEA, whilst 
other non-K+ channels are blocked in the presence of TEA (Sanchez and Blatz, 1992). 
Studies have demonstrated that TEA blocks rat neuronal Cl-- selective channels at 
concentrations similar to that are used to inhibit K+ channels (Sanchez and Blatz, 
1992; Sanchez and Blatz, 1994). Other studies have reported that Cl--selective 
channels of lobster walking nerve have been inhibited upon treatment with TEA 
(Lukács and Moczydlowski, 1990). It is also reported that a commonly used 
pharmacological compound to determine the implication of K+ channels, is the 4-
Aminopyridine (4AP), which did not block fast Cl- channels at concentrations up to 5 
mM (Sanchez and Blatz, 1992). Whereas, other derivatives of quaternary ammonium 
compounds inhibited fast Cl- channels (Sanchez and Blatz, 1992). Tetra-
methylammonium ion (TMA) decreased single Cl- channel currents at concentrations 
higher than 100 mM (Sanchez and Blatz, 1992). These findings suggest that a 
blocking effect by TEA itself, cannot be used as a sufficient indicator of a K+ channels 
implication in a process (Sanchez and Blatz, 1992).  
Taking account previous studies and our pharmacological data as an overall, 
Glibenclamide might affect the BKPyV life cycle not through the inhibition of K+ 
channels, but rather by blockade of another ion channel, such as CFTR. For that 
reason, a more-detailed pharmacological analysis was performed using modulators 
of CFTR in order to study a potential requirement of CFTR in the BKPyV life cycle. 
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High-throughput screening has identified very potent and selective inhibitors of CFTR 
including, the thiazolidinone, CFTR172, and the glycine hydrazides, GlyH-101 (Caci 
et al., 2008; Tang et al., 2009; Linsdell, 2014; Ehrhardt et al., 2016). An in-depth 
investigation of CFTR172 inhibitor in infected RPTE cells was performed and 
interestingly we identified that CFTR172 causes similar effects on a BKPyV infection 
as Glibenclamide. Firstly, we demonstrated that 10 μM of CFTR172 could cause a 
significant decrease of BKPyV VP1 positive cells and not due to cytotoxicity effect 
(Figure 4.11). Furthermore, that effect occurred at an MOI-independent way, as is 
shown in Figure 4.12, following IncuCyte ZOOM analysis. CFTR172 modulator 
caused a decrease on BKPyV infection not only at a protein level, but also at a DNA 
level. Approximately 80% reduction of viral genome copy numbers was observed 
upon treatment with CFTR172 (Figure 4.13). CFTR172 treatment also decreased the 
titres of the released BKPyV progeny by approximately 80% compared to the no-drug 
control, as is shown in Figure 4.14. Based on these findings, we suggest that CFTR 
might be involved in the BKPyV life cycle. 
CFTR silencing experiments, using siRNA molecules against CFTR mRNA, showed 
that by knocking down 50% of CFTR expression, there is a greater than 20% 
reduction of BKPyV VP1 expression (Figure 4.20). These results strongly support our 
hypothesis about a CFTR-requirement for a successful BKPyV infection into RPTE 
cells. In a recent study a high-throughput siRNA screen for BKPyV was performed in 
order to identify host cell factors that are involved in BKPyV entry and intracellular 
trafficking (Zhao and Imperiale, 2017). A whole-genome siRNA screen for BKPyV 
infection was carried out in RPTE cells, utilizing more than 18,000 human siRNA 
pools. The same host gene was targeted by four unique siRNAs contained in each 
pool. Data revealed that by targeting CFTR there was an approximately 22.3% 
decrease of BKPyV infection in its natural host cells (Zhao and Imperiale, 2017). 
These findings were in agreement with our data supporting the hypothesis that CFTR 
is required for a successful BKPyV infection in RPTE cells. Although, further 
investigation is required in order to improve the level of CFTR knocking down, since 
50% reduction of protein expression was achieved in this work. Whilst, inhibitors that 
target specifically CFTR are likely to block all of the CFTR activity in cells and for that 
reason the effect on BKPyV infection is more profound compared to the data from the 
silencing experiments.  
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Another type of ion channel that play significant roles in kidneys is the renal outer 
medullary K+ channel (ROMK). ROMK or Kir1.1 is a member of the inwardly-rectifier 
K+ channels and is an ATP-dependent ion channel that regulates the transportation 
of K+ in and out of cells (Welling and Ho, 2009). ROMK can also control K+ secretion 
in the cortical collecting duct (CCD) and K+ recycling in the thick ascending limb (TAL) 
of the nephron (Ho et al., 1993). Molecular and gene knockout studies suggested that 
an ABC protein is essential as a co-factor for ROMK. A combination of SUR with 
ROMK can lead to a weakly inwardly-rectifier ion channel, which is ATP-dependent 
showing similar properties as the native ion channel complex. However, CFTR is 
more important than SUR in kidneys and both ROMK and CFTR are expressed in the 
TAL and CCD membranes (Crawford et al., 1991). As CFTR regulates ROMK and 
are closely linked, the potential role of ROMK in the BKPyV life cycle was also 
examined. VU591 is a chemical compound that targets selectively ROMK and was 
utilized in order to examine a potential requirement of ROMK for a successful BKPyV 
infection. Infected RPTE cells were treated with VU591, although no effect on BKPyV 
VP1 was observed after Western blot analysis (Figure 4.15). However, we could not 
conclude whether ROMK is critical for the BKPyV life cycle, since we provided 
evidences based on only a pharmacological analysis using one ROMK modulator. 
Zhao and Imperiale, (2017) performing a whole-genome siRNA screen for BKPyV 
infection, they indicated that there was an approximately 70% decrease of BKPyV 
infection by targeting KCNJ1 (ROMK gene). Therefore, a more detailed investigation 
is required in order to identify whether CFTR acts synergistically with ROMK in BKPyV 
infected RPTE cells and are both critical for a BKPyV infection. 
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Table 4. 2 List of ion channel modulators used in this study. Infected RPTE cells were treated with the following ion channel modulators and their impact 
on BKPyV life cycle, VP1 protein production, viral progeny, BKPyV genome replication and cell viability are shown below.  
Ion channel Inhibitor Inhibition of life 
cycle 
BKPyV VP1 protein BKPyV progeny BKPyV genome 
replication 
Reduced cell 
viability 
Broad-spectrum K+ 
channel 
TEA (20mM) Yes 60% reduction   No 
Broad-spectrum K+  
channel 
KCl (30mM) Yes 50% reduction   10% reduction 
Broad-spectrum K+  
channel 
NaCl (30mM) No No   No 
Broad-spectrum K+ 
channel 
Quinidine (50μM) No No   25% reduction 
Inward-rectifier K+ 
channel 
BaCl2 (1mM) No No   No 
Votage-gated   K+ 
channel 
4-Aminopyridine 
(0.5mM) 
No No   No 
ATP-sensitive  K+ 
channel 
Glibenclamide (20μM) Yes 80% reduction 80% reduction 80% reduction 25% reduction 
Ca2+-activated  K+ 
channel 
Apamin (0.5μM) No No   10% reduction 
ATP-sensitive  K+ 
channel 
Tolbutamide (150μM) Yes 20% reduction   No 
Mitochondrial ATP-
sensitive  K+ channel 
5-Hydroxydecanoate 
(500μM) 
No No   10% reduction 
Kir6.1 ATP-sensitive  
K+ channel 
U-37883A (50μM) No No   No 
ATP-sensitive  K+ 
channel 
Diazoxide (Activator) 
(50μM) 
Yes Reduction   No 
ATP-sensitive  K+ 
channel 
Pinacidil (Activator) 
(20μM) 
No No   No 
CFTR CFTR172 (10μM) Yes 80% reduction 80% reduction 80% reduction Reduction (≥30μM) 
ROMK VU591 (5-20μM) No No   Reduction (≥20μM) 
Change in pH NH4Cl (6.25mM) Yes 40% reduction   No (Data not shown) 
CFTR siRNA Yes >20% reduction   Not tested 
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4.3.2 CFTR is critical at an early stage of the BKPyV life cycle 
BKPyV does not encode polymerases and for that reason is dependent on host cell 
DNA machinery to replicate its genome and complete its life cycle. BKPyV must enter 
the nucleus to reach the host DNA replication machinery by travelling through the 
cytoplasm. As a result, the exploitation of host cell factors is essential for BKPyV 
(Zhao and Imperiale, 2017). Previous studies have proposed that several host cell 
factors play significant roles in BKPyV entry into the host cells and the intracellular 
trafficking. For the initiation of a successful BKPyV infection, BKPyV binds to GD1b 
or GT1b on host cell membrane and enters host cell (RPTE cells) through a 
clathrin/caveolin-independent way (Low et al., 2006; Zhao et al., 2016). Following the 
step of endocytosis, BKPyV enters to endosomes, as other polyomaviruses, in order 
to traffic through the ER (Querbes et al., 2006; Liebl et al., 2006; Engel et al., 2011; 
Ashok and Atwood, 2003). An acidic microenvironment and maturation of endosomes 
are also a critical next step for a BKPyV infection (Jiang et al., 2009) which, in turn, 
leads to activation of sorting intracellular machinery that includes the recruitment of 
Rab5, Rab7, Rab9, Rab11 and Rab18 proteins (Liebl et al., 2006; Qian et al., 2009; 
Engel et al., 2011; Zhao and Imperiale, 2017) Following sorting through the late 
endosomes, trafficking vesicles reach the ER along with microtubules between 8 to 
12 hours post-infection (Eash and Atwood, 2005; Jiang et al., 2009).  
To gain a better understanding of the importance of CFTR in the BKPyV life cycle, 
time-of-addition experiments were carried out. Western blot analysis revealed that 
upon treatment with both Glibenclamide or CFTR172, there was a decrease of BKPyV 
VP1 expression during the first 12 hours post-infection and not at a later stage of the 
virus life cycle or during virus binding/entry (Figure 4.16). These results suggested 
that host cell CFTR is involved in a process occurred before BKPyV reaches the ER 
but after initial BKPyV binding and penetration. To have a more in-depth 
understanding of this time-course, a more detailed time-of-addition assay was 
performed. Infected RPTE cells were treated with Glibenclamide or CFTR172 at 
different time-points of this early stage. Western blot analysis indicated that CFTR 
plays a crucial role during the first 4 hours of the course of infection, since blockade 
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of CFTR at these time-points caused a decrease of BKPyV VP1 which was recovered 
upon treatment at later time-points (Figure 4.17). 
Previous studies have shown that a low-pH step is essential for BKPyV soon after 
internalization. It has been reported that acidification occurred in the adenovirus 
endosomal escape process as well (Jiang et al., 2009; Wiethoff et al., 2005).  This 
acidification facilitates conformational changes of the viral capsid, which leads to 
further virion disassembly (Jiang et al., 2009). Alternatively, this low-pH 
microenvironment might be important for BKPyV so as certain proteases to be 
functional as it was reported during reovirus capsid disassembly (Ebert et al., 2002). 
To achieve a characterization of the intracellular trafficking pathway of BKPyV in its 
natural host, a pharmacological analysis was performed by treating infected cells with 
agents that block distinct cellular processes. Members of the polyomavirus family, 
including JCPyV and MPyV, require a low-pH step for a successful infection (Ashok 
and Atwood, 2003; Liebl et al., 2006). However, it is demonstrated that SV40 is not 
dependent on an acidification step since is known to enter the caveosome, a pH-
neutral organelle (Ashok and Atwood, 2003; Pelkmans et al., 2001). Studies have 
shown that BKPyV infection in Vero cells requires an acidification step (Eash et al., 
2004). To identify the pH dependence of a BKPyV infection in RPTE cells, treatment 
with NH4Cl was performed. NH4Cl is known to disrupt the acidification of intracellular 
compartments. Data revealed that NH4Cl inhibits BKPyV infection and the inhibitory 
effect was independent of BKPyV MOIs (Figure 4.18). Similar results were observed 
when treatments under identical conditions were carried out in previous studies (Jiang 
et al., 2009), supporting our findings.  
To have a better insight into BKPyV trafficking, time-of-addition assays were 
performed in the presence of NH4Cl. Treatments were carried out at various time-
points post-absorption. Results after Western blot analysis showed that the low-pH 
requirement occurred early during infection, within the first 8 hours of infection (Figure 
4.19). Similar time-of-addition assays have been conducted under identical treatment 
conditions in previous studies. The low-pH requirement occurred very early during 
infection, between the first 2 hours of BKPyV infection. Beyond this time-point, NH4Cl 
was no longer able to block BKPyV infection (Jiang et al., 2009). These findings are 
partially in agreement with our proposed time-course since the inhibitory effect was 
observed at later time-points as well (Figure 4.19). 
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Electron microscopy studies have shown that BKPyV is localized in caveosome-like 
vesicles (Drachenberg et al., 2003). Moreover, colocalization of caveolin 1, which is 
the main component of caveosome, with labelled BKPyV (Moriyama et al., 2007), 
suggest that BKPyV enters caveosome, which is a pH-neutral compartment, en route 
to the nucleus (Pelkmans et al., 2001). The colocalization of BKPyV and caveolin 1 
peaks at about for 4 hours post-infection according to Moriyama et al., (2007), 
therefore an acidic endosomal/lysosomal compartment is likely to be involved in 
BKPyV transportation before entering the caveosome. Taken together previous 
studies and our time-of-addition assays, we suggest that CFTR is required at an event 
that occurs at a very early stage of the BKPyV life cycle, which coincides with the 
stage that acidification occurs. In addition to this, studies have reported that CFTR is 
critical for vesicular acidification since it counteracts proton pumps in endosomes and 
facilitates further acidification (Bradbury, 1999), which also support our hypothesis 
about the CFTR requirement for a productive BKPyV infection.  
Previous studies have demonstrated that host ion channels are involved in virus 
intracellular trafficking and particularly in the critical step of vesicles acidification 
(Hover et al., 2016). A member of K+ channel family, K2P is required for a successful 
bunyavirus (BUNV) infection. Time-of-addition assays indicated that K+-sensitive 
steps are critical within the first 6 hours post-infection without including the initial virus 
binding/penetration or later stages of the virus life cycle including the mRNA 
transcription and translation (Hover et al., 2016). This implicated the functionality of 
host K+ channels during BUNV transportation through the endocytic pathway (Hover 
et al., 2016). A more recent study revealed that BUNV traffics through endosomes 
containing high [K+], which impacts on virions infectivity (Hover et al., 2018). 
Moreover, blockade of K+ channels may lead to alteration of K+ distribution across the 
endosomal system, which results in arrest of BUNV trafficking in endosomes (Hover 
et al., 2018). Other studies have also indicated that endosomal pH and [K+] are critical 
for an influenza A virus (IAV) infection (Stauffer et al., 2014). There is a K+ gradient 
from the intracellular to extracellular environment and the [K+] is increased with 
trafficking along the intracellular endocytic pathway (Scott and Gruenberg, 2011). 
Thus, a decrease of pH and a gradual change in the overall ionic milieu in endocytic 
vesicles were critical for an IAV infection (Stauffer et al., 2014).  
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Here, we show for the first time that BKPyV requires cellular CFTR channels to infect 
its natural host, RPTE cells. Time-of-addition assays revealed that CFTR is critical for 
the virus during a very early stage of the BKPyV life cycle after virus penetration, but 
before BKPyV reaches the nucleus. It was also determined that a low-pH step, 
occurring within the initial hours post-infection, is critical for the BKPyV life cycle. 
Accumulating evidences suggest that host ion channels control the overall ionic milieu 
and pH of endocytic vesicles, indicating their importance. Several viruses exploit host 
ion channels in order to facilitate their trafficking along the endocytic network. 
Therefore, a more in-depth investigation is required to dissect the exact mechanism(s) 
by which CFTR impacts on the BKPyV life cycle in RPTE cells.  
 
4.3.3 CFTR inhibitors as potential therapeutics against BKPyV 
To this date, the cornerstone of PVAN therapy is the reduction of immunosuppressive 
regimen, indicating the importance of host’s immune system to battle the reactivation 
of BKPyV in renal transplant recipients (Thangaraju et al., 2016; Wojciechowski and 
Chandran, 2016). Unfortunately, tailoring of immunosuppression leaves the risk of 
kidney acute rejection (Johnston et al., 2010). Currently, there is no clinical evidence 
to support any particular treatment against PVAN, although many approaches are 
suggested based on evidenced anti-viral activity in vitro (Lamarche et al., 2016). 
Several of the current therapeutic regimens have been characterized as highly 
nephrotoxic and have not been undergone clinical trials. Hence, there is an urgent 
need to identify novel anti-viral drugs to treat PVAN, without risking a transplant acute 
rejection.  
Here, we reported for the first time the requirement of host cell CFTR for a successful 
BKPyV infection in its natural host, RPTE cells, in vitro. For the first time, it is reported 
that Glibenclamide, a clinically available drug, inhibits BKPyV infection. Glibenclamide 
is a sulfonylurea anti-diabetic drug for type 2 diabetes (Balsells et al., 2015) and is an 
intermediate-acting drug with its active metabolites to be eliminated by the liver by 
approximately 50% (Jönsson et al., 1994; Jönsson et al., 1998). It does not exhibit 
any severe side effects and the mechanism of its action as an anti-diabetic implicates 
the direct secretory effect on the pancreatic islet beta-cells. Glibenclamide treatment 
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causes the closing of ATP-sensitive K+ channels on the cell membranes of pancreatic 
beta-cells, which leads to depolarization and opening of voltage-dependent Ca2+ 
channels. Therefore, Ca2+ influx is mediated which results in subsequent stimulation 
of insulin release (Aguilar-Bryan et al., 1995). 
Moreover, studies have shown that the potency and pharmacological properties of 
other CFTR inhibitors, including CFTR172, and their efficacy in various pre-clinical 
models, support further development for therapy of Polycystic Kidney Disease (PKD) 
and enterotoxin-mediated secretory diarrheas (Verkman et al., 2013). Accumulating 
evidence suggest that CFTR is the major apical membrane Cl- pathway in secretory 
diarrheas caused by the bacterial enterotoxins released in cholera and Travelers’ 
diarrhea (Field, 1979; Venkatasubramanian et al., 2010). In vivo studies have 
reported that dosage of μg of CFTR172 can block intestinal fluid secretion in a rat-
model (Ma et al., 2002) and in mice (Thiagarajah et al., 2004) indicating a potential 
novel treatment for secretory diarrheas. PKD is one of the most common human 
genetic diseases and is the main cause of chronic kidney failure. In PKD massive 
enlargement cysts filled with fluid are observed, which ultimately result in destruction 
of normal renal tissue progressively (Torres et al., 2007). The cyst growth implicates 
fluid secretion into the cyst lumen and alterations in morphology of surrounding 
epithelial cells, which express CFTR and are of tubular origin (Brill et al., 1996). 
Studies have identified that CFTR172 completely blocked the growth of cysts in 
mouse embryonic kidney cyst models (Yang et al., 2008). 
In this work, we identified that two CFTR inhibitory compounds block the BKPyV life 
cycle at a very early stage, in vitro, by a yet unknown mechanism which might implies 
on intracellular vesicular acidification. CFTR172 has potential clinical applications and 
Glibenclamide is already a clinically available drug. Thus, we suggest at least one 
potential therapeutic agent pharmacologically safe for a potential PVAN treatment. 
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 Polyomaviruses and host ion channels 
5.1 Introduction 
5.1.1 Investigation of polyomavirus’ life cycles 
It is of great importance to study human polyomaviruses as primary infection is usually 
asymptomatic, although under certain circumstances including immunosuppression, 
severe diseases can occur. Two major examples are JCPyV/BKPyV-associated 
diseases and Trichodysplasia Spinulosa (TS), a rare skin disease that occurs in 
immunosuppressed patients infected with Trichodysplasia Spinulosa virus (TSPyV). 
Some polyomaviruses have been reported to encode oncogenic proteins and are 
therefore linked with human cancers. Merkel cell polyomavirus (MCPyV) for example, 
was first detected in individuals with an aggressive malignant skin cancer, Merkel cell 
carcinoma (Feng et al., 2008).  
JCPyV is closely related to BKPyV and SV40 showing approximately 70-80% 
homology in the coding regions, however regulatory non-coding regions are 
considerably divergent (Frisque and White, 1992). Studies have shown that the 
variation in the regulatory region determines the tissue or species specificity of each 
polyomavirus (Bollag et al., 1989; Haggerty et al., 1989). Epidemiological studies 
have identified seven types of JCPyV, each with multiple subtypes which are linked 
with distinct human populations (Cubitt et al., 2001). JCPyV is the causative agent of 
PML, a clinical complication that cause visual deficit, cognitive impairment and motor 
dysfunction. This severe disease progresses slowly causing death within 4-6 months, 
although symptoms may vary due to the different size and location of the lesion 
(Major, 2011; Saribas et al., 2011). PML is characterized by progressive damage or 
inflammation of the white matter of the brain and occurs amost exclusively in patients 
with sever immune deficiency, including AIDS sufferers, individuals receiving 
chemotherapy and other patients suffering from autoimmune diseases (Major, 2011). 
   
191 
 
MCPyV was first identified in 2008 (Feng et al., 2008) using digital transcriptome 
subtraction (Feng et al., 2007) and its viral genome shares higher similarities with the 
African Green Monkey lymphotropic polyomavirus, although it is classified in the 
Alphapolyomavirus genus which includes mammalian virus species (Calvignac-
Spencer et al., 2016). MCPyV is strongly correlated with a rare but malignant and 
aggressive form of skin cancer, Merkel cell carcinoma (MCC) (Arora et al., 2012; 
Spurgeon and Lambert, 2013). MCC is mainly diagnosed in the elderly receiving 
immunomodulatory therapies, such as transplant recipients and AIDS sufferers 
(Engels et al., 2002). MCPyV is mainly detected on human skin, however the mode 
of virus transmission is unclear (Schowalter et al., 2010). Two mutational events are 
critical for MCPyV induced MCC. Firstly, the MCPyV genome is integrated into the 
host. Secondly, mutated TAg is unable to initiate DNA replication due to the loss of 
helicase function (Shuda et al., 2008).  
SV40 or simian vacuolating virus 40 causes a lifelong infection in rhesus macaque 
monkeys and was first discovered in 1960 (Sweet and Hilleman, 1960). SV40 causes 
an asymptomatic infection in immunocompetent rhesus monkeys, but causes a 
severe disease in immunosuppressed monkeys. Primary kidney cells extracted from 
rhesus macaques were used to manufacture inactivated polio vaccines in the 1950s. 
During the process of the inactivation, SV40 was more resistant than poliovirus and 
as a result, polio vaccines were contaminated with live SV40 stocks. Several million 
people worldwide, were vaccinated with these polio vaccines and exposed to SV40 
inoculum (Shah and Nathanson, 1976). The correlation of SV40 and tumour formation 
in humans is a controversial research area and there is no strong epidemiological 
evidence that implicates SV40 in cancer development (Strickler et al., 1998). 
However, SV40 genomic sequences have been detected in several tumour types in 
humans such as mesotheliomas, brain tumours, lymphomas and osteosarcomas 
(Bergsagel et al., 1992; Pepper et al., 1996; Wong et al., 2002). It is suggested that 
the prevalence of SV40 tumour positivity may be variable due to the differing sources 
and geographical areas of specimens (Butel, 2012).  
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5.1.2 Chapter Aims 
In our previous studies, host factors required during a BKPyV infection were 
investigated. Use of the inhibitors Glibenclamide and CFTR172 led to a significant 
decrease of both viral proteins and DNA levels, suggesting that CFTR plays a critical 
role during the BKPyV life cycle. Based on the pharmacological data, CFTR was 
observed as required during an early event of an infection, following binding and initial 
entry of BKPyV into the host cells but prior to virus reaching the nucleus. Thus, CFTR 
modulation was revealed as a druggable target to inhibit the BKPyV entry process. 
BKPyV is classified as a member of the Betapolyomavirus genus that also includes 
JCPyV and SV40, which cause severe clinical complications (Calvignac-Spencer et 
al., 2016). Moreover, MCPyV is an emerging pathogen which is strongly associated 
with a malignant form of cancer (Arora et al., 2012; Spurgeon and Lambert, 2013). 
Therefore, there is also a need to identify therapeutics, which target specifically these 
viruses. In the previous Chapter, we demonstrated a potential druggable target to 
block the BKPyV life cycle in its natural host cells, thus the effects of CFTR modulation 
on JCPyV, SV40 and MCPyV were investigated and described in this Chapter. 
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5.2 Results 
5.2.1 Examination of CFTR expression in different cell lines 
It was first necessary to confirm that CFTR is expressed in cells that are susceptible 
to infection by the viruses under investigation. Cell lysates from RPTE, Vero, 
HEK293TT and SVG-A cells were produced and CFTR expression assessed by 
Western blot analysis. Human primary renal proximal tubular epithelial (RPTE) cells 
were used in pharmacological analysis as is the most physiologically relevant cell line 
to study the BKPyV life cycle, but they can also be used to investigate the SV40 life 
cycle. Vero cells are kidney cells extracted from the African green monkey and utilized 
as a commonly used cell line as previous studies have suggested that are susceptible 
to infection by both BKPyV and SV40. Moreover, human embryonic kidney cells 
(HEK293TT) were utilized to determine the impact of CFTR modulation on MCPyV 
infection, as they are one of the few cell lines that can be efficiently transduced with 
VLPs. In addition, human foetal glial cells (SVG-A) were used to investigate the 
JCPyV life cycle as they are the most physiologically relevant cell line to its natural 
host cells. 
The corresponding Western blots were probed with a CFTR antibody and GAPDH as 
a loading control. An approximate 165 kDa band was identified in all samples 
presenting the CFTR expression (Figure 5.1). The expression levels of CFTR were 
comparable across the different cell lines, although lower levels were observed in 
RPTE cells. In addition to this, lower expression levels of GAPDH were detected in 
the same sample suggesting that less total protein was loaded from RPTE sample 
(Figure 5.1-Lane 1). These results suggest that all tested cell lines display CFTR 
expression providing the potential to target CFTR function during virus infection of 
these cultured cell lines. 
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Figure 5. 1 CFTR expression in different cell lines. RPTE, Vero, HEK293TT and SVG-A cells were lysed, 
and total protein from cell lysates was separated by SDS-PAGE. CFTR and the loading control GAPDH 
were detected for each cell line by Western blot analysis. Blots are shown (n= 1).   
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5.2.2 Generation of crude JCPyV and SV40 virus 
5.2.2.1 Enzymatic digestions and re-ligation of the JCPyV genome 
Appropriate preparation of JCPyV genome was necessary in order to generate 
infectious JCPyV that could be used in subsequent experiments. Approximately 10 
μg of pBR322 Mad-1 JCPyV plasmid was digested with the EcoRI-HF and re-ligated 
by the T4 DNA ligase following the same methodology as previously described (see 
Section 3.2.1.1) for the preparation of the BKPyV genome.  Digested products were 
run on 0.8% agarose gels and separation of the JCPyV genome from the backbone 
plasmid DNA was confirmed (Figure 5.2A). It was also identified that the JCPyV 
genome was separately re-ligated from the backbone plasmid DNA (Figure 5.2B).  
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Figure 5. 2 Digestions and ligations of JCPyV genome. A. Two independent digestions of pBR322 Mad-1 JCPyV plasmid (10 μg each) were loaded onto a 0.8% 
agarose gel and run for 40 minutes at 80 V. Lane 1: 6 μl of DNA ladder 1 kb; Lane 2, 3: 6 μl of digested pBR322 Mad-1 JCPyV plasmid. B. Re-ligated products were 
loaded onto a 0.8% agarose gel and run for 40 minutes at 80 V. Lane 1: 6 μl of DNA ladder 1 kb; Lane 2, 3: 6 μl of purified and ligated products (n= 2).
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5.2.2.2 Transfection of the JCPyV genome into SVG-A cells 
The methodology to generate an infectious JCPyV stock is summarized in Figure 
5.3A. Initially, 8 μg of re-ligated JCPyV genome was transfected into SVG-A cells 
using Lipofectamine 2000 in a ratio 1-part of DNA: 2-parts of Lipofectamine (see 
Section 2.4.2) and incubated for a total 20 days. Cell supernatants were collected, 
cells lysed and stored for the analysis of intracellular and secreted viral proteins. The 
major capsid protein, VP1, was used as a marker of infection.  
Cell pellets were lysed, and total protein was separated by SDS-PAGE. Released 
proteins in media samples were also separated by SDS-PAGE. The corresponding 
Western blots were probed with a hybridoma VP1 antibody and with a GAPDH 
antibody as a loading control. The presence of VP1 in every sample of cell pellets 
was confirmed showing a clear band at the expected molecular weight of 
approximately 42 kDa (Figure 5.3B). However, secreted VP1 protein was not detected 
in cell supernatants (Data not shown).  
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Figure 5. 3 JCPyV production in SVG-A cells. A. Schematic representation of the JCPyV production 
protocol. SVG-A cells were transfected with 8 μg of JCPyV genome and incubated for 20 days. B. Total 
protein of cell lysates from transfected cells was separated by SDS-PAGE and probed for VP1 (pAb597) 
as a marker of JCPyV transfection, and GAPDH as a loading control. Representative blots are shown 
from 3 flasks of transfected SVG-A cells (n= 2). 
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5.2.2.3 Digestions and re-ligation of the SV40 genome 
Preparation of the SV40 genome was performed to generate infectious stock that 
could be used in virus assays. Initially, 4 µg of pUC-SV40 was digested with the 
restriction enzyme KpnI-HF and re-ligated by the T4 DNA ligase following the same 
methodology as previously described (Section 3.2.1.1) for the preparation of the 
BKPyV genome. Digested products were run on 0.8% agarose gels and bands were 
visualized under UV to confirm that the SV40 genome was separated from the 
backbone plasmid DNA (Figure 5.4). Re-ligated products were purified by ethanol 
precipitation, quantified using a spectrophotometer and run on 0.8% agarose gels. 
Bands were visualized under UV light to confirm that SV40 genomes were re-ligated 
from the backbone plasmid DNA (Figure 5.4).  
 
 
 
 
 
 
 
 
 
Figure 5. 4 Preparation of SV40 genomes. Two independent digestions (4 μg each) and re-ligations of 
pUC-SV40 plasmid were loaded onto a 0.8% agarose gel and run for 40 minutes at 80 V. Lane 1: 6 μl 
of DNA ladder 1 kb; Lane 2, 3: 6 μl of digested pUC-SV40 plasmid. Lane 4, 5: 6 μl of purified and ligated 
products. 
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5.2.2.4 Transfections of SV40 genomes into Vero cells 
To generate an infectious SV40 stock, Vero cells were transfected with 4 μg of re-
ligated SV40 genomes, using the NanoJuice transfection kit in a ration 1-part of DNA: 
2-parts of Core reagent: 3-parts of Booster (see Section 2.4.3) and incubated for 7 
days (Figure 5.5A). Cell suspensions were collected, and cells were lysed for the 
assessment of intracellular and extracellular VP1 expression as an indicator of virus 
production. VP1 expression was confirmed in cell lysates and supernatants of 
transfected cells as indicating the presence of intracellular and secreted virus (Figure 
5.5B). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 5 SV40 production in Vero cells. A. Schematic representation of the SV40 production protocol. 
Vero cells were transfected with 4 μg of SV40 genome and incubated for 7 days. B. Total protein of cell 
lysates and supernatants collected from transfected cells was separated by SDS-PAGE. VP1 (pAb597) 
expression was assessed as a marker of SV40 transfection. GAPDH was probed as a loading control. 
Representative blots are shown (n= 3). 
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5.2.3 CFTR ion channel is required for a successful JCPyV infection 
Previous studies demonstrated a requirement for the CFTR channel during the 
BKPyV life cycle. It was therefore investigated whether this requirement was also 
essential for a closely related polyomavirus, JCPyV. JCPyV infectious supernatants 
were generated and human foetal glial cells (SVG-A cells) were infected with JCPyV 
at an MOI of 0.5 for 2 hours at 37oC. Following infection, cells were treated with 20 
μM of Glibenclamide or 10 μM of CFTR172 for a total of 5 days post-infection. Cells 
were lysed and JCPyV infection assessed through the expression of VP1. Both CFTR 
modulators decreased VP1 protein expression compared to no-drug controls, with 
CFTR172 causing a greater decrease in virus infections (Figure 5.6A). CFTR172 
caused approximately 40% reduction of VP1, whilst Glibenclamide led to a 30% 
decrease in VP1 expression (Figure 5.6B). The concentrations that were inhibitory to 
JCPyV did not cause any effect on cell health when assessed via cell viability assays 
(Figure 5.6C). Taken together, these data suggest that CFTR dependence is 
conserved during the BKPyV and JCPyV life cycles into their natural host cells, 
respectively. 
To support the pharmacological data, the effects of Glibenclamide on the resting 
membrane potential of SVG-A cells was investigated, DiBAC4(3) was added to SVG-
A cells treated with 20 μM of Glibenclamide for 5 days and DiBAC4(3) fluorescence 
assessed by flow cytometry. Glibenclamide led to a depolarization of plasma 
membrane evidenced by the 0.4-fold increase in fluorescence observed following 
drug treatments, compared to no-drug controls (Figure 5.6D). These results indicate 
that Glibenclamide treatment leads to depolarization of SVG-A cells.  
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Figure 5. 6 CFTR inhibition reduces JCPyV infection. A. SVG-A cells were infected with JCPyV at an 
MOI of 0.5 and treated with 20 μM of Glibenclamide or 10 μM of CFTR172 for 5 days. Total protein of 
cell lysates from infected cells was separated by SDS-PAGE and probed for VP1 (pAb597) as a marker 
of JCPyV infection, and GAPDH as a loading control. Representative blots are shown from three 
independent infections. B. Densitometry analysis was performed of Western blots. Values represent the 
mean ±SD normalized to the no-drug control (n= 3). C. SVG-A cells were treated as above, and cell 
viability assessed via MTT assays. Values represent the mean ±SD normalized to the no-drug control 
(n= 3). D. SVG-A cells were treated with 20 μM of Glibenclamide and incubated for 5 days. 20 μM of 
DiBAC4(3) was added to treated cells and flow cytometry analysis of total cell fluorescence was 
measured. Values represent the mean ±SD normalized to the untreated control (n= 3) (*, significant 
difference at the p ≤ 0.05 level).  
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5.2.4 Role of CFTR channel during SV40 and BKPyV infection of Vero cells 
To determine if there was also a role for the CFTR channel during the SV40 life cycle, 
we first studied infection of Vero cells, which are a cell line routinely used in the study 
of BKPyV and SV40. For this reason, Vero cells were infected with SV40 at an MOI 
of 0.5 for 2 hours and subsequently treated with 20 μM of Glibenclamide or 10 μM of 
CFTR172 for 48 hours. Cells were then fixed, and SV40 infection assayed through 
staining for VP1 as a marker of virus production. Using IncuCyte ZOOM analysis, an 
accumulation of VP1 was observed in the nucleus of infected cells, 48 hours post-
infection, the expression of which was unaffected by Glibenclamide and 
approximately 10% reduced by CFTR172 treatment (Figure 5.7A). Since functional 
analysis of CFTR has not been performed in Vero cells, it was important to confirm 
the impact of CFTR modulation in this cell line. To achieve this, the anti-BKPyV 
activity of Glibenclamide or CFTR172 was re-assessed in Vero cells. Cells were 
infected with BKPyV (MOI of 0.5) for 2 hours and then treated with Glibenclamide or 
CFTR172 under identical conditions. Cells were lysed 48 hours post-infection, and 
VP1 expression assessed by Western blot analysis. When VP1 expression was 
assessed ± CFTR modulation, no impact on VP1 expression upon treatment with the 
modulators was observed (Figure 5.7C). Thus, it is likely that the CFTR is not an 
essential host factor for BKPyV/SV40 infection of Vero cells.  
Cell toxicity was also assayed in Vero cells, which were treated with 20 μM of 
Glibenclamide or 10 μM of CFTR172. Treated cells were incubated for 48 hours 
before the MTT analysis. Since both drugs did not have any effect on VP1 expression, 
data as it was expected indicated that both CFTR modulators did not have an effect 
on cell viability (Figure 5.7D). 
Given these data, the ability of Glibenclamide to influence the resting membrane 
potential of Vero cells was investigated. Vero cells were treated with 20 μM of 
Glibenclamide for 48 hours and DiBAC4(3) was added to treated cells. Flow cytometry 
analysis revealed that Glibenclamide retained the ability to cause depolarization of 
Vero cells as evidenced by the 0.3-fold increase in fluorescence in Glibenclamide 
treated cells compared to no-drug controls (Figure 5.7E). These results indicate that 
whilst Glibenclamide can modulate ion channel function in Vero cells, the 
204 
 
Glibenclamide sensitive channels are not required for SV40/BKPyV production in this 
cell line. 
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Figure 5. 7 CFTR inhibition does not reduce SV40 or BKPyV infection of Vero cells. A. Vero cells were infected with SV40 at an MOI of 0.5 and treated with 20 μM 
of Glibenclamide or 10 μM of CFTR172 for 48 hours. Vero cells were fixed and stained with a primary anti-VP1 (1:250) (pAb597) antibody and a secondary anti-
mouse alexa fluor-conjugated 488. SV40 VP1 was used as a marker of SV40 infection. Subcellular localization of VP1 protein was detected in the nucleus of SV40 
infected cells. B. Positive infected cells were calculated by IncuCyte ZOOM and normalized to the no-drug control. Values represent the mean ±SD of positive 
infected cells (n= 3). C. Vero cells were infected with BKPyV at an MOI of 0.5 and treated with 20 μM of Glibenclamide or 10 μM of CFTR172 for 48 hours totally. 
Total protein of cell lysates from infected cells was separated by SDS-PAGE and probed for VP1 (pAb597) as a BKPyV infection marker, and GAPDH as a loading 
control. Representative blots are shown from three independent infections. D. Vero cells were treated as above, and cell viability assessed via MTT assays. Values 
represent the mean ±SD normalized to the no-drug control sample (n= 3). E. Vero cells were treated with 20 μM of Glibenclamide and incubated for 48 hours. 20 
μM of DiBAC4(3) was added to treated cells and flow cytometry analysis of total cell fluorescence was measured. Values represent the mean ±SD normalized to the 
no-drug control (n= 3) (*, significant difference at the p ≤ 0.05 level).
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5.2.5 Role of CFTR ion channel during SV40 infection of RPTE cells 
Given the surprising lack of effects of CFTR modulation in Vero cells, we next tested 
whether CFTR was required during SV40 infection of primary human RPTE cells. 
Cells were infected with SV40 at an MOI of 0.5 for 2 hours and 20 μM of Glibenclamide 
or 10 μM of CFTR172 added to infected cells for a further 48 hours. Cells were fixed, 
and SV40 infection assayed through staining for VP1 as a marker of virus production 
using IncuCyte ZOOM analysis. SV40 VP1 staining was again observed in the 
nucleus of infected cells, 48 hours post-infection (Figure 5.8A). Interestingly, an 
approximate 40%-50% reduction of VP1 expression was observed upon treatment 
with Glibenclamide or CFTR172, respectively, compared to no-drug control sample 
(Figure 5.8B). Glibenclamide was also confirmed to cause membrane depolarization 
assessed through DiBAC4(3) fluorescence in these cells (Figure 5.8C). Taken 
together, these data suggest that host cell CFTR channels are similarly required for 
SV40 infection in RPTE cells.
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Figure 5. 8 CFTR blockade decreases SV40 infection of RPTE cells. A. RPTE cells were infected with SV40 at an MOI of 0.5 and treated with 20 μM of Glibenclamide 
or 10 μM of CFTR172 for 48 hours. RPTE cells were fixed and stained with a primary anti-VP1 (1:250) (pAb597) antibody and a secondary anti-mouse alexa fluor-
conjugated 488. SV40 VP1 was used as a marker of SV40 infection. Subcellular localization of VP1 protein was detected in the nucleus of SV40 infected cells. B. 
Positive infected cells were normalized to the no-drug control sample. Values represent the mean ±SD of positive infected cells (n= 3). C. RPTE cells were treated 
with 20 μM of Glibenclamide and incubated for 48 hours. 20 μM of DiBAC4(3) was added to treated cells and flow cytometry analysis of total cell fluorescence was 
measured. Values represent the mean ±SD normalized to the untreated control (n= 3) (*, significant difference at the p ≤ 0.05 level).
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5.2.6 Role of CFTR channel during SV40 and BKPyV infection of HEK293TT 
cells 
To identify the effect of CFTR modulation on SV40 infection, HEK293TT cells were 
infected with SV40 (MOI of 0.5) and treatments of 20 μM of Glibenclamide or 10 μM 
of CFTR172 were performed. Cells were lysed, total protein was separated by SDS-
PAGE and probed for SV40 VP1 as previously described. In the HEK293TT cell 
system, neither Glibenclamide or CFTR172 influenced VP1 protein expression 
differing from the data obtained from primary RPTE cells (Figure 5.9A). Thus, in 
contrast to primary kidney models, SV40 infection does not require functional CFTR 
channels in HEK293TT cells. 
To confirm drug activity in HEK293TT cells, BKPyV infection assays were performed 
in the presence of Glibenclamide or CFTR172. HEK293TT cells were infected with 
BKPyV (MOI of 0.5) for 2 hours in the presence of both CFTR modulators and VP1 
expression assessed by Western blot analysis from cell lysates 48 hours post-
infection. VP1 expression decreased by approximately 50% in the presence of 
CFTR172, whilst a more modest decrease of approximately 10% of VP1 expression 
was observed upon treatment with Glibenclamide, compared to no-drug controls 
(Figure 5.9B and C). Cell viability assays in these cell lines confirmed that the 
reduction in VP1 expression was not due to cell toxicity, as cell viability was 
unaffected in both treatment conditions (Figure 5.9D). Furthermore, Glibenclamide 
led to depolarization of the HEK293TT cell membrane to levels consistent with those 
observed in Vero/RPTE cells (Figure 5.9E). These results indicate that CFTR 
modulation can regulate ion channel function in HEK293TT cells, but CFTR channel 
influences only BKPyV production and not SV40 in this cell line.
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Figure 5. 9 CFTR is required for a successful BKPyV infection but not for an SV40 infection of HEK293TT cells. A. HEK293TT cells were infected with SV40 at an 
MOI of 0.5 and treated with 20 μM of Glibenclamide or 10 μM of CFTR172 for 48 hours. Total protein of cell lysates from infected cells was separated by SDS-PAGE 
and probed for VP1 (pAb597) as a marker of SV40 infection, and GAPDH as a loading control. Representative blots are shown from three independent infections. 
B. HEK293TT cells were infected with BKPyV at an MOI of 0.5 and treated with 20 μM of Glibenclamide or 10 μM of CFTR172 for 48 hours. Total protein of cell 
lysates from infected cells was separated by SDS-PAGE and probed for VP1 (pAb597) as a marker of BKPyV infection, and GAPDH as a loading control. 
Representative blots are shown from three independent infections. C. Densitometry analysis of Western blots was performed. Values represent the mean ±SD 
normalized to the no-drug control (n= 3). D. HEK293TT cells were treated as above and cell viability assessed via MTT assays. Values represent the mean ±SD 
normalized to the untreated control sample (n= 3). E. HEK293TT cells were treated with 20 μM of Glibenclamide and incubated for 48 hours. 20 μM of DiBAC4(3) 
was added to treated cells and flow cytometry analysis of total cell fluorescence was measured. Values represent the mean ±SD normalized to the untreated control 
(n= 3).
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5.2.7 The role of CFTR ion channel in the MCPyV life cycle 
5.2.7.1 Generation of BKPyV VLPs 
To examine the role of host cell CFTR during the MCPyV life cycle, more 
pharmacological-based experiments were performed. MCPyV VLPs were kindly 
provided to our group (Samuel Dobson) and were generated from a codon-modified 
MCPyV expression plasmid for dual expression of VP1/VP2 (pwM2m) together with 
a reporter plasmid encoding EGFP (pEGFP-C1). Before the analysis using MCPyV 
VLPs, BKPyV VLPs were also generated. 
HEK293TT cells were transfected with a reporter plasmid encoding for EGFP 
(pEGFP-C1) together with a codon-modified BK polyomavirus expression plasmid for 
VP1 genotype Ia (pIaw) in order to generate VLPs, which their capsids consist of VP1 
protein only and EGFP encapsidated. Transfected cells were harvested 48 hours 
post-transfection and VLPs purified using Optiprep gradients. Following the 
purification, fractions were collected by gravity flow (Hurdiss et al., 2016). Seventeen 
samples were collected and 20 μl of each fraction separated by SDS-PAGE to detect 
VP1. VP1 was detected in most of the fractions at the expected molecular mass (42 
kDa) (Figure 5.10A). To examine the infectivity of BKPyV VLPs, naïve HEK293TT 
were transduced with 10 μl of each of the collected fractions and analysed using the 
IncuCyte ZOOM screening 48 hours post-transduction. The results revealed that only 
the HEK293TT transduced with the 6th and 7th fractions were positive for EGFP 
expression (approximately 60%), suggesting that only BKPyV VLPs collected from 
the 6th and 7th fractions encapsidated EGFP (Figure 5.10B). Samples from these 6th 
and 7th fractions were assessed by cryo-EM (Performed by Daniel Hurdiss), which 
demonstrated that BKPyV VLPs have identical size and morphology to native BKPyV 
virions (Figure 5.10C). 
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Figure 5. 10 Generation and purification of BKPyV VLPs. HEK293TT cells were co-transfected with pIaw 
and pEGFP-C1 and incubated for 48 hours. Samples were collected, BKPyV VLPs were purified by 
Opriprep gradients and fractions collected by gravity flow and further analysed. A. 20 μl of each fraction 
was separated by SDS-PAGE. VP1 (pAb597) was detected as a marker of BKPyV infection. 
Representative blots are shown (n= 2). B. 10 μl of each fraction was used to transduce naïve HEK293TT 
cells for 48 hours. The presence of EGFP protein was detected in the 6th and 7th fractions by IncuCyte 
ZOOM screening. Representative images are shown. C. Cryo-electron micrograph of purified VLPs 
suspended in vitreous ice. Scale bars, 100 nm.  
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5.2.7.2 CFTR channel is required for MCPyV and BKPyV VLPs transduction of 
HEK293TT cells 
MCPyV VLPs were used to study the effect of CFTR modulators on MCPyV VLPs 
transduction in a cell line that is susceptible to this virus. BKPyV VLPs were also 
utilized in order to perform a pharmacological analysis for both polyomaviruses under 
identical conditions. HEK293TT cells were used to set up the VLP system. Firstly, 
HEK293TT cells were transduced with MCPyV VLPs for 2 hours and subsequently 
treated with 20 μM of Glibenclamide or 10 μM of CFTR172 for 72 hours. Cells were 
imaged using IncuCyte ZOOM analysis to assess the EGFP expression, since EGFP 
was encapsidated in MCPyV VLPs virions containing both VP1 and VP2 proteins in 
their capsids. The data revealed an approximate 30% and 40% reduction of 
transduced cells in the presence of Glibenclamide or CFTR172, respectively, 
compared to no-drug control samples (Figure 5.11A). These data implicate a role of 
CFTR during a successful MCPyV VLPs transduction. 
Similar experiments were carried out using BKPyV VLPs as a control. HEK293TT 
cells were transduced with BKPyV VLPs and Glibenclamide or CFTR172 were added 
under identical treatment conditions. IncuCyte ZOOM analysis of EGFP showed that 
both modulators led to a modest reduction in cells transduced with BKPyV VLPs, but 
these effects were not as potent as those observed for MCPyV VLPs (10% decrease 
of EGFP upon treatment with Glibenclamide and 20% reduction in the presence of 
CFTR172) (Figure 5.11B). Taken together these data suggest that both modulators 
did not work as potent using the BKPyV VLP system compared to native BKPyV 
virions.  
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Figure 5. 11 Effect of CFTR modulation on HEK293TT cells transduced with MCPyV and BKPyV VLPs. 
HEK293TT cells were transduced with MCPyV (A) and BKPyV (B) VLPs for 2 hours at 37oC. Cells were 
treated with 20 μM of Glibenclamide or 10 μM of CFTR172 and incubated for 72 hours. Live cells were 
imaged using the IncuCyte ZOOM equipment and EGFP fluorescence measured. Data represent the 
mean ±SD of fluorescent intensity normalized to the untreated control samples (n= 3) (*, significant 
difference at the p ≤ 0.05 level; **, significant difference at the p ≤ 0.01 level).  
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5.3 Discussion 
5.3.1 A requirement for CFTR activity during the JCPyV life cycle 
In the Chapter 4 it was shown that BKPyV requires the function of host cell CFTR 
channels to complete its infectious life cycle in RPTE cells. Based on time-of-addition 
experiments it was proposed that CFTR is important at a post-entry stage of the virus 
life cycle, which may include endosome acidification that is critical for a successful 
viral infection. The main aim of the experiments described in this Chapter was to study 
the involvement of host cell CFTR channels in other polyomaviruses’ life cycles (Table 
5.1). 
JCPyV is an emerging human pathogen that is closely related to BKPyV, that causes 
severe clinical complications in immunosuppressed individuals. JCPyV infectious 
stocks were generated (Figure 5.3) and CFTR protein expression was confirmed in a 
JCPyV susceptible cell line, SVG-A cells (Figure 5.1). Stages of the JCPyV infection 
cycle have been well defined including viral attachment to the host cell serotonin 
receptor 5HT2A and alpha (2-6)-linked sialic acids (Elphick et al., 2004; Gee et al., 
2004). Pho et al., (2000) demonstrated that JCPyV enters through a clathrin-
dependent endocytic pathway, although the mechanism of virion transportation to the 
nucleus is less well understood. T antigens are produced and TAg initiates viral 
genome replication and regulates the viral late promoter (Lynch and Frisque, 1990; 
Lashgari et al., 1989). The translation of late viral genes follows, which leads to the 
generation of structural proteins, VP1, VP2 and VP3 and non-structural but regulatory 
protein, the agnoprotein. Structural proteins form the virion capsid and along with viral 
DNA genomes are packaged and newly synthesized viral progeny is released by a 
poorly defined process (Seth et al., 2004). 
As JCPyV enters endosomes the virions are exposed to a low pH-environment 
leading to conformational changes and virion uncoating (Bayer et al., 1998; Mellman 
et al., 1986; Suzuki et al., 2001). Ashok and Atwood, (2003) determine the role of 
acidification in the JCPyV life cycle. There was an approximate 60-80% reduction of 
JCPyV infection upon treatment with ammonium chloride (NH4Cl), known to neutralize 
endosomal pH. These results suggested that JCPyV requires an acidification step at 
a very early stage of the course of infection to complete its life cycle successfully. The 
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acidification step is similarly critical to BKPyV infection. Time-of-addition assays 
suggested that viral entry was the stage of life cycle requiring CFTR functionality 
(Chapter 4). It was demonstrated that the inhibition of CFTR resulted in a reduction 
of JCPyV infection (Figure 5.6). Performing time-of-addition experiments in JCPyV 
infected glial cells combined with an assessment of CFTR modulation on endosomal 
pH may reveal if CFTR channel function influences endosome acidification explaining 
its contribution to the JCPyV life cycle. 
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Table 5. 1 Effect of CFTR modulators on other polyomaviruses’ life cycle. Impact of Glibenclamide (20 μM) and CFTR172 (10 μM) on VP1 protein expression and 
cell viability are shown below. 
 
 
 
  
 
 Vero cells HEK293TT cells RPTE cells SVG-A cells 
 Glib CFTR172 Cell 
viability 
Glib CFTR172 Cell 
viability 
Glib CFTR172 Cell 
viability 
Glib CFTR172 Cell 
viability 
BKPyV No No No 10% 
reduction 
50% 
reduction 
No 80% 
reduction 
80% 
reduction 
No    
BKPyV VLP    10% 
reduction 
20% 
reduction 
No       
JCPyV          30% 
reduction 
40% 
reduction 
No 
SV40 No 10% 
reduction 
No    40% 
reduction 
50% 
reduction 
No    
MCPyV VLP    30% 
reduction 
40% 
reduction 
No       
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5.3.2 Host cell CFTR channels modulation inhibits SV40 production in a cell 
type-dependent manner 
Simian virus 40 (SV40) is also a closely related polyomavirus to BKPyV. During virus 
entry, SV40 binds to the major histocompatibility complex class I antigens on the host 
cell surface (Atwood and Norkin, 1989; Breau et al., 1992) and is internalized via a 
caveolae-dependent endocytosis (Anderson et al., 1996; Kartenbeck et al., 1989). 
Live fluorescence microscopy in CV-1 cells (derived from Cercopithecus aethiops 
monkey kidneys) revealed that SV40 is transported from plasma membrane into 
vesicles positive for caveolin 1. These organelles were not co-stained with 
intracellular markers of lysosomes/endosomes or ER/Golgi apparatus. Following this 
step, SV40 is localized in larger organelles with a non-acidic pH environment, prior to 
sorting into tubular vesicles. These tubular vesicles facilitate transportation along 
microtubules to the smooth ER compartment (Pelkmans et al., 2001). It has been also 
demonstrated that treatment with NH4Cl on SV40 infected glial cells (SVG-A cells) 
does not impact on SV40 production, implicating no requirement for an acidic pH 
environment during virus entry in glial cells (Ashok and Atwood, 2003). To determine 
the role of host cell CFTR channels during SV40 infection, pharmacological analysis 
was first performed in Vero cells (African green monkey kidney cells), an SV40 cell 
line in which CFTR expression was confirmed (Figure 5.7A and B). Given the lack of 
pH dependence of SV40 entry in these cells, it was speculated that a lack of 
requirement of endosome acidification, renders SV40 entry independent of CFTR 
function and is thus insensitive to CFTR modulation. 
There is accumulating evidence that SV40 can infect humans (Butel et al., 1999; 
Garcea and Imperiale, 2003) leading to analysis of the SV40 life cycle in human cell 
lines. Low et al., (2004) performed infection assays on RPTE cells to identify if SV40 
is capable of infecting human primary kidney cells. They identified that SV40 could 
not successfully enter RPTE cells without the exogenous expression of GM1 
gangliosides. Further investigations (Low et al., 2004) suggested that SV40 can infect 
RPTE cells as SV40 DNA was detected in infected RPTE cells by Southern blot, but 
whether this SV40 remained on cell surface or was internalized was not investigated. 
In this study, infection assays in two human cell lines that express CFTR were 
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performed (Figure 5.1). SV40 was shown to infect human RPTE cells (Figure 5.8) and 
HEK293TT cells (Figure 5.9A) as SV40 VP1 protein was detectable following infection 
of both cell lines. Furthermore, differences in the impact of CFTR channel inhibition 
on SV40 production were observed. A significant decrease of SV40 VP1 expression 
occurred in infected RPTE cells upon treatment with CFTR modulators (Figure 5.8). 
Conversely, no effects on SV40 infection in HEK293TT cells was observed (Figure 
5.9A). The discrepancy between the cell lines may suggest that SV40 is internalized 
and trafficked to the nucleus through cell type-specific mechanisms, some of which 
are CFTR dependent. 
Similarly, Vero and HEK293TT cells were infected with BKPyV and treated with CFTR 
modulators. BKPyV VP1 expression was detected in both Vero (Figure 5.7C) and 
HEK293TT cells (Figure 5.9B), suggesting that BKPyV can infect both monkey-
derived cell lines (Figure 5.7C) and human cells (Chapter 4 and Figure 5.10B). 
However, blockade of CFTR function had an impact on BKPyV production only in 
HEK293TT cells (Figure 5.9B) and not in Vero cells (Figure 5.7C). These results may 
strengthen the hypothesis that cell type-specific endocytic pathways are co-opted by 
polyomaviruses en route to the nucleus.  
Polyomaviruses are dependent on different endocytic pathways to infect their hosts. 
SV40 enters host cells using a caveolar-mediated endocytic pathway (Anderson et 
al., 1996; Pelkmans et al., 2002; Stang et al., 1997), whereas JCPyV utilizes a 
clathrin-mediated endocytic pathway (Pho et al., 2000). Murine polyomavirus (MPyV) 
is found to enter host cells via a caveolar/or clathrin-independent endocytic pathway 
(Gilbert and Benjamin, 2000). Disruption of caveolar function had no impact on the 
successful MPyV infection in primary baby mouse kidney (BMK) epithelial cells and 
NIH 3T3 fibroblasts, whereas SV40 infection was inhibited in the same cell lines. 
These data highlighted that two related viruses enter the same cell lines following 
different endocytic pathways as dictated by the virus (Richterova et al., 2001).  
Notably, the same virus may utilize different cellular endocytic pathways for uptake in 
different cell lines (Gilbert et al., 2003). Cytoskeletal elements are most likely involved 
in the directed trafficking of a virus (Sodeik, 2000). Studies have shown that 
intracellular trafficking may vary significantly amongst different viruses of the same or 
related groups (Kasamatsu and Nakanishi, 1998). Receptor-mediated endocytosis 
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occurs during adenovirus infection and following penetration of endosomal 
membrane, the viral particles are released into the cytoplasm. Then adenovirus 
utilizes microtubules to reach the nucleus (Miles et al., 1980; Suomalainen et al., 
1999). Previous studies have demonstrated that in cells with disrupted microtubules, 
adenovirus relies on a transportation mechanism independent on microtubules 
(Glotzer et al., 2001). Moreover, ecotropic murine leukemia virus has been found to 
utilize actin cytoskeleton in both NIH 3T3 fibroblasts and XC cells, although 
microtubules were also required for transportation only in XC cells (Kizhatil and 
Albritton, 1997). These findings highlighted that the cell type can influence the 
mechanism by which the same virus traffics within different cells, (Kizhatil and 
Albritton, 1997; Glotzer et al., 2001) supporting our hypothesis as well. Furthermore, 
a virus may have the ability to use different pathways to enter host cells. A successful 
influenza virus infection is dependent on an acidification step early during infection, 
using a clathrin-mediated endocytic pathway as a primary route (Marsh and Helenius, 
1989). However, blockade of both clathrin- and caveola-mediated endocytic pathways 
did not stop the influenza virus to infect cells (Sieczkarski and Whittaker, 2002). 
Influenza virus utilizes sialic acid as the primary host cell receptor, similar to MPyV 
and the relative lack of specificity of the primary receptors for a specific endocytic 
route may contribute to the use of alternative entry pathways (Gilbert et al., 2003). 
 
5.3.3 CFTR inhibition influences MCPyV infection 
Merkel cell polyomavirus (MCPyV) is one of the most recently identified human 
polyomavirus and is strongly linked with Merkel cell carcinoma (Spurgeon and 
Lambert, 2013). Currently little is known about the life cycle and viral genome 
replication of MCPyV, consequently, events occurring following virus penetration into 
host cells up to the delivery of viral genome into the nucleus are not fully understood 
(Schowalter et al., 2012). 
Previous studies have identified that gangliosides GT1b might be a potential host cell 
receptor for MCPyV (Erickson et al., 2009). However, following studies revealed that 
MCPyV pseudovirions require sulfated glycosaminoglycans and particularly heparan 
sulfate for a successful entry in A549 cells (Schowalter et al., 2011). It is shown that 
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in Lec2 cells lacking sialylated glycans, MCPyV pseudovirions efficiently bound to 
host cell receptor, although there was no gene transduction. These data led to the 
hypothesis that glycosaminoglycan might be a primary receptor and sialylated glycan 
serves as a post-attachment co-receptor for an efficient MCPyV pseudovirion entry 
and gene transduction (Schowalter et al., 2011).  
Schowalter et al., (2012) performed infectivity assays using MCPyV pseudovirions on 
a panel of 60 different cancer cell lines. They identified that in transformed melanocyte 
cell lines and human skin-derived primary keratinocytes, MCPyV entry occurred. 
However, MCPyV pseudovirus could not successfully enter the transformed 
keratinocytes (HaCat) and primary melanocytes did not support an infection. As a 
result, a cautious approach to cell line models to examine the MCPyV life cycle was 
proposed, with skin cells representing the most preferential sites for MCPyV infection 
(Spurgeon and Lambert, 2013). A more recent study identified that human dermal 
fibroblasts are able to sustain MCPyV replication in a cell culture system (Liu et al., 
2016). 
To determine the role of host cell CFTR channels in the MCPyV life cycle, 
pharmacological analysis of CFTR modulators using MCPyV pseudovirions was 
performed. MCPyV pseudovirions were generated in HEK293TT cells and transduced 
cells were treated with CFTR modulators. Both Glibenclamide and CFTR172 were 
found to decrease virus transduction (Figure 5.11A) suggesting that CFTR influences 
MCPyV pseudovirus transduction. However, to identify the exact role of CFTR in the 
MCPyV life cycle, infection assays using native MCPyV could be required. Moreover, 
further pharmacological analyses could be performed in a more physiologically 
relevant cell system, which would be more relevant to MCPyV natural hosts. 
 In this study, we also used BKPyV VLPs as a control to the VLP system. BKPyV 
pseudovirus was generated in HEK293TT cells using an EGFP expression vector and 
a VP1 modified expression vector. The presence of VP1 protein after VLPs 
purification and morphological features of generated VLPs were confirmed by 
Western blotting and cryo-electron microscopy, respectively (Figure 5.10). 
HEK293TT cells were transduced with BKPyV VLPs and treated with CFTR 
modulators, further analysed by IncuCyte ZOOM analysis for the EGFP expression. 
Interestingly, data showed that BKPyV transduction in HEK293TT cells was 
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moderately inhibited by CFTR modulation (Figure 5.11B), which was in contrast with 
the level of reduction of VP1 expression in infection assays using BKPyV native 
virions.   
Accumulating evidences that implicate host ion channels in the life cycles of many 
viruses suggest that CFTR or other host ion channels might influence the 
Polyomaviridae life cycle in a cell type-specific manner. Further studies are now 
required to fully dissect the role of CFTR channels during virus entry to reveal the 
mechanism(s) behind its cell type-specific effects, and its cell type-specific inhibition 
as a potential pan Polyomaviridae inhibitor. 
 
5.3.4 Glibenclamide affects resting membrane potential 
Membrane excitability in cell-based assays requires accurate and precise 
measurements. Patch-clamp recording is the gold standard for monitoring ion channel 
modulations (Hamill et al., 1981). This technique allows the monitoring of ion channel 
gating, activation, inactivation, drug effects and ion selectivity, although the ease of 
use of patch-clamp is low and is not a high-throughput technique (Baxter et al., 2002). 
Current technologies used for monitoring ion channels include radioactive flux 
assays, automated patch-clamp techniques, radioligand binding and optical recording 
techniques such as fluorescence and bioluminescence detection (Baxter et al., 2002). 
Optical readouts of ion channel functionality are sensitive and versatile and for that 
reason are favorable for high-throughput screening among the other methods 
(Denyer et al., 1998; González et al., 1999). Intracellular ion concentrations, as well 
as measurement of membrane potentials can be monitored by fluorescence readouts 
(Denyer et al., 1998). Modifications of ion channels leading to fluctuations of 
intracellular Ca2+ concentration can be measured using fluorescent probes including 
Calcium Green and Fluo-3 (Denyer et al., 1998). Furthermore, there are several 
fluorescent dyes that indicate changes in membrane potential, such as bisoxonol, 
styryl and fluorescence resonance energy transfer-based voltage-sensitive dyes 
(González et al., 1999).  
The bisoxonol fluorescent dye, bis-(1,3-dibutylbarbituric acid) trimethine oxonol, or 
DiBAC4(3) (Epps et al., 1994), has been the reagent used in this study to measure 
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membrane potential. Redistribution of the dye indicates changes in the membrane 
potential. An increase in fluorescence intensity indicates cell depolarization 
(membrane potential become more positive), while a decrease in fluorescence 
indicates hyperpolarization (membrane potential become more negative) (Baxter et 
al., 2002). 
Cl- channels contribute to membrane potential and control cell volume and 
intracellular pH (Okada et al., 2004). Studies have shown that cell cycle and 
proliferation are regulated by Cl- currents (Kunzelmann, 2005). CFTR is an ATP-gated 
Cl- channel and controls ion fluxes across the cell membrane (Li and Naren, 2010; 
Hallows et al., 2000). It is demonstrated that several membrane transport proteins are 
controlled by CFTR, such as the outwardly-rectifying Cl- channel (Gabriel et al., 1993), 
Ca2+-activated Cl- channel (Wei et al., 2001), the epithelial sodium channel (ENaC) 
(Stutts et al., 1997), sodium/hydrogen exchanger (Ahn et al., 2001), the anion 
exchanger (Lee et al., 1999) and aquaporin 9 water channel (Pietrement et al., 2008). 
Thus, CFTR function is critical for the fluctuation of membrane potential (Zhu et al., 
2018). Recent studies revealed that a significant decrease in DiBAC4(3) fluorescence 
intensity was observed upon treatment with the CFTR inhibitor GlyH-101, suggesting 
that CFTR inhibition leads to cell membrane hyperpolarization (Zhu et al., 2018). 
Whereas, agonist-mediated activation of CFTR results in cell membrane 
depolarization (Maitra et al., 2013). 
In this study, screening of CFTR channel modulations was performed using the 
DiBAC4(3) fluorescence dye. RPTE, SVG-A, Vero and HEK293TT cells, respectively, 
were treated with 20 μM of Glibenclamide and fluorescence intensity of DiBAC4(3) 
dye was measured by flow cytometry. Similar shifts were observed in all cell lines 
upon treatment with Glibenclamide (Figure 5.8C; Figure 5.6D; Figure 5.7E; Figure 
5.9E). An increase of fluorescence intensity was observed suggesting that 
Glibenclamide, the CFTR inhibitor, cause cell membrane depolarization. However, at 
this stage of the study we could not suggest whether this shift caused through CFTR 
inhibition or another Glibenclamide sensitive channels since Glibenclamide targets K+ 
channels as well. Further screening of membrane potential upon treatment with the 
inhibitory compound CFTR172 is required to fully dissect the role of CFTR as a 
determinant of cell membrane potential.  
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 Summary and Conclusion 
BK polyomavirus (BKPyV) is a pathogen infecting the majority of the population 
worldwide. Whilst a primary infection is usually asymptomatic in healthy individuals, 
BKPyV can cause severe clinical complications in immunocompromised individuals, 
including polyomavirus-associated nephropathy (PVAN) in renal transplant 
recipients. Currently, there is no clinically available therapeutic intervention against 
BKPyV and the number of kidney transplants is increasing significantly. Therefore, 
there is an urgent need to study the BKPyV life cycle in order to identify potential 
targets that can be exploited for anti-viral therapeutic development.  
Ion channels play critical roles in kidney physiology and regulate a number of 
processes. In addition, they are required during the life cycles of several viruses, 
implicating them as attractive candidate proteins required for a successful BKPyV 
infection. The main aims of this work were to investigate the roles of host ion channels 
in the BKPyV life cycle and to validate them as potential novel anti-viral therapeutics.  
This study established a cell culture system using human primary kidney epithelial 
cells (RPTE) to study the BKPyV life cycle in the most physiological relevant cell 
system to BKPyV host cells. It also identified and optimized a method for 
measurement of infectious BKPyV titres using a fluorescent-based microscopy 
technique, the IncuCyte ZOOM analysis. This high-throughput method provided us 
with sensitive and accurate measurements of viral infectivity and was used to assess 
and validate pharmacological compounds having BKPyV VP1 expression as an 
infection marker. 
Notably, time-course of BKPyV infection indicated the time-points during the BKPyV 
life cycle in which genome replication and late viral gene expression occur. Moreover, 
it was also identified at which time-point the newly synthesized viral progeny is 
released from infected RPTE cells. These findings were supported by previous 
published studies and determined all the critical steps of the BKPyV life cycle. 
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It is established in the literature that viruses manipulate host intracellular machineries 
to favour their life cycles. Several viruses encode their own ion channels known as 
viroporins highlighting the need for regulation of ion homeostasis during their life 
cycles. However, other viruses exploit host ion channels to facilitate different 
processes. Therefore, a strategy to identify novel anti-viral targets is to study virus 
and host interactions, including interactions with host ion channels, and to investigate 
their importance in viruses’ life cycle. K+ channel family is the most widely distributed 
ion channel family across all the different cell types and regulates several intracellular 
processes in kidneys. In addition, an array of modulatory compounds to K+ channel 
family members are available and well-characterized. Therefore, K+ channel family 
was selected for initial investigations. 
Initial screening revealed that tetraethylammonium (TEA), a broad-spectrum K+ 
channel blocker impacted on BKPyV infection causing a decrease on BKPyV VP1 
production. A more detailed pharmacological analysis showed the potential molecular 
identity of specific K+ channels required for a successful BKPyV infection. 
Pharmacological data suggested that the clinically available drug, Glibenclamide, the 
ATP-sensitive K+ channel blocker caused a drastic inhibition of BKPyV VP1 
production at concentrations that did not impact on cell viability. Moreover, there was 
experimental evidence that Glibenclamide inhibited BKPyV VP1 expression in a dose-
dependent manner regardless of the multiplicity of BKPyV infection. It was also 
demonstrated that Glibenclamide had an impact not only at a protein level but also at 
a DNA level causing a significant reduction of viral genome replication. Notably, 
Glibenclamide was found to decrease the infectivity of the newly synthesized viral 
progeny. Taken together these data identify a requirement for Glibenclamide sensitive 
ion channels during the BKPyV life cycle in human primary RPTE cells.  
Glibenclamide is known to cause blockade of ATP-sensitive K+ channels. Although 
by utilizing other pharmacological compounds that target, specifically, components of 
this ion channel complex, no effect on a BKPyV infection was observed. 
Consequently, it was speculated that Glibenclamide inhibits BKPyV through a 
different mechanism and not due to the inhibition of ATP-sensitive K+ channels. 
Glibenclamide is an open-channel blocker of the cystic fibrosis transmembrane 
conductance regulator (CFTR), a Cl- permeable channel, as well. As CFTR is 
abundantly expressed in human kidneys, a potential role for CFTR in the BKPyV life 
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cycle was investigated through performing pharmacological analysis in the presence 
of CFTR172, a specific inhibitor of CFTR channel. Findings showed that CFTR172 
affected the BKPyV life cycle similarly with Glibenclamide, suggesting for the first time 
that renal expressed CFTR is sensitive to Glibenclamide and a host factor required 
during a successful BKPyV infection. Knock down experiments supported the 
importance of CFTR in the BKPyV life cycle, as a decrease in CFTR expression also 
led to a reduction in VP1 production.  
A major finding was that CFTR is required at very early stage of the BKPyV life cycle 
confirmed by performing time-of-addition experiments. Data demonstrated that CFTR 
was critical for BKPyV infection within the first 4 hours of infection without affecting 
the stage of binding/penetration to host cell. It was suggested that CFTR might be 
implicated in early events occurring during the endosomal transportation of BKPyV 
towards the ER compartment. 
 There is experimental evidence that CFTR is expressed in different cell types, which 
are susceptible to other polyomaviruses, including JC polyomavirus (JCPyV), SV40 
and Merkel cell polyomavirus (MCPyV). Pharmacological analysis in the presence of 
Glibenclamide or CFTR172 indicated that there was a requirement of host CFTR ion 
channel for a successful BKPyV, JCPyV, SV40 and MCPyV infection, respectively, in 
certain cell lines in vitro. It was proposed that polyomaviruses studied in this work, 
followed different endocytic pathways towards the nucleus, which might be cell type-
dependent showing a requirement for CFTR in a cell type-dependent manner as well.  
In conclusion, host CFTR ion channel is highly likely to be crucial for BKPyV since 
blockade of the channel’s functionality results in inhibition of BKPyV infection. CFTR 
might be implicated in early events within the first 4 hours post-infection, including 
events occurring during the endocytic trafficking pathway of BKPyV and particularly 
during the transportation to the ER. Previous studies demonstrated that host ion 
channels are involved in acidification occurring at early stages during a viral infection. 
CFTR, potentially, might be involved in acidification of intracellular compartments to 
facilitate partial uncoating and further conformational changes of BKPyV virions 
before reaching the ER. Further research is needed to identify the exact role and 
mechanism(s) of CFTR function during a BKPyV infection. Exploiting host CFTR ion 
channel as potential drug target could help to combat other polyomavirus-related 
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diseases since there could be experimental evidence for a CFTR requirement during 
other polyomaviruses infection.  
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